Drug, bio-affecting and body treating compositions inventions 08/07

20070202052 - Method for increasing the expression of pulmonary surfactant protein-b: The present invention is directed to a novel method for increasing the expression of pulmonary surfactant protein-B in an infant. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the infant.... Agent: Richard D. Schmidt Bristol-myers Squibb Company

20070202058 - Compositions for treating gastric reflux: Methods and compositions for treating gastric reflux or the pain associated therewith comprising orally administering therapeutically effective amounts of certain amino acids in a pharmaceutically acceptable composition are described herein.... Agent: Gary Calton

20070202069 - Polymers containing silicone copolyol macromers and personal care compositions containing same: Dimethicone copolyol polymers are synthesized from dimethicone copolyol macromers. Polymers containing the macromer repeating units are useful in a variety of applications including personal care, textile and industrial formulations to deliver softness, lubricity, fixative, humidity resistance, water repellency, gloss, surface modification, and surfactant properties.... Agent: Legal Department Lubrizol Advanced Materials, Inc

20070202091 - Nutraceutical composition and method for promoting the rejuvenation of cells in warm-blooded animals including humans: A nutraceutical composition and method for promoting the rejuvenation of cells in warm-blooded animals including humans employing mitochondrial energy production-inducing agent for inducing the mitochondrial energy production to proceed from a lower energy production state to a higher energy production state and a nutraceutical composition for supporting the metabolic requirements... Agent: Allen R. Kipnes, Esq. Watov & Kipnes, P.C.

20070202039 - Solid-phase preparation of [18f]fluorohaloalkanes: n

20070202040 - Blood clot-targeted nanoparticles: Emulsions comprising nanoparticles formed from high boiling perfluorochemical substances, said particles coated with a lipid/surfactant coating are made target-specific by directly coupling said nanoparticles to a targeting ligand. The nanoparticles may further include biologically active agents, radionuclides, and/or other imaging agents.... Agent: Morrison & Foerster LLP

20070202044 - Antibody therapy: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.... Agent: Faegre & Benson LLP Patent Docketing

20070202041 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20070202042 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20070202043 - Cytotoxicity mediation of cells evidencing surface expression of trop-2: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20070202045 - Serum albumin binding peptides for tumor targeting: Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.... Agent: Genentech, Inc.

20070202047 - Polyamine-substituted ligands for use as contrast agents: and optionally at least one of the carboxylic groups of the chelating molecule is further reacted with a monoalkylamine having 1 to 18 carbon atoms to form an amide bond; provided that at least one of R1, R2 is other than H. Furthermore, the invention relates to contrast agents for... Agent: Connolly Bove Lodge & Hutz LLP

20070202046 - Implantable device formed from polymer blends: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents... Agent: Philip S. Johnson Johnson & Johnson

20070202048 - Methods, systems, and reagents for delivery to bone of an osteoinductive factor with a contrast agent: The present invention is directed to methods, systems and reagents for providing contrast media that are compatible with osteoinductive factor induced bone formation.... Agent: Fox Rothschild, LLP

20070202049 - Oral dosage form comprising an antimisuse system: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form... Agent: Patton Boggs LLP

20070202051 - Aerosols for sinunasal drug delivery: A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nasal cavity or of the paranasal sinuses. The aerosol is characterised in that its pressure is not constant, but pulsates at a frequency of about 10 to 90 Hz. The mass median... Agent: Edwards Angell Palmer & Dodge LLP

20070202050 - Pharmaceutical formulations: An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent comprising said solution is a pleconaril-dissolving glyceride oil, and the solution is suitable for inhalation administration as an aerosol mist.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070202054 - Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use... Agent: Innovar, LLC

20070202055 - Pharmaceutical formulations: An aspect of the present invention provides for a medicament suitable for administration as a nasal inhalant including an aqueous carrier and suspended therein particulate pleconaril, the aqueous carrier including a thixotropic composition including microcrystalline cellulose and a polymer selected from an alkali metal carboxyalkylcellulose, a polyvinylpyrrolidone polymer, and mixtures... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070202053 - Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient: The invention provides a formulation to be administered as dry powder for inhalation suitable for efficacious delivery of low-dosage strength active ingredients to the low respiratory tract of patient. In particular, the invention provides a formulation comprising microparticles constituted of microparticles of a low-dosage strength active ingredient and microparticles of... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070202057 - Disintegrable oral films: A water soluble film that is disintegrable in the oral cavity to deliver an active agent is provided. The disintegrable film includes at least one water soluble polymer and an active agent. Also provided are methods for preparing the disintegrable oral film and for using the disintegrable film to administer... Agent: Novartis Corporate Intellectual Property

20070202056 - Oral composition for improving mouth environment: A solid oral composition for providing a mouthwash efficacious effect comprising a hygroscopic base, carbamide peroxide, and a bacterial immobilizing agent.... Agent: James Sonntag James Sonntag, Patent Attorney

20070202059 - Stable one-part aqueous tooth whitening composition: The invention relates to a high-temperature stable, one-part, aqueous tooth bleaching composition for contacting a tooth surface. The composition comprises a bleaching agent comprising a high level of a aqueous hydrogen peroxide. The bleaching agent is derived from multiple components within the composition and comprises at least about 15% by... Agent: Rudoler & Derosa LLC Attn: Docket Clerk

20070202061 - Cosmetic skincare applications employing mineral-derived tubules for controlled release: Compositions and methods pertaining to the topical treatment of skin are disclosed. The present invention relates to topical compositions for regulating the condition of skin, especially for regulating visible and/or tactile discontinuities in skin associated with skin aging, environmental affects and the like. One embodiment of the present invention relates... Agent: Basch & Nickerson LLP

20070202060 - Retinoid-containing preparations: Preparations comprising a. at least one retinoid, b. at least one water-soluble antioxidant, c. at least one oil-soluble antioxidant and d. 0.01 to 10% by weight of at least one UV filter, wherein, in the preparations, per part by weight of retinoid, at least 1 part by weight of one... Agent: Connolly Bove Lodge & Hutz, LLP

20070202062 - Natural deodorant compositions comprising renewably-based, biodegradable 1,3-propanediol: Disclosed herein are all natural or substantially natural deodorant and antiperspirant compositions comprising 1,3-propanediol wherein the 1,3-propanediol in said all natural or substantially natural deodorant or antiperspirant composition has a bio-based carbon content of about 1% to 100%. In addition, it is preferred that the 1,3-propanediol be biologically-derived, and wherein... Agent: Mccarter & English, LLP Basil S. Krikelis

20070202063 - Benefit agent containing delivery particle: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070202064 - Rheology modifier/hair styling resin: A rheology modifier/hair styling resin which is a crosslinked, linear poly(vinyl amide/polymerizable carboxylic acid) copolymer exhibits advantageous hair care properties of high viscosity and long-lasting curl retention.... Agent: International Specialty Products William J. Davis, Esq.

20070202067 - Stable oil-in-water and water/oil/water multiple emulsions and hair treating compositions comprising them: The present invention provides an oil-in-water or water/oil/water multiple emulsion, or a mixture thereof, comprising (A) a organopolysiloxane elastomer crosslinked with polyether chains and (B) at least one thickener selected from the group of a polyacrylamide homo- or copolymer, a cellulose ether, a non-silicone cationic polymer or a thickening system... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070202068 - Hair styling cream: The present invention relates to hair styling creams comprising a crosslinked silicone polymer; an alkoxylated compound selected from polyethylenoxides and polyalkoxylated silicone compounds; emulsifier; a fatty phase; and an aqueous phase. The cream can be transferred into rope-, thread-, or fiber-like structures when distributed in the hands. It gives a... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070202070 - Moisture retention polymer compound: The present invention relates to (1) a moisture retention polymer compound comprising a structural unit including a multi-branched polysaccharide derivative in which the hydroxyl group (OH) may be substituted by OR wherein R represents a hydrogen atom, a hydrocarbon having 1 to 30 carbon atoms, or a hydrocarbon having 1... Agent: Sughrue Mion, PLLC

20070202071 - Emulsions comprising a dendritic polymer and use of a dendritic polymer as an emulsification agent: The invention relates to novel emulsions comprising a dendritic polymer. The invention also relates to the use of a dendritic polymer as an emulsification agent. The inventive emulsions are suitable for use in the cosmetics, detergents, paint and coatings industries.... Agent: Jean Louis Seugnet Rhodia Inc

20070202065 - Process for permanently reshaping the hair using particular aminosilicones: A process for permanently reshaping keratin fibres, comprising the application to the keratin fibres, before reducing and/or after the fixing, of a pre-treatment and/or post-treatment cosmetic composition comprising, in a cosmetically acceptable medium, at least one aminosilicone, as defined herein, in non-microemulsified form.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070202072 - Ethoxylated polyurethane viscosity enhancers: The invention provides personal care products comprising fatty ethoxylated dimeric urethane compounds that enhance the viscosity of constituent water based surfactant systems. In compositions and methods of the invention, ethoxylated nonionic, urethane dimers increase the viscosity of water based surfactant systems and serve as thickeners. These thickeners produce clear solutions... Agent: Coleman Sudol Sapone, P.C.

20070202073 - Personal care and cosmetics compositions comprising biologically-based mono and di esters: Personal care compositions comprising esters of 1,3-propanediol and acceptable carriers are provided. The esters can have at least 3% biobased carbon, and the compositions can further comprise 1,3-propanediol that is biologically-derived. Also provided are processes for producing personal care compositions comprising esters of 1,3-propanediol and acceptable carriers. The processes comprise... Agent: Mccarter & English, LLP Basil S. Krikelis

20070202066 - Cosmetic preparation for eyelash: The present invention relates to a cosmetic for eyelash comprising a film-forming polymer (a) having a rate of change in polymer content (ΔW) of 13% or more, and water, wherein a content of the film-forming polymer (a) is 0.6 to 50% by mass. The cosmetic for eyelash according to the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070202074 - Polymeric precursors of non-absorbable, in situ-forming hydrogels and applications thereof: The present invention is directed toward an injectable, single- or multiple-component polymeric liquid precursor of an in situ-forming, non-absorbable, flexible, and resilient hydrogel or semi-solid that can be used in non-surgical, minimally invasive treatment of herniated disc.... Agent: Leigh P. Gregory Attorney At Law

20070202075 - Tissue adhesives and sealants and method for their use: Compositions provided by mixing a biotin-containing component and an avidin-containing component are useful as an adhesive or sealant for medical/surgical uses.... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070202076 - Methods and compositions for the targeted delivery of therapeutics: Disclosed herein are compositions and methods for the targeted delivery of a therapeutic agent. In one aspect, the invention pertains to glycopolymer-based particles complexed with a nucleic acid-based therapeutic. Other aspects of the invention relate to methods for treating various conditions by administering the particle compositions of the invention. In... Agent: Olson & Hierl, Ltd.

20070202077 - Use of high-dose oxazaphosphorine drugs for treating immune disorders: This disclosure relates, at least in part, to methods of eliminating adverse immune reactions in a subject in need thereof including those associated with autoimmune diseases, allergic reactions and transplant rejection, including administration of a lymphocytotoxic non-myeloablative amount of a oxazaphosphorine drug to the subject.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070202078 - Method of treating viral infections: A method of pharmaceutical therapy includes co-administering: (A) interferon or derivative thereof with a low dose of B ribavirin ≦400 mg/day or ≦6 mg/kg/day), or related compound, where (B) provides a clinically effective blood level in portal circulation but less than clinically effective blood level in peripheral circulation, thereby providing... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070202079 - Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases: The invention relates to therapeutic compositions useful in treating prostate cancer. In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial is preferably sodium stibogluconate and biological equivalents thereof. The therapeutic composition comprises an effective amount of pentavalent antimonial that can be used in treating... Agent: Morgan Lewis & Bockius LLP

20070202080 - Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin: The present invention relates to a novel gene delivery system and recombinant adenovirus comprising the relaxin-encoding sequence to enhance transduction efficiency of transgenes, a pharmaceutical anti-tumor composition comprising the recombinant adenovirus, a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated... Agent: The Rafferty Patent Law Firm

20070202081 - Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano: Described herein is a gene therapeutic approach to the prevention and treatment of vascular disease and coronary heart disease; in particular, atherosclerosis. The inventive methods may be used in the prevention and treatment of atherosclerosis, as well as any disease or physiological condition in which atherosclerosis plays a role. The... Agent: Davis Wright Tremaine LLP

20070202082 - Promoters for rna interference: This invention provides vector systems based on the promoters of Epstein-Barr virus-encoded small RNAs that can be used to express and deliver desired RNA molecules such as small hairpin RNAs in mammalian cells. Such small hairpin RNAs are useful for RNA interference.... Agent: Cooper & Dunham, LLP

20070202087 - Composition: The present invention provides the use of the probiotic micro organism deposited under the accession number NCIMB 41117, in the manufacture of a composition for the treatment of non specific dietary sensitivity in a dog or a cat. The present invention also provides a method for the treatment of non... Agent: Fulbright & Jaworski, LLP

20070202088 - Microorganisms and methods for treating poultry: An isolated Bacillus strain LSSAO1 is provided. When fed to a bird, this and other Bacillus strains described herein provide benefits to the birds. For example, administration of the one or more Bacillus strain can increase low G+C, gram positive bacteria in the gastrointestinal flora of the bird. These type... Agent: Whyte Hirschboeck Dudek S.c.

20070202089 - Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof: The present invention provides insecticidal polypeptides related to Bacillus Cry2 polypeptides. Nucleic acids encoding the polypeptides of the invention are also provided. Methods for using the polypeptides and nucleic acids of the invention to enhance resistance of plants to insect predation are encompassed.... Agent: Pioneer Hi-bred International, Inc.

20070202084 - Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects: A method for treating an osteochondral defect or a chondral defect in a subject includes implanting a composite in a site of the osteochondral or chondral defect. The composite includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070202083 - Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis: The present invention features methods for transplanting organs, tissues and individual cells. Also featured are methods for maintaining cells in vitro and for enhancing survival and/or function of cells following transplantation. The methods include the administration of carbon monoxide in an amount sufficient to enhance cell survival and/or function.... Agent: Fish & Richardson PC

20070202085 - Systems and methods for monitoring immune responses and predicting outcomes in transplant recipients: The present invention is related to transplant rejection. In particular, the present invention relates to determining the functional status of alloreactive T cells and correlating the functional status to in vivo immune responses (e.g., tolerance, rejection, or absence of rejection mediated by T cells). The present invention finds use in... Agent: Medlen & Carroll, LLP

20070202086 - Vascular stem cells and uses thereof: The present invention relates to a method for obtaining a cell population enriched in vascular stem cells. Vascular stem cells can be used for a variety of purposes, especially in cell therapy for the treatment of ischemic diseases, including peripheral ischemia and myocardial infarction.... Agent: Young & Thompson

20070202090 - Water soluble form of coenzyme q10 in the form of an inclusion complex with beta-cyclodextrin, process of preparing, and use thereof: An inclusion complex comprising coenzyme Q10 and β-cyclodextrin, its manner of preparation, and its use in products, such as, for example, pharmaceuticals, cosmetics, and aliments is disclosed. β-cyclodextrin is dissolved in water at a temperature elevated above room temperature, such as, for example, between 55° C. and water's boiling temperature.... Agent: Smith Moore LLP

20070202092 - Use of beta-1,3 (4)-endoglucanohydrolase beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function: A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds... Agent: Cook, Alex, Mcfarron, Manzo, Cummings & Mehler Ltd

20070202093 - Systems and methods to reduce gel retraction: Methods for ameliorating stent graft migration and endoleak using treatment site-specific cell growth promoting compositions in combination with stent grafts are disclosed. Also disclosed are application of cell growth promoting compositions such as, but not limited to, autologous platelet gel compositions directly to treatment sites during or after stent graft... Agent: Medtronic Vascular, Inc.IPLegal Department

20070202094 - Timp3 as vegf inhibitor: Polypeptides or proteins comprising tissue inhibitor of mettaloproteinases-3 (TIMP3) or variants of TIMP3 can be used to substantially inhibit vascular endothelial growth factor (VEGF) binding to VEGF receptor-2 (VEGFR2/KDR/Flk-1)) without substantially inhibiting VEGF binding to VEGF receptor 1 (VEGFR1/Flt-1).... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20070202095 - Chlorine dioxide based cleaner/sanitizer: This invention relates to an improved chlorine dioxide solution or liquid mixture containing a phosphate and, as well, as to a composition for forming the chlorine dioxide and phosphate liquid mixture. This improved chlorine dioxide solution is used to clean and/or sanitize without causing corrosion. The corrosion nature of the... Agent: Gus Hampilos Patent Counsel

20070202096 - Xaf genes and polypeptides: methods and reagents for modulating apoptosis: The invention provides novel XAF nucleic acid sequences. Also provided are XAF polypeptides, anti-XAF antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070202098 - Her2/neu optimized fc variants and methods for their generation: The present invention relates to Her2/neu optimized Sc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070202097 - Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof: The present application describes novel monoclonal antibodies, fragments and derivatives thereof which recognise mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Also described are methods which utilise the monoclonal antibodies. Further, a soluble form of MAdCAM-1 is described as well as methods which utilise its presence in a subject.... Agent: Edwards Angell Palmer & Dodge LLP

20070202099 - Antibody drug: The present invention provides an agent for improving the blood stability of an endogenous ligand, which comprises an antibody that has affinity to the mammalian endogenous ligand but substantially does not neutralize the same, and the above-described agent for the prophylaxis and/or treatment for a disease for which an increase... Agent: Edwards Angell Palmer & Dodge LLP

20070202101 - Combination therapy using anti-egfr antibodies and anti-hormonal agents: The invention relates to a combination therapy for the treatment of tumors and tumor metastases, preferably breast and prostate tumors, comprising administration of anti-EGFR (Her1) antibodies and anti-hormonal agents, optionally together with cytotoxic/chemotherapeutic agent. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20070202100 - Pd-1, a receptor for b7-4, and uses therefor: The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070202106 - Compositions and methods for the treatment of cancer: The present invention includes compositions and methods for the treatment, diagnosis and prognosis of cancers by detecting the level of IL-13 expression in cancerous cells in the tissue microenvironment as an indicator of controlling the type of immune response mounted against the cancer.... Agent: Chalker Flores, LLP

20070202103 - Compounds for targeting: The invention provides a compound comprising a target specific portion and an effector portion wherein the target specific portion comprises or consists of a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody and the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070202105 - Domain antibody construct: (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein said modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between... Agent: Morrison & Foerster LLP

20070202102 - High-yield method for the production of human antibodies blocking the biological activity of a human cytokine: The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFNα, IL-4, TNFα and TGFβ, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070202104 - Treatment of spondyloarthropathies using tnfalpha inhibitors: Methods for treating spondyloarthropathies, including ankylosing spondylitis, using TNFα inhibitors are described.... Agent: John D. Conway, Esq. Abbott Bioresearch Center, Inc.

20070202108 - Glycoprotein vi antibodies and methods thereof: The present invention describes antibodies generated against platelet membrane glycoprotein VI-(GPVI), methods of producing the anti-GPVI antibodies, and the use of these antibodies as research and immunotherapeutic agents, in particular, as antithrombotic therapeutic agents.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070202107 - Novel kinases: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the of PTK's and STK's have been identified... Agent: Foley And Lardner LLP Suite 500

20070202110 - Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer: The present invention relates to angiogenesis inhibiting molecules that are the monoclonal antibody H33 or fragments or derivatives thereof, to their use in the treatment of cancer, in particular the treatment of solid tumors and to therapeutic and diagnostic compositions comprising them. The invention relates in particular to humanized derivatives... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070202112 - Compositions and methods for detecting cancer and for inhibiting metastatis: The present invention relates to compositions and methods for detecting cancer (e.g., prostate cancer) and for inhibiting metastasis (e.g., associated with prostate cancer). In particular, the present invention provides methods of detecting vimentin expression and secretion and for characterizing cancer (e.g., prostate cancer). In addition, the present invention provides methods... Agent: Medlen & Carroll, LLP

20070202113 - Cytotoxicity mediation of cells evidencing surface expression of trop-2: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20070202109 - Method of diagnosing breast cancer: Compositions and objective methods for detecting, diagnosing, and treating breast cancer (BRC) are described herein. In particular, the present invention describes three BRC-associated genes, referred to herein as A5657, B9769, and C7965, up-regulated in BRC cells as compared to normal cells. In one embodiment, the diagnostic method involves determining the... Agent: Townsend And Townsend And Crew, LLP

20070202114 - P38 mapk pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target: Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen... Agent: Fulbright & Jaworski, LLP

20070202111 - Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis: The present invention provides a methods and compositions for inhibiting tumor growth and/or metastasis involving the administering to a subject with a laminin 5-secreting tumor of an amount effective to inhibit tumor growth and/or metastasis of an antibody that binds to one or more epitopes of the laminin 5 γ2... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070202115 - Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin: The present invention concerns a preparation for preventing and/or treating a tissue change, wherein the tissue change involves tissue of mesenchymal origin or tissue changes derived therefrom and the preparation contains an antiviral agent.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070202116 - Treatment of micro-organism infection: The present invention is concerned with novel antibodies, medicaments, pharmaceutical packs, methods of manufacture of medicaments and methods for the treatment of micro-organism infections, particularly for the treatment of Staphylococcal infections such as S. aureus infections including MRSA infections.... Agent: Fish & Richardson PC

20070202117 - Compositions and methods of modulating the immune response: The present invention provides methods and compositions of enhancing the immune response to an antigen.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070202118 - Novel peroxiredoxin defense system from mycobacterium tuberculosis: The present invention relates to methods of preventing and treating tuberculosis in a subject infected with Mycobacterium tuberculosis. The method involves inhibiting AhpD in the subject under conditions effective to make the pathogen susceptible to antimicrobial reactive nitrogen intermediates or reactive oxygen intermediates. The present invention also relates to methods... Agent: Nixon Peabody LLP - Patent Group

20070202119 - Method of therapy: Numerous diseases have been linked to the production of regulator cells. The present invention relates to the observation that the immune system is cycling in these diseases. Based on these observations, the present invention provides methods for treating diseases such as cancer and a HIV infection. The present invention also... Agent: Faegre & Benson LLP Patent Docketing

20070202121 - Spas-1 cancer antigen: Compounds and methods for inducing protective immunity against cancer are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more SPAS-1 proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and pharmaceutical compositions for immunization against cancer, or... Agent: Bozicevic, Field & Francis LLP

20070202120 - Yellow fever mosquito deoxyribonucleoside kinases and its use: This invention relates to mosquito multisubstrate deoxyribonucleoside kinases and their use in gene therapy. More specifically the invention provides novel deoxyribonucleoside kinases derived from Aedes aegypti. In further aspects the invention provides novel polynucleotides encoding the mosquito deoxyribonucleoside kinases, vector constructs comprising the polynucleotide, host cells carrying the polynucleotide or... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070202122 - Non-splicing variants of gp350/220: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use... Agent: Johnathan Klein-evans

20070202123 - Fusion proteins comprising dp-178 and other viral fusion inhibitor peptides useful for treating aids: The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular carrier group fused to a gp41-derived DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LA1 gp41 protein, or fragments, analogs or homologs of... Agent: Jones Day

20070202124 - Method for the production of purified invasin protein and use thereof: A method for production of highly purified invasin proteins is disclosed. Also disclosed are vaccine and adjuvant compositions comprising highly purified invasin proteins and the use of highly purified adjuvant proteins to induce an immune response and for administration of drugs.... Agent: Senniger Powers

20070202125 - Inhibiting rejection of a graft: Disclosed are methods for inhibit rejection of a graft in a patient. The methods involve treating the graft with a molecule which binds to a co-stimulatory protein of antigen-presenting cells. Useful molecules include chimeras having enzymatically inactive polypeptides bonded to polypeptides which bind to co-stimulatory proteins of antigen-presenting cells. Also... Agent: Fish & Richardson PC

20070202126 - Bio-derived 1,3-propanediol and its conjugate esters as natural and non irritating solvents for biomass-derived extracts, fragrance concentrates, and oils: Compositions comprising 1,3-propanediol and an extraction product are provided, and the 1,3-propanediol in the composition is biologically derived. Also provided are processes for extracting an extract from a source. These processes comprise providing an ester of 1,3-propanediol and mixing the 1,3-propanediol ester with the source. This serves to extract the... Agent: Mccarter & English, LLP Basil S. Krikelis

20070202127 - Nucleic acids encoding dp-178 and other viral fusion inhibitor peptides useful for treating aids: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides... Agent: Jones Day

20070202128 - Immunomodulatory oligonucleotides: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides... Agent: Wolf Greenfield & Sacks, P.C.

20070202129 - Use of the neurotoxic component of a botulinum toxin for the treatment of pain associated with muscle activity or contracture: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20070202130 - Anthrax antigens and methods of use: Anthrax antigens are provided that find use as immunogens and vaccines.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070202131 - Use of mycrobacterial vaccines in cd4+ or cd8+ lymphocyte-deficient mammals: Methods of treating a mammal that is deficient in CD4+ and/or CD8+ lymphocytes are provided. The methods comprise inoculating the mammal with an attenuated mycobacterium in the M. tuberculosis complex. In these methods, the mycobacterium comprises two deletions, wherein a virulent mycobacterium in the M. tuberculosis complex having either deletion... Agent: Amster, Rothstein & Ebenstein LLP

20070202132 - Allergenic proteins and peptides from dog dander and uses therefor: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity... Agent: Lahive & Cockfield, LLP

20070202133 - Benzimidazole compounds for modulating ige and inhibiting cellular proliferation: The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer... Agent: Knobbe Martens Olson & Bear LLP

20070202134 - Muc1 antagonist enhancement of death receptor ligand-induced apoptosis: The present invention relates to methods of enhancing death receptor-induced apoptosis in MUC1 expressing cells comprising contacting the MUC1 expressing cells with an effective amount of a MUC1 antagonist.... Agent: Fulbright & Jaworski L.L.P.

20070202135 - Ionized compositions and methods of use therefore: This invention relates to methods for preparing an ionic composition suitable for use as a cosmetic product, products containing such compositions, and containers for containing and dispensing such products.... Agent: Buchanan, Ingersoll & Rooney LLP

20070202138 - Antimicrobial compositions and method: Compositions for antimicrobial, antibacterial, antiviral, fungicidal and sporicidal applications comprise a mixture of alkyl betaine and alkyl amine oxide components together with a protonating agent. The compositions are particularly effective in the treatment and elimination of microorganisms in planktonic cell form as well as in sessile cell form in biofilms.... Agent: Pearne & Gordon LLP

20070202137 - Device for sensing of motile living organisms and uses thereof: The present invention relates to the field of devices for studying behaviour of motile living organisms in a multiplexed array format. The present invention provides devices comprising a solid porous support having first and second surfaces, said first surface comprising an agent and/or condition delineating behavioural and/or physical barriers for... Agent: Amster, Rothstein & Ebenstein LLP

20070202136 - Method for reducing the contamination properties of a surface by micro-organisms: A method for reducing the contamination properties by micro-organisms of a surface made of a mineral material, the surface having an area of at least 0.1 m2, the method including the following steps: a) application, onto the surface to be treated, of a layer of a solution or of an... Agent: Young & Thompson

20070202139 - Use of microcapsules for making paints and lacquers: The invention provides microcapsules having an average diameter of 0.1 to 25 μm, obtained by a process (a) or (b), wherein, (a1) preparing an aqueous emulsion comprising actives and optionally oil components and/or emulsifiers; (a2) treating the emulsifier with an aqueous solution of anionic polymers to form a matrix; (a3)... Agent: Cognis Corporation Patent Department

20070202140 - Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery: Disclosed herein are methods of preventing, inhibiting, or ameliorating complications associated with cardiopulmonary bypass surgery by the use of a thrombin receptor antagonist compound. Among the thrombin receptor antagonist compounds useful in these methods are those of Formulas I and II, described herein. Examples of such thrombin receptor antagonists include:... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070202141 - Synthetic aggregation pheromone for manipulating the behaviour of codling moth, cydia pomonella, larvae: This invention relates to a composition and procedure for manipulating the behaviour of codling moth larvae, Cydia pomonella (L.) (Lepidoptera: Olethreutidae). In particular, this invention relates to the use of specific pheromone components for manipulating the behaviour of C. pomonella larvae. A composition of chemicals for manipulating the behaviour of... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20070202142 - Biomaterial, injectable implant comprising it, its method of preparation and its uses: This invention relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or... Agent: Greenberg Traurig, LLP

20070202143 - Direct application of non-toxic crosslinking reagents to restabilize surgically destabilized intervertebral joints: A method of improving the resistance of collagenous tissue subject to elevated collagenous tissue stress as a result of tissue removing surgical decompression surgery, comprising contacting at least a portion of the remaining collagenous tissue with an effective amount of a crosslinking reagent.... Agent: Robert Berliner Berliner & Associates

20070202146 - Implantable device formed from polymer and plasticizer blends having modified molecular structures: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents... Agent: Philip S. Johnson Johnson & Johnson

20070202144 - Coated implants, their manufcturing and use thereof: The present invention relates to a method of coating of a device, preferably implants, with a substance comprising the steps of (a) contacting said device into a solution of said substrate or substance, and (b) drying said device while being submerged in said solution. The present invention also relates to... Agent: Faegre & Benson LLP Patent Docketing

20070202148 - High density fibrous polymers suitable for implant: This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry,... Agent: Kensey Nash Corporation

20070202145 - Method for incorporation of bioactives into a porous hydrophobic polymer scaffold: This idea represents a method for incorporation of a therapeutic molecule, preferably a protein or a growth factor, into a biodegradable scaffold, specifically one that is made of a foam nonwoven composite. The process utilizes a solvent preferably tertiary butanol to facilitate the infiltration of the particles of the therapeutic... Agent: Philip S. Johnson Johnson & Johnson

20070202147 - Poly(ester amide)-based drug delivery systems with controlled release rate and morphology: A method of forming a coating on a medical device having a controlled morphology is described.... Agent: Squire, Sanders & Dempsey LLP

20070202149 - Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings: Coatings for medical devices, methods of making the coatings, and methods of using them are described.... Agent: Lahive & Cockfield, LLP

20070202150 - Implantable device formed from polymer and plasticizer blends: A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents... Agent: Philip S. Johnson Johnson & Johnson

20070202151 - Intravesical drug delivery device and method: Implant devices for intravesical administration and local drug delivery. The device has a body which includes a hollow tube formed of a biocompatible material; at least one reservoir in the tube which contains a drug; and one or more apertures through which the drug can be released. The device is... Agent: Sutherland Asbill & Brennan LLP

20070202152 - Method for encapsulation of orally ingested materials to alter the site of digestion, site of action, or stability: Comestible materials encapsulated by a film-forming composition including a plant protein source and methods of forming the same are provided. The film-forming composition affects the site of digestion of the comestible material within the digestive tract of an animal or a human thereby allowing the material to be most effectively... Agent: Hovey Williams LLP

20070202153 - Liquid concentrated formula: The invention pertains to a liquid complete nutritional composition suitable for feeding cachectic patients, having an energy density of at least 1.45 kcal/ml. The composition comprises a protein fraction in an amount of 7.8-12 g per 100 ml, a carbohydrate fraction, and a lipid fraction. At least 70 wt. %... Agent: Foley And Lardner LLP Suite 500

20070202154 - Process for promoting overall health of an animal: The process of the present invention comprises an animal food composition that is fed to animals and is pro-nutritional, and is convenient to the pet owner. When the pet owner feeds the animal food composition to the animal, the ingested composition promotes a healthy body weight in the animal and... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070202156 - Adhesive preparation comprising sufentanil and methods of using same: The present invention provides percutaneously absorbable adhesive preparations and transdermal compositions comprising Sufentanil, which are obtained from economic starting materials, have a constitution simpler than that of conventional Sufentanil adhesive preparations, and have effective skin permeability. The preparations and compositions comprise two polyisobutylenes having different molecular weights, a tackifier, a... Agent: Foley And Lardner LLP Suite 500

20070202155 - Low dose no donor-containing transdermal patch: The present invention is drawn to a transdermal patch for the delivery of a nitroglycerin or other NO donor. The patch can comprise a backing layer, and a nitroglycerin-containing composition or other NO donor-containing composition which is supported at least in part by the backing layer. The transdermal patch can... Agent: Thorpe North & Western, LLP.

20070202157 - Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides: An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.... Agent: Fulbright & Jaworski L.L.P.

20070202158 - Methods of administering water-soluble prodrugs of propofol for extended sedation: A method of administering a prodrug of propofol, preferably O-phosphonooxymethyl propofol disodium salt, comprises the oral, intragastric, or intraintestinal administration of the prodrug in amounts sufficient to induce or maintain a generalized anesthetized state, a conscious sedated state, or to treat insomnia, anxiety, nausea, vomiting, pruritus, epilepsy, and a range... Agent: Banner & Witcoff, Ltd.

20070202159 - Pharmaceutical composition comprising stabilized statin particles: The present invention relates to stabilized statin particles and process for preparation thereof.... Agent: Ranbaxy Inc.

20070202160 - Solid-state form of celecoxib having enhanced bioavailability: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of... Agent: Pharmacia Corporation Global Patent Department

20070202161 - Pharmaceutical formulations: Capsule formulations are provided containing at least two different fill compositions which are prevented from mixing either by providing both of the fill compositions as solids or by providing a physical barrier which separates the fill compositions so that they are prevented from mixing. The invention has the advantage that... Agent: Leydig Voit & Mayer, Ltd

20070202162 - Extended release pharmaceutical compositions: The present invention relates to extended release pharmaceutical compositions comprising a beta-blocker drug or a pharmaceutically acceptable salt thereof, wherein said composition comprises at least two extended release portions, each portion having an in vitro dissolution profile that is different from another portion.... Agent: Dr. Reddy's Laboratories, Inc.

20070202164 - Andrographis extract formulations: A pharmaceutical formulation containing 50-90% by weight a powdered extract of Andrographis paniculata and 5-50% by weight a powdered blocking agent. The formulation may further contain a pore-forming agent, a filler, a lubricant, or a glidant. Also described are a method for preparing this pharmaceutical formulation and a method for... Agent: Occhiuti Rohlicek & Tsao, LLP

20070202163 - Fast-disintegrating epinephrine tablets for buccal or sublingual administration: Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations substantially equivalent to those achieved by traditional injectable dosage forms comprising epinephrine injected either subcutaneously or intramuscularly.... Agent: Wilson Sonsini Goodrich & Rosati

20070202165 - Method for a supplemental dietary composition having a multi-phase dissolution profile: The present invention relates to a method and composition for achieving a multi-phasic dissolution prolife through the process of fine-milling to increase the rate of dissolution of ingredients. The ingredients to be fine-milled are ingredients suitable for use in supplemental dietary compositions.... Agent: Kenyon & Kenyon LLP

20070202166 - Method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients: The present invention relates to a method for increasing the rate of bioavailability of orally administered supplemental dietary ingredients through the process of fine-milling to increase the rate of dissolution of the ingredients. The ingredients to be fine-milled are ingredients suitable for use in supplemental dietary compositions.... Agent: Kenyon & Kenyon LLP

20070202167 - Hyoscyamine dosage form: A pharmaceutical dosage form which comprises two or more different hyoscyamine formulations, at least one of the formulations being an immediate release hyoscyamine formulation and at least one other one being a controlled release hyoscyamine formulation. This abstract is neither intended to define the invention disclosed in this specification nor... Agent: Greenblum & Bernstein, P.L.C

20070202168 - Composition comprises sustained-release fine particles and manufacturing method thereof: The present invention relates to a composition comprising sustained-release fine particles, characterized in that it contains sustained-release fine particles that can be used in quick-disintegrating tablets in the buccal cavity, one or more fillers selected from the group consisting of sugars or sugar alcohols, and one or more binders for... Agent: Townsend And Townsend And Crew, LLP

20070202170 - Dual-release compositions of a cyclooxygenase-2 inhibitor: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of... Agent: Pharmacia Corporation Global Patent Department

20070202169 - Lansoprazole orally disintegrating tablets: The invention provides orally disintegrating tablets that readily disintegrates in the mouth, releasing enteric coated drug sub-tablets.... Agent: Kenyon & Kenyon LLP

20070202171 - Method of producing a pharmaceutical composition: With the object of providing a method for producing a pharmaceutical composition comprising a drug-containing layer, a first functional layer provided to one side of the drug-containing layer either directly or via an intermediate layer, and a second functional layer provided to the other side of the drug-containing layer either... Agent: Posz Law Group, PLC

20070202172 - Metoprolol succinate e.r. tablets and methods for their preparation: The present invention provides extended release pharmaceutical compositions of a beta blocker such as, but not limited to, metoprolol succinate as the active ingredient and methods of preparing such extended release pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20070202173 - Biodegradable, non-toxic biological adhesive for use in abdominal surgery: A biological adhesive formulation comprising dextrin, at least one adhesiveness modifier agent, and at least one antibiotic is suitable for promoting healing of tissue in a patient, for example, to prevent anastomosis of a surgical wound in the digestive system of a patient, and for affixing a prosthesis during a... Agent: Millen, White, Zelano & Branigan, P.C.

20070202174 - New mandelic acid derivatives and their use as thrombin inhibitors: There is provided a compound of formula (I) wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus,... Agent: Morgan Lewis & Bockius LLP

20070202175 - Pharmaceutical composition and process: The present invention relates to a pharmaceutical composition comprising a solid suspension prepared by hot melt extrusion of isobutyric acid (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl ester; hydrochloride salt (I) and a polyethylene glycol (PEG)/polypropylene glycol (PPG) block copolymer.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070202177 - Antimicrobial compositions and methods for locking catheters: Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least... Agent: David W. Highet, Vp And ChiefIPCounsel Becton Dickinson And Company

20070202176 - Bacteria support material: The present invention relates to a composite material made of non-metallic inorganic grains and plastics particles. The composite material is particularly suitable as a carrier material for bacteria for use in sewage treatment plants. It is characterized by a large surface suitable for the colonization of bacteria and also by... Agent: Lahive & Cockfield, LLP

20070202178 - Drug delivery matrices to enhance wound healing: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070202179 - Low dose pharmaceutical products: This invention relates to a method of formulating dosage forms of pharmaceutically active ingredients and to solid dosage forms produced thereby wherein the dosage form contains a very low dose, more especially an ultra-low dose of the pharmaceutically active ingredients.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070202181 - Low hygroscopic aripipazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070202180 - Nanoparticulate carverdilol formulations: The present invention is directed to nanoparticulate carvedilol compositions having improved pharmacokinetic profiles, improved bioavailability, dissolution rates and efficacy. In one embodiment, the nanoparticulate carvedilol composition has an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070202186 - Apparatus and formulations for suprachoroidal drug delivery: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space... Agent: Beyer Weaver LLP

20070202183 - Composition and method for preparing alginate nanocapsules: The present invention discloses a method for preparing alginate nanocapsules, including the steps of: (a) forming a water-in-oil emulsion including an alginate in water, an oil, and at least one nonionic surfactant; and (b) separating the aqueous phase and oil phase to obtain the semisolid form alginate nanocapsules; and (c)... Agent: Anna Wu

20070202184 - Liquid compositions including microencapsulated delivery vehicles: Microencapsulated delivery vehicles comprising an active agent are disclosed. In one embodiment, the microencapsulated delivery vehicles are heat delivery vehicles capable of generating heat upon activation. The microencapsulated heat delivery vehicles may be introduced into wet wipes such that, upon activation, the wet wipe solution is warmed resulting in a... Agent: Senniger Powers (kcc)

20070202185 - Microencapsulated delivery vehicles having fugitive layers: Stabilized substantially fluid-impervious microencapsulated delivery vehicles comprising an active agent are disclosed. The microencapsulated delivery vehicles have improved rupture force strength. In one embodiment, the microencapsulated delivery vehicles are heat delivery vehicles capable of generating heat upon activation. The microencapsulated heat delivery vehicles may be introduced into wet wipes such... Agent: Senniger Powers (kcc)

20070202182 - Preparing solid formulation of nanoparticles of pharmaceutical ingredient, including at least micron-sized particles: A slurry is prepared in which nanoparticles of a pharmaceutical ingredient have been formed within a solvent. A solid formulation of the nanoparticles of the pharmaceutical ingredient is prepared from the slurry, without employing electrostatic collection. The solid formulation of the nanoparticles includes at least micron-sized particles.... Agent: Hewlett Packard Company

20070202187 - Dosage forms: Dosage forms comprising therapeutically active compounds are disclosed herein.... Agent: Allergan, Inc.

20070202188 - Use of alkene carboxlic acid n alkylamides as flavouring agents: s

20070202189 - Acellular bioabsorbable tissue regeneration matrices: The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration... Agent: Choate, Hall & Stewart LLP Patent Department

20070202191 - Bone graft materials derived from mineralized gelatin: The present invention provides novel methods of forming mineralized gelatin carriers from bone. The present invention further provides mineralized gelatin carriers themselves; bone products that include such mineralized gelatin carriers including DBM bone products; and kits that include mineralized gelatin carriers formed from bone. The present invention further provides methods... Agent: Globus Medical, Inc. Attn: Brian Malm

20070202190 - Bone graft materials derived from mineralized gelatin: The present invention provides novel methods of forming mineralized gelatin carriers from bone. The present invention further provides mineralized gelatin carriers themselves; bone products that include such mineralized gelatin carriers including DBM bone products; and kits that include mineralized gelatin carriers formed from bone. The present invention further provides methods... Agent: Globus Medical, Inc. Attn: Brian Malm

20070202192 - Fungical mixtures for controlling rice pathogens: 2) phosphorous acid H3PO3, its alkali metal or alkaline earth metal salts or derivatives releasing them II in a synergistically effective amount, methods for controlling harmful fungi using mixtures of the compound I with the compound II, the use of the compound I with the compound II for preparing such... Agent: Birch Stewart Kolasch & Birch

20070202193 - Inhibition of reactive oxygen species and protection of mammalian cells: Methods and compositions useful for neuronal protection in retinal cells in vitro and the protection of mammalian cells from reactive oxygen species in vivo are provided. Ultrafine nano-size cerium oxide particles, less than 10 nanometers in diameter, have been provided to decrease reactive oxygen species (ROS) in retina tissue that... Agent: Law Offices Of Brian S Steinberger

20070202194 - Preparation for the prevention and/or treatment of vascular disorders: The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol,... Agent: Foley And Lardner LLP Suite 500

20070202195 - Delivery of functional ingredients: The present invention relates to a primary composition comprising all essential nutrients of a fruit or a plant material, which has an increased stability, bio-availability and miscibility; and the process of forming the same. It also relates to an oral composition that contains the primary composition in a foodstuff, in... Agent: Bell, Boyd & Lloyd LLP

20070202197 - Pawpaw and/or peach derived composition: There is provided a process for making a composition suitable for topical application comprising the steps of a) heating at least one fruit and/or vegetable pulp to up to a temperature in the range of about 40° C. to 100° C.; b) mixing between 1 and 40% w/w of a... Agent: Viviana Amzei Ipac Consultants

20070202196 - Plant extract mixtures and their uses: A composition comprising extract of one or more plants of one or more of the following plant families: Cissus, Vernonia and Brillantasia. Such compositions have beneficial activity principally in controlling weight gain and obesity, especially in conjunction with chitosan or a chitosan derivative and an antioxidant such as vitamin C.... Agent: Greenberg Traurig LLP (la)

20070202198 - Process of obtaining thylakoids from photosynthetic organisms; plant fractions obtained from the process; pure thylakoids; and methods of use of thylakoids as ros scavengers, photo-protectors, biosensors biofilters and bioreactors: This invention relates to a process by which an extract comprising integral thylakoids is obtained. The resulting extract is a potent dynamic antioxidant useful as a ROS (reactive oxygen species) scavenger. This extract is intended to be used for the treatment or prevention of diseases involving the generation of ROS,... Agent: Godfrey & Kahn S.c.

20070202199 - Compositions for enhancing sexual responsiveness: A topical composition which enhances sexual responsiveness of a mammal is disclosed. An effective dosage of a peripheral vasodilator, an absorption enhancer and, optionally, a vasoconstrictor and an alpha receptor blocker are combined with a pharmaceutically-acceptable topical vehicle to produce the composition. The compositions are applied topically to the penis... Agent: Sheridan Ross PC

20070202200 - Method of inhibiting weight regain after weight loss: A composition for reducing the weight of a human. The composition is provided in the form of a capsule comprising an effective amount of capsaicin and/or analogs thereof, L-tyrosine, supplemental caffeine and/or and analogs thereof, green tea extract containing catechin and caffeine, and embodiments which include calcium. The invention is... Agent: Gordon & Rees LLP

20070202201 - Pharmaceutics of treaditiional chinese medicine of treating aids and preparation method thereof: The present invention provides a pharmaceutics of traditional Chinese medicine for treating AIDS and preparation method thereof, said pharmaceutics is prepared from Geranium, Root of Membranous Milkvetch, Herba Solani Nigri, Honeysuckle Flower, Flower of Common Bombax, Fruit of Belleric Terminalia, Herba Hedyotis Diffusae, Pomegranate Rind, Radix Oryzae, Fructus Trapae. The... Agent: J C Patents, Inc.

20070202203 - Anti-ageing composition: The invention relates to a composition containing, in a physiologically acceptable medium, at least: hyaluronic acid and/or one of its salts; at least one extract of soybean proteins; and at least one compound of formula (I) as described herein. This composition is useful for preventing and/or decreasing the signs of... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070202202 - Method for enhancing the content of soybean seed gamma-aminobutyric acid: The present invention relates to a display apparatus including a display part displaying a digital signal that includes a pixel clock, frequency adjusting part adjusting a frequency of the pixel clock, and a controller controlling the frequency adjusting part to adjust the frequency of the pixel clock of the digital... Agent: O'keefe, Egan, Peterman & Enders LLP

20070202204 - Plant extract mixtures and their uses: A composition comprising extract of one or more plants of one or more of the following plant families: Cissus, Vermonia and Brillantasia. Such compositions have beneficial activity principally in controlling light gain and obesity, especially in conjunction with chitosan or a chitosan derivative and an antioxidant such as vitamin C.... Agent: Greenberg Traurig LLP (la)

20070202205 - Carbohydrase inhibitors derived from chestnut and use thereof: The present invention provides a plant-derived carbohydrase inhibitor, wherein the inhibitor is effective for preventing or alleviating diabetes, or preventing obesity, and foods, drinks, and medicines containing the same. The present invention is accomplished by use of an α-amylase inhibitor or an α-glucosidase inhibitor as a carbohydrase inhibitor that is... Agent: Fitch, Even, Tabin & Flannery

20070202206 - Morinda citrifolia leaf juice and leaf extract based formulations: A method and composition for inhibiting certain enzymes, where such inhibition results in various health benefits is provided. More particularly, a method and composition using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4)... Agent: Kirton And Mcconkie

20070202207 - Use of naturally occurring epoxidised molecules from vernonia galamensis: Epoxidised oil, epoxidised wax or epoxidised fatty acid ester recovered from Vernonia Galamensis seeds provide topical medicament preparations which are effective in preventing and treating various different forms of skin diseases, skin lesions and wounds. These epoxidised oil, epoxidised wax or epoxidised fatty acid ester recovered from Vernonia Galamensis seeds... Agent: Koppel, Patrick & Heybl

20070202208 - Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity: The invention provides hops (Humulus lupulus) extracts or derivatives thereof for use in treating a patient prophylactically and/or therapeutically for ulcerogenic-type disorders of the stomach and/or intestines. The ulcerogenic disorders can be of the type chemically induced, environmentally-induced, infection-induced, and/or stress-induced. The invention also provides a pharmaceutical composition comprising an... Agent: Mcdermott Will & Emery LLP

20070196273 - Oral dtpa for radionuclide chelation: A composition for oral radionuclide chelation therapy comprises a DTPA chelate selected from Zn-DTPA and Ca-DTPA and a permeation enhancer that preferentially increases jejunal uptake of the DTPA chelate. The composition has a DTPA chelate bioavailability of at least 10% of the chelate when orally administered to a mammal.... Agent: Richard Aron Osman

20070196288 - Method of treating periodontitis and of reducing dentinal sensitivity: An improved method of treating periodontitis includes the steps of: creating a formulation containing a lanthanide-containing protease inhibitor; and applying the formulation to a periodontal area. The lanthanide may be cerium chloride, samarium chloride, lutetium chloride, cerium chloride heptahydrate, lutetium chloride hexahydrate, samarium chloride hexahydrate, gadolinium, gadolinium nitrate, gadolinium chloride,... Agent: Phillips Lytle LLP Intellectual Property Group

20070196348 - Compositions and methods for the induction and maintenance of quality sleep: Supplemental compositions, and methods for administering same to a user, are provided for promoting a restful night's sleep by speedily inducing a person to fall asleep and to maintain sleep, as well as alleviating minor aches and pains so as to further improve the quality of a person sleep. The... Agent: Kenyon & Kenyon LLP

20070196271 - Compositions and methods related to serotonin 5-ht1a receptors: Contemplated substituted arylpiperazinyl compounds, and most preferably 18F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with 18F-fluorine in a single step. Still further, contemplated compounds exhibit high... Agent: Rutan & Tucker, LLP. Hani Z. Sayed

20070196270 - Compounds as ccri antagonists: n

20070196272 - Oral delivery of therapeutic agents using tight junction agonists: The present invention provides compositions and methods for the administration of the compositions to mammals. The compositions comprise therapeutic agents and an intestinal absorption enhancing amount of one or more tight junction agonists. Tight junction agonists include zonulin and/or ZOT receptor agonists. Methods of the invention include orally administering compositions... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20070196269 - Pharmaceutical composition: The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and/or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and/or the immune cells are antagonists of TGF-beta... Agent: Jacobson Holman PLLC

20070196275 - Diagnostic imaging compositions, their methods of synthesis and use: Conjugate molecules comprising a ligand bonded to a polymer are disclosed. One such conjugate molecule comprises a ligand bonded to a polymer, a chelating agent bonded to the polymer, and a radioisotope chelated to the chelating agent. The conjugate molecules may be useful in detecting and/or treating tumors or biological... Agent: Lori Stiffler, Baker Botts L.L.P. One Shell Plaza

20070196274 - Immunoconjugates with improved efficacy for the treatment of diseases: The invention provides therapeutic or diagnostic antibodies with modified N— or C-terminal sequences that are enriched with lysine or tyrosine residues. These lysine or tyfosine residues can be used to couple radioisotopes, cytotoxic agents, or detectable labels. The increased stoichiometric ratios of these agents in the antibody conjugates lead to... Agent: Nixon Peabody, LLP

20070196276 - Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof: The present application describes a monoclonal antibody selected from the group consisting of monoclonal antibody DS6, monoclonal antibodies that specifically bind to the antigen or epitope bound by monoclonal antibody DS6, and fragments of the foregoing that specifically bind to the antigen or epitope bound by monoclonal antibody DS6. Methods... Agent: Myers Bigel Sibley & Sajovec

20070196277 - Compositions and methods for the direct therapy of tumors: The present invention provides methods for the treatment of tumors, such as spinal metastases, using compositions that permit the introduction of chemotherapeutics intratumorally while concurrently visualizing the procedure. Thus, in certain embodiments, the invention concerns a composition comprising a chemotherapeutic, an alcohol and an iodinated contrast agent (e.g., iodouracil) that... Agent: Fulbright & Jaworski L.L.P.

20070196278 - Compositions and methods for locating an internal bleeding site: The present invention relates to medical diagnostic techniques and more particularly to compositions and methods for locating an internal bleeding site in a subject.... Agent: Medlen & Carroll, LLP

20070196279 - Methods for treating progressive neurodegenerative disorders: Disclosed herein is a method for treating a progressive neurodegenerative disorder by systemically administering a composition containing an effective amount of a G-CSF receptor agonist. The composition can also be administered to inhibit the onset of a progressive neurodegenerative disorder in a subject at high risk thereof. A further method... Agent: Occhiuti Rohlicek & Tsao, LLP

20070196280 - In vivo magnetic resonance spectroscopy of aspartate transaminase activity: A non-invasive method of assessing aspartate aminotransferase (AST) activity in vivo, comprising performing in vivo magnetization transfer spectroscopy on an organ of a living subject in which AST activity is to be measured, and determining a change in magnetic resonance signal intensity of reactants in an AST catalyzed reaction.... Agent: Klarquist Sparkman, LLP

20070196284 - Liposomal assembly for therapeutic and/or diagnostic use: Composition for diagnostic or therapeutic use which comprises an assembly comprising an active agent. The assembly comprises a liposome and a plurality of micellar components associated thereto, said micellar components being associated to the outer surface of the envelope of said liposome through a substantially electrostatic interaction. When an active... Agent: Bracco Research Usa Inc.

20070196281 - Method and articles for remote magnetically induced treatment of cancer and other diseases, and method for operating such article: This invention describes unique treatment methods and innovative articles that can be placed in a human or animal body to enable controlled destruction of diseased tissue. The methods include destruction of diseased cells and tissues by magnetically controlled motion and an externally controllable drug delivery process with a capability to... Agent: Patent Docket Administrator Lowenstein Sandler PC

20070196283 - Composition for transfection of dna into the liver: A composition useful for ultrasound facilitated in vivo transfection of DNA into liver cells of a mammal comprises (a) an ultrasonic contrast agent comprising protein-stabilized gas-filled microspheres, and (b) plasmid DNA encoding apo A1. Preferably, the gass in the microspheres is air, nitrogen oxygen, or a fluorocarbon gas. In some... Agent: Olson & Hierl, Ltd.

20070196282 - Medical diagnostic ultrasound with temperature-dependent contrast agents: A temperature characteristic is detected with medical diagnostic ultrasound. Microbubble contrast agents have a phase change near 37 degrees Celsius. The phase change alters the pressure required to destroy the contrast agent or cause absorption of the contrast agent. Since the contrast agents are sensitive to local temperature, ultrasound may... Agent: Siemens Corporation Intellectual Property Department

20070196286 - Aerosol composition comprising formoterol: The use of a dry powder comprising (A) formoterol, or a pharmaceutically. acceptable salt or solvate thereof, or solvate of said salt, and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of from 400 μg to 5000 μg per μg of (A) for the preparation of an... Agent: Novartis Corporate Intellectual Property

20070196285 - Novel combination of anticholinergics - b2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases: The invention relates to novel combinations based on anticholinergics, β2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.... Agent: Venable LLP

20070196287 - Methods for bleaching and desensitizing teeth: Composition and methods include a dental bleaching agent, potassium nitrate a fluoride salt for enhanced whitening and reduced tooth sensitivity. The potassium nitrate and fluoride salt both reduce or eliminate tooth sensitivity that may otherwise be caused by the bleaching agent. For prolonged treatment of teeth, lower quantities of potassium... Agent: Workman Nydegger (f/k/a Workman Nydegger & Seeley)

20070196293 - Compositions and methods for treating photo damaged skin: The present invention is drawn to formulations, methods, and solidified layers for topical delivery of an immune modulating agent for treatment of photo damaged skin. The formulation can include an immune modulating agent, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system having... Agent: Thorpe North & Western, LLP.

20070196295 - Cosmetic compositions and methods of making and using the compositions: Cosmetic compositions which, when applied to the skin, mask skin imperfections and provide more uniform skin tone are described. The compositions can be formulated to address the needs of users having a specific skin tone. The compositions include one or more pigments (e.g., iron oxides) and may also include reflective... Agent: Merchant & Gould PC

20070196291 - Cosmetic comprising a silicone polymer: s

20070196292 - Personal care composition comprising dehydroacetate salts: Personal care composition comprising a dehydroacetate salt, and a dermatologically acceptable carrier, wherein the pH of said composition is about 7.0 and greater.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070196294 - Photostable sunscreen compositions comprising dibenzoylmethane compound uv-a filters and s-triazine compounds: Photostable sunscreen compositions containing at least one dibenzoylmethane compound UV-A screening agent and at least one particular s-triazine compound have improved effectiveness with respect to UV-A radiation.... Agent: Buchanan, Ingersoll & Rooney PC

20070196289 - Use of licochalcone a or of an extract of licochalcone a from radix glycyrrhizae inflatae against skin aging: Use of licochalcone A or of an extract containing licochalcone A from Radix Glycyrrhizae inflatae in cosmetic and dermatological preparations for the treatment and prophylaxis of the symptoms of intrinsic and/or extrinsic skin ageing and the treatment and prophylaxis of the damaging effects of ultraviolet radiation on the skin.... Agent: Greenblum & Bernstein, P.L.C

20070196290 - Uv filters in powder form: The present invention relates to UV filters in powder form, obtainable by spray-drying or freeze-drying a dispersion comprising UV filters, processes for the preparation of UV filters in powder form, and compositions comprising UV filters in powder form.... Agent: Millen, White, Zelano & Branigan, P.C.

20070196296 - Personal care compositions: Personal care compositions comprising an active component, use of such compositions, and methods of marketing such compositions. The personal care compositions can be applied topically, ingested orally, injected, or used as part of a regimen.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070196298 - Cosmetic and dermatological formulations with natural pigments and methods of use: Pigments from plant products can be combined with a cosmetic carrier formulation to create a cosmetic and/or dermatological product for transferring color to the skin of the person. A plant product extract or reformulation, such as a concentrate, flake or powder of the plant, can be combined with a cosmetic... Agent: Blakely Sokoloff Taylor & Zafman

20070196299 - Personal care compositions comprising responsive particles: Personal care compositions comprising responsive particles. In one aspect, the responsive particle comprises: (1) a particle core having an interfacial surface, (2) a first polymer having a first property, and (3) a second polymer having a contrasting property. The first polymer and the second polymer are attached at different locations... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070196297 - Production of photoluminescent silicon nanoparticles having surfaces that are essentially free of residual oxygen: The present invention relates to a method for preparing photoluminescent silicon nanoparticles having uniformly hydrogen-terminated surfaces that are essentially free of residual oxygen. The present invention also relates to a method of preparing a blue-emitting photoluminescent silicon nanoparticle. The present invention further relates to a composition that includes a photoluminescent... Agent: Nixon Peabody LLP - Patent Group

20070196301 - Cosmetic composition with a volumizing effect: e

20070196300 - Multi-phase, emulsion-containing compositions: The invention relates to a composition, especially a cosmetic composition, containing (a) an external oil phase; (b) an internal aqueous phase; and (c) an internal water-in-oil emulsion.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070196302 - Polymetal hydroxychloride processes and compositions: enhanced efficacy antiperspirant salt compositions: The invention describes processes for the production of basic aluminum compounds, including aluminum chlorohydrate, basic zirconium compounds, and basic aluminum zirconium compounds. The process produces products of a wide range of basicities. The products formed by the present invention are comprised of low molecular weight species characteristic of enhanced efficacy... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070196303 - Stable buffered aluminum compositions having high hplc bands iii and iv containing calcium/strontium: A novel aluminum antiperspirant active composition of enhanced efficacy is provided. The composition is activated by both heat and acid and characterized by having high HPLC Band III and high HPLC Band IV, prepared by the addition of an acid such as AlCl3 to (1) the aluminum calcium and/or strontium... Agent: Arthur J. Plantamura General Chemical Performance Products LLC.

20070196304 - Odor eliminating foot powder composition: A powder composition for eliminating foul odors associated with bromhidrosis and hyperhidrosis includes aluminum potassium sulfate in an amount of between 22% and 62% by weight, zinc oxide in an amount of between 8% and 36% by weight, and zinc undecylenate in an amount of between 6% and 34% by... Agent: Robert M. Downey, P.A.

20070196305 - Method for identifying hair conditioner-resistant hair-binding peptides and hair benefit agents therefrom: A method for identifying hair conditioner-resistant hair-binding peptides is described. The hair conditioner-resistant hair-binding peptides bind strongly to hair from a hair conditioner matrix and are stable therein. Peptide-based benefit agents, such as hair conditioners and hair colorants, based on the hair conditioner-resistant hair binding peptides are described. The peptide-based... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070196308 - Antiperspirant clear gel with low glycol content: An elastomer-free, suspension-free, water-in-oil emulsion as a clear gel with a viscosity >150,000 centipoise; and an overall level of silicone emollients ≦3 weight % as: (a) an internal phase comprising a glycine-free antiperspirant active stabilized by Betaine; and a glycol system having ≦7.5 weight % propylene glycol; and (b) an... Agent: Colgate-palmolive Company

20070196309 - Linear silicone resins in personal care applications: The present invention relates to the use in personal care products of a series of novel silicone polymers (referred to as linear silicone resin) that by are made by the hydrosilylation reaction of a terminal vinyl silicone and a terminal silanic hydrogen polymer. The properties make the compounds very useful... Agent: Anthony J O'lenick Jr

20070196310 - Stable vitamin c compositions: Disclosed is a composition comprising ascorbic acid or a derivative thereof, a silicone containing compound, and an essential oil, wherein at least 50% of the initial amount of the ascorbic acid in the composition remains stable when the composition is stored for at least 1 month at room temperature. The... Agent: Fulbright & Jaworski L.L.P.

20070196313 - Cleansing compositions containing film: A composition comprising a cleanser base and a plurality of film pieces, wherein the composition has a moisture content of about 22% or less. Also, a method of making a composition, comprising the steps of combining pieces of film with a cleansing material to make a cleansing mixture, and forming... Agent: Colgate-palmolive Company

20070196311 - Methods and kits for topical administration of hyaluronic acid: The present invention provides a method for treating the skin of a subject comprising (a) applying an HA liquid to an area of the skin, wherein the HA liquid comprises hyaluronic acid, hyaluronate, cosmetically acceptable salts of hyaluronic acid, intramolecular esters of hyaluronic acid and/or intermolecular esters of hyaluronic acid;... Agent: Kenyon & Kenyon LLP

20070196312 - Methods and kits for topical administration of hyaluronic acid: The present invention provides a method for treating the skin of a subject comprising (a) applying an HA liquid to an area of the skin, wherein the HA liquid comprises hyaluronic acid, hyaluronate, cosmetically acceptable salts of hyaluronic acid, intramolecular esters of hyaluronic acid and/or intermolecular esters of hyaluronic acid;... Agent: Kenyon & Kenyon LLP

20070196314 - Treatment and composition for achieving skin anti-aging benefits by corneum protease activation: Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing... Agent: Fulbright & Jaworski L.L.P.

20070196315 - Botanical extract compositions and process for preparing same: The present invention relates generally to the use of botanical extract compositions, which contain ingredients with self-preserving properties for use in cosmetic or dermatological compositions.... Agent: Forrest L. Collins

20070196307 - Method for lengthening keratin fibers: There is a method for lengthening keratin fibers. The method has the steps of a) applying to the keratin fibers a composition having a solvent and one or more polymers soluble or solubilizable in the solvent b) allowing the solvent to evaporate. The composition is applied in an amount sufficient... Agent: Charles N. J. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070196306 - Process for coating eyelashes: The disclosure relates to a process for coating keratin fibers, comprising the application to the keratin fibers of at least one coat of at least one dry-applicable composition presented in the form of a stick. The disclosure also relates to a process for coating keratin fibers, comprising placing the fibers... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070196317 - Body care composition: There is body care composition including botanical oils. The composition includes tea tree oil; lavender oil; myrrh; and/or sandalwood oil. There is a surfactant base such as but not limited to shampoo and/or a mild dishwashing detergent. The tea tree oil may be from about 2%, 5%, or 8% to... Agent: Advantia Law Group

20070196318 - Cosmetic herbal compositions: Herbal cosmetic skin care compositions formulated to combat conditions associated with oxidative stress are provided. The compositions contain effective amounts of one of several active agents, including an herbal agent derived from one or more of the plant species, as well as cosmetically acceptable carriers. Other agents that may be... Agent: Bozicevic, Field & Francis LLP

20070196316 - Stimulation of hair growth by ginkgo biloba flavanoids: Flavanoid components of the Ginkgo biloba tree are useful to stimulate the growth of hair and are thus treatment of alopecia or baldness.... Agent: Morrison & Foerster LLP

20070196319 - Methods of producing, marketing and using odor control compositions: Odor control compositions include a source of nitrogen, a non-salt source of oxygen, and a surfactant. The compositions added to a biomass in a concentration sufficient to produce a noticeable stimulation of aerobic activity. Preferred compositions include at least one of ammonium nitrate and urea, as well as calcium nitrate,... Agent: Rutan & Tucker, LLP. Hani Z. Sayed

20070196320 - Bioadhesive compositions and their use in medical electrodes: This invention relates to bioadhesive compositions, which are particularly, but not exclusively, useful for making medical electrodes and to medical electrodes based on such compositions. A first bioadhesive composition comprises: 10 (i) 28-60 wt % of a copolymer comprising repeating units derived from one or more monomers selected from olefinically... Agent: David Silverstein Andover-ip-law

20070196321 - In vivo stimulation of intestinal transporters for excretion of nitrogenous wastes: A method for stimulating active transporters of metabolic waste, in particular urea and creatinine, in the GI tract of a mammal, comprising the step of administering an effective amount of a concentrator activation agent to the intestinal tract of the mammal, is disclosed. Methods for concentrating metabolic wastes in the... Agent: Bell, Boyd & Lloyd LLP

20070196322 - Method of preparing the colon for virtual colonoscopy: An osmotic laxative followed by a bowel movement, followed by a stimulant laxative produces safe and effective cleansing of the colon with a minimal volume of liquid remaining in the colon in preparation for visualizing the interior of the colon by virtual colonoscopy. Administering to a patient a reduced volume... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070196323 - Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs: The present invention is drawn to adhesive solidifying formulations, and methods for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a polyvinyl alcohol. The solvent vehicle can include a volatile solvent system including water and an alcohol solvent, e.g., ethanol, propanol, and/or isopropanol,... Agent: Thorpe North & Western, LLP.

20070196324 - Cellulite skin treatment methods and compositions: Methods for treating cellulite-affected areas on a human body include applying, to affected skin areas, while dry, a skin scrub that includes certain oils, menthone glycerin acetal, and certain organic extracts, then removing the scrub, moistening the affected areas, and applying a skin cream that includes caffeine, certain organic extracts... Agent: Wagner, Anderson & Bright, LLP

20070196325 - Compositions and methods for dermally treating infections: The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug which can treat various skin infections, such as fungal, bacterial, and/or viral skin infections. The formulation can include an anti-infective drug, a solvent vehicle, and a solidifying agent.... Agent: Thorpe North & Western, LLP.

20070196326 - Process for the preparation of polyorganosilylated carboxylate monomers or polymers thereof: e

20070196327 - Nitric oxide releasing polymers: This invention relates to compositions comprising carbon-based diazeniumdiolates attached to hydrophobic polymers that releases nitric oxide (NO). The carbon-based diazeniumdiolated polymers release NO spontaneously under physiological conditions without subsequent nitrosamine formation. The present invention also relates to methods of preparing the carbon-based diazeniumdiolated polymers, compositions comprising such polymers, methods of... Agent: Foley And Lardner LLP Suite 500

20070196328 - Preservative for medical devices: The invention relates to the field of disinfection and preservation of surfaces of medical devices. The object of the invention is to make available a disinfectant that provides effective decontamination of medical devices while at the same time being toxicologically safe. This object is achieved through the use of solution... Agent: Jacobson Holman PLLC

20070196329 - Disinfection efficacy of lens care regimen for rigid gas permeable contact lenses: A rigid gas permeable lens care composition. The composition includes a disinfecting amount of at least one biguanide antimicrobial agent and a straight chain polyether surfactant based upon PEO-PPO-PEO, PPO-PEO-PPO and combinations thereof. In one embodiment, the straight chain polyether surfactant has an HLB value of less than or equal... Agent: Paul T. Lavoie Bausch & Lomb Incorporated

20070196331 - Methods and compositions for mobilizing stem cells: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the... Agent: Biotechnology Law Group C/o Portfolioip

20070196330 - Methods of using n-{[2-(2,6-dioxo(3-piperidyl)-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl-carboxamide for the treatment and management of myelodysplastic syndromes: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active... Agent: Jones Day

20070196332 - Cytotoxic agents comprising taxanes and their therapeutic use: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent... Agent: Sughrue, Mion, Zinn, Macpeak & Seas, PLLC

20070196333 - Composition comprising mixtures of ifn-alpha subtypes: A composition of human interferon-alpha (IFN-α) subtypes produced from human lymphoblastoid cells is disclosed. These purified IFN-α composition comprise higher specific activities and may be applied in the treatment of cancers, viruses, and immuno diseases.... Agent: Baker & Mckenzie LLP

20070196338 - Heparin and heparan sulfate binding chimeric vectors: The present invention is based on the finding that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. In some embodiments, a substitution of a single amino acid that is unique to the AAV6 capsid (Lys-531) among other AAVs that... Agent: Myers Bigel Sibley & Sajovec

20070196335 - Immune modulation by regulating expression of the \"minor\" gene in immune dendritic cells: Mitogen induced nuclear orphan receptor (MINOR) is described as inducing apoptosis in dendritic cells (DCs). Downregulation of its expression results in a downregulation of apoptosis. A novel approach of inhibiting DC apoptosis is described employing small interfering RNA (siRNA) that targets MINOR. Improved DC-based vaccines exhibiting longer lifespan of DCs,... Agent: Edwards Angell Palmer & Dodge LLP

20070196336 - Method for constructing recombinant herpes simplex virus: A method is provided for rapidly and reliably constructing recombinant herpes simplex virus (HSV) capable of expressing a target protein in cancer cells. The method for constructing recombinant HSV as claimed in the present invention comprises a first step of inserting into a herpes simplex virus (HSV) genome, a BAC... Agent: Morgan Lewis & Bockius LLP

20070196339 - Modified hpv e6 and e7 genes and proteins useful for vaccination: Described are DNA sequences encoding an E6 or E7 fusion protein of HPV, wherein said DNA sequences are characterized by a combination of the following features: original codons are exchanged by codons which lead to an enhanced translation in a mammalian cell, they contain a deletion resulting in the production... Agent: Intellectual Property / Technology Law

20070196334 - Modified vectors for organelle transfection: The present disclosure provides compositions and methods for direct transfection of organelle DNA in living cells. More particularly, the present disclosure is based on the use of viral vectors that contain localization signals specific for the target organelle. In one embodiment a viral vector that has been modified to express... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070196337 - Recombinant perforin, expression and uses thereof: The present invention relates to retroviral vectors capable of driving the expression of perforin in a cell and a method of expressing recombinant perforin in a cell. The present invention also relates to recombinant perforin polypeptides and nucleic acid molecules derived therefrom and uses thereof. Also encompassed are screening assays... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070196346 - Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer: A genetic vaccine construct comprising a poxvirus vector which incorporates and, on administration to a subject, expresses in a cell of said subject a sequence of nucleotides encoding a prostate-specific polypeptide, wherein said poxvirus vector does not productively infect said subject. The genetic vaccine construct is for treatment of prostate... Agent: Scully, Scott, Murphy & Presser, P.C.

20070196340 - Modulation of pathogenicity: g

20070196341 - Preventive and/or remedy for inflammatory bowel diseases: The present invention relates to a preventive and/or a therapeutic agent for inflammatory bowel diseases containing a fermentation product of a propionic acid bacterium as an active ingredient.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070196345 - Antibody recognizing proliferative human liver cells, proliferative human liver cells and functional human liver cells: The invention provides a monoclonal antibody which specifically recognizes proliferative human hepatocytes, a method for isolating proliferative human hepatocytes by using the antibody, and a method for inducing to differentiate the proliferative human hepatocytes to functional human hepatocytes. Further, the invention provides the proliferative human hepatocytes and functional human hepatocytes... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070196343 - Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease: Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according... Agent: Ernest D. Buff Ernest D. Buff & Associates, LLC

20070196342 - Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects: A composite for treating an articular defect includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor and a cellular differentiation factor, which is impregnated in, or coupled to, the hyaluronic acid derivative. In one embodiment, carboxyl functionalities of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070196344 - Methods for identifying materials that can help regulate the condition of mammalian keratinous tissue: Methods for identifying materials that can help regulate the condition of mammalian keratinous tissue (e.g., skin, hair, and/or nails), and the use of such materials selected by such methods (e.g., preparation of cosmetic compositions). The methods can also be used to generate data that can be used to support marketing... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070196347 - Methods for preventing neurological events: The present invention relates to therapeutic methods for preventing or reducing neurological events utilizing a glycosaminoglycan and a serpin, including complexes and conjugates thereof. Methods of the present invention may be advantageous for preventing or reducing neurological events prior to, or during medical or surgical procedures, and after a neurological... Agent: Mccarthy Tetrault LLP

20070196349 - Whitening composition containing reduced coenzyme q: The present invention provides a cosmetic or food composition which is excellent in a skincare effect, particularly an effect of whitening the skin browned due to ultraviolet radiation or aging, and which can be safely used for many mammals. The present invention provides a whitening composition comprising reduced coenzyme Q... Agent: Sughrue Mion, PLLC

20070196350 - Compositions and methods for effecting controlled posterior vitreous detachment: A composition comprises plasmin or an enzymatically equivalent derivative thereof and at least an anti-inflammatory medicament. The composition can be used to effect or induce a controlled posterior vitreous detachment (“PVD”) to prevent, treat, or ameliorate a potential complication of a pathological ocular condition. Such a composition can be administered... Agent: Bausch & Lomb Incorporated

20070196351 - Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity: A method of treatment of native, non-denatured tissue to increase resistance to tearing, fissuring, rupturing, and/or delamination, comprising the step of: contacting at least a portion of the tissue with an effective amount of a reagent that increases crosslinks in the tissue.... Agent: Berliner & Associates

20070196352 - Vegf-induced genes and their therapeutic use: The present invention concerns products for therapeutic use comprising a gene, or product thereof, identified as upregulated by VEGF (vascular endothelial growth factor). Products of the invention can be used, for example, in arterioprotection or promoting angiogenesis.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070196353 - Method for reducing allergenicity in indoor spaces: According to this invention, allergenicity in an indoor space is reduced by denaturing allergens in allergen reservoirs that are capable of producing respiratory or skin reactions and physically removing the allergens from the allergen reservoirs in the indoor space. The allergen reservoirs may also be treated with pesticides and fungicides/fungistats... Agent: Hunton & Williams LLP Intellectual Property Department

20070196354 - Method of treating diabetes by inhibiting degradation of at least one of crebl1, atf6, and hnf-4 alpha by htra: The present invention found the interaction of CREBL1 and HNF-4α with HtrA2 and revealed for the first time that CREBL1, ATF6, and HNF-4α are degraded by active HtrA2. In addition, the present invention provides a means for inhibiting the degradation of at least one of CREBL1, ATF6, and HNF-4α, comprising... Agent: Kilyk & Bowersox, P.l.l.c.

20070196355 - Method to treat atherosclerosis: A theory has been presented that provides a simplified explanation of a cohesive mechanism of embryological development, hemostasis, coagulation, wound repair and tissue maintenance that operates continuously in the animal body to oppose the effects of stress. The theory endeavors to fit all known facts, and is based on the... Agent: Cislo & Thomas, LLP

20070196356 - Topical bite care composition: The present invention is directed to a topical bite care composition for treating insect bites. The composition contains a steroid and a proteolytic enzyme and/or an antipruitic. The composition can be applied to the skin in any liquid form over the affected area.... Agent: Stuart D. Frenkel Frenkel & Associates

20070196357 - Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution: Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can... Agent: Leydig Voit & Mayer, Ltd

20070196358 - Seed treatment pesticidal compositions: An aqueous seed treatment insecticidal and/or nematicidal composition in the form of a suspension comprising (A) at least one insecticide and/or nematicide in an amount of at least 3 weight %, based on the total weight of the composition, and (B) at least two surface active compounds, wherein (i) at... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070196359 - Halosuccinimide biocide: The present invention relates to biocides. More particularly, the present invention relates to a novel solution that is an effective high level disinfectant biocide. The present invention biocide includes a halide substituted N-succinimide in an aqueous solution in the pH range of 2-6. The biocide also includes N-succinimide as a... Agent: Faegre & Benson Attn: Patent Docketing

20070196362 - Computational methods and systems to bolster an immune response: The present application relates, in general, to a system and/or method for detection and/or treatment.... Agent: Searete LLC Clarence T. Tegreene

20070196361 - Long term administration of pharmacologically active agents: In accordance with the present invention, there are provided methods useful for the treatment of a subject having an infirmity. Invention methods comprise administering to a subject a sub-therapeutic dose level of a pharmacologically active agent (such as the anticancer drug paclitaxel) effective against an infirmity over an administration period... Agent: Morrison & Foerster LLP

20070196360 - Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors: Maleimide and succinimide derivatives were found to be effective topoisomerase II catalytic inhibitors. Due to this property, the maleimide and succinimide derivatives were investigated for their use as cytostatic agents and thus in the treatment of cancer. The compounds of the invention can be used in combination treatments with other... Agent: Foley And Lardner LLP Suite 500

20070196365 - Immunoglobulin heavy chain variants expressed in mesenchymal cells and therapeutic uses thereof: Mesenchymal cells are unexpectedly found to express specific truncated versions of immunoglobulin (Ig) superfamily members, Igμ heavy chain and Igδ heavy chain variants. Mesenchymal Ig heavy chain gene products either directly or indirectly control hemopoietic stem cells. Ectopic expression, RNAi or antibody therapy can be used to modulate Ig heavy... Agent: Winston & Strawn LLP Patent Department

20070196363 - Method for making multispecific antibodies having heteromultimeric and common components: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody... Agent: Heller Ehrman LLP

20070196364 - Pharmaceutical formulation and process: A process for lyophilization or freeze-drying of a pharmaceutical product is provided and a liquid formulation suitable for lyophilization. In particular, a process for lyophilization or freeze-drying a liquid formulation that includes a protein active agent, a bulking agent and a saccharide stabilizing agent is provided. The saccharide to bulking... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070196367 - Methods of preventing and treating alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system: This invention proposes that the best therapeutic strategy for treating and/or preventing Alzheimer's disease (AD), age related macular degeneration (AMD) and other diseases that exhibit extra-cellular debris deposits, such as atherosclerosis, is the inhibition of the complement pathway. A model for the accumulation of extra-cellular debris through the activation of... Agent: Valentin Dinu

20070196366 - Methods for treating cancer using an immunotoxin: The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific... Agent: Heller Ehrman LLP

20070196368 - Method for controlled induction of somatic mutations and use thereof in proteomics: The invention concerns a method for inducing somatic mutations in vitro or ex vivo, comprising (1): adding to the cells to be mutated, in culture conditions and in a medium suited to said cells, of at least a combination of anti-IgM and anti-CD19 and/or anti-DC21 antibodies, while (2) said anti-IgM... Agent: Marina Larson & Associates, LLC

20070196369 - Mhc-peptide complex binding ligands: Disclosed are protein ligands comprising an immunoglobulin heavy chain variable (VH) domain and an immunoglobulin light chain variable (VL) domain, wherein the proteins bind a complex comprising an MHC and a peptide, do not substantially bind the MHC in the absence of the bound peptide, and do not substantially bind... Agent: Martin D. Moynihan Prtsi, Inc.

20070196371 - Soluble il-17rcx4 and methods of using in inflammation: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes... Agent: Zymogenetics, Inc. Intellectual Property Department

20070196370 - Type 2 cytokine receptor and nucleic acids encoding same: The present invention provides novel isolated CRF2-12 polynucleotides and polypeptides encoded by the CRF2-12 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-12 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-12 polypeptide, polynucleotide or antibody. The invention additionally provides methods in... Agent: Finnegan Henderson, LLP/wyeth

20070196373 - Anti-tnf antibodies and peptides of human tumor necrosis factor: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070196374 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20070196376 - Binding proteins specific for insulin-like growth factors and uses thereof: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain... Agent: Knobbe Martens Olson & Bear LLP

20070196372 - Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8): The invention provides a human KLK8 which is associated with the cardiovascular diseases, dermatological diseases, neurological diseases, metabolic diseases, cancer disorders, urological diseases, gastroenterological diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, neurological... Agent: Banner & Witcoff, Ltd.

20070196375 - Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers: A method for delivering a biologic to a human with Alzheimer's-related dementia, comprising administering the biologic parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human's head below the horizontal. The method further includes delivering a TNF antagonist to the brain of a... Agent: Ezra Sutton, Esq.

20070196377 - Gene encoding a guanmine nucleotide exchange factor and the gene product thereof: A gene encoding a novel protein that works as a guanine nucleotide exchange factor (GEF) for a Rho family protein being one group of small GTP-binding proteins, namely, a polynucleotide shown by the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO:... Agent: Kilyk & Bowersox, P.l.l.c.

20070196378 - Hyphae-specific cell wall proteins of candida: Nucleic acids that code a cell wall protein required for the hyphal development of Candida; fragments of the nucleic acids; vectors containing the nucleic acids or nucleic acid fragments; host cells containing the vectors; cell wall proteins coded by the nucleic acids; antibodies directed against the proteins; methods for producing... Agent: Ostrolenk Faber Gerb & Soffen

20070196379 - Methods for treating congestive heart failure: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.... Agent: Klauber & Jackson

20070196380 - Extracellular matrix to treat malignancy in mammals: The invention is compositions and methods for inhibiting growth of an abnormally proliferating cell in a mammal; methods include inhibiting growth of abnormally proliferating cells after tumor resection, and methods of recruiting stem cells to a site of malignancy; compositions include liquid or semi-solid extracellular matrix compositions having specified concentrations... Agent: Leigh Hunt Firestone

20070196381 - Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions: Herbal based compositions for enhancing immunomodulation in mammals are disclosed in which a combination of herbal products and extracts thereof are included for their complementary and substantially simultaneous effect on different parts of the immune cascade. In preferred aspects, the herbal products and extracts thereof include a mixture of Shiitake... Agent: Lucas & Mercanti, LLP

20070196382 - Saccharomyces cerevisiae strains for hyper-producing glutathione and gamma-glutamylcysteine and processes of use: The present invention provides a biologically pure culture of Saccharomyces cerevisiae strain YA02032 or YA03083, which culture has a characteristic nature capable of producing glutathione and the precursor thereof, γ-glutamylcysteine. A composition comprising the culture and a process for the production of glutathione and/or the precursor thereof, γ-glutamylcysteine, are also... Agent: Ladas & Parry

20070196383 - Green algal extract containing astaxanthin having high storage stability: The present invention provides means for increasing the storage stability of astaxanthin in a green algal extract, and a green algal extract containing astaxanthin having high storage stability. The present invention provides a green algal extract comprising astaxanthin at a concentration of 0.5 to 20 wt % expressed in terms... Agent: Le-nhung Mcleland

20070196384 - Novel glycolipid adjuvant compositions: This invention relates to compositions and methods of preparing stable adjuvant diluent stock solutions and final adjuvant solutions comprising glycolipids, weak acids, alcohols, nonionic surfactants and buffers.... Agent: Pharmacia & Upjohn

20070196386 - Stable retrovirus and methods of use: The present invention is a mutant retroviral protease which confers an increase in retroviral stability. Retroviruses expressing the instant mutant retroviral protease exhibit at least a 2-fold increase in infectivity half-life as compared to wild-type retrovirus. Unexpectedly, a Gly119Glu mutation in the protease enhances retroviral stability in the presence of... Agent: Licata & Tyrrell P.C.

20070196385 - Method of treating hepatitis c infection: The present invention provides the use of PEG-IFN-α conjugates in association with ribavirin for the treatment of chronic hepatitis C infections. The present invention also provides a method for treating chronic hepatitis C infections in patients in need of such treating comprising administering an amount of PEG-IFN-α conjugate in association... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070196388 - Cold-adapted equine influenza viruses: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity,... Agent: Heska Corporation Intellectual Property Dept.

20070196387 - Novel assay for the separation and quantification of hemagglutinin antigens: The present invention relates to novel methods for separating hemagglutinin (HA) antigens, comprising the steps of applying a reduced and derivatized antigen preparation comprising solubilized HA antigens and a detergent in a pH controlled solution, on a Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) column; and eluting the HA antigens from the... Agent: Trask Britt

20070196390 - Equine herpesvirus vaccine: A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus) and an adjuvant. The adjuvant can include a cross-linked olefinically unsaturated carboxylic acid polymer which may have bioadhesive properties. The vaccine may also... Agent: Foley & Lardner LLP

20070196389 - Viral gene products and methods for vaccination to prevent viral associated diseases: Methods of vaccination to prevent virus-associated diseases, which methods generally result in an increase of virus-specific memory T cells that provide or restore host immunity and result in control of the viral-associated disease process. Polypeptides and DNA sequences for achieving these results are also described. In some embodiments, the virus... Agent: Calfee Halter & Griswold, LLP

20070196391 - Mucosal boosting following parenteral priming: Mucosal immunization using one or more antigens following parenteral administration of the same or different antigens is described.... Agent: Banner & Witcoff, Ltd.

20070196392 - Development of a chlamydia sp. vaccine strain: The invention involves the discovery that Chlamydia sp. strains can be cured of their plasmids by treatment with novobiocin, and that plasmid-deficient strains are defective in infecting cells under standard conditions, but can infect cells if centrifuged onto the host cells. But it is found that plasmid-deficient strains with wild-type... Agent: Hugh Mctavish Mctavish Patent Firm

20070196393 - Recombinant neospora antigens and their uses: The present invention provides isolated bovine Neospora cultures. Also provided are recombinant immunodominant Neospora antigens. The cultures and antigens are used to develop diagnostic assays for the detection of Neospora infections in cattle and other animals. Also provided are pharmaceutical compositions for the treatment and prevention of Neospora infections.... Agent: Townsend And Townsend And Crew, LLP

20070196394 - Immunogenic compositions comprising liver stage malarial antigens: A vaccine composition comprising a Th1-inducing adjuvant in combination with a protecting Liver Stage Antigen or immunological fragment thereof of a human malaria parasite, especially Plasmodium falciparum, with the proviso that when the immunological fragment is an immunological fragment of LSA-3 the Th1-inducing adjuvant is not Montanide. In one preferred... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070196395 - Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain: Small molecular-weight non-peptidic compounds block Lck SH2 domain-dependent interactions. The inhibitors omit phosphotyrosine (pY) or related moieties.... Agent: Millen, White, Zelano & Branigan, P.C.

20070196399 - Enteric-coated preparation covered with enteric coating material for site-specific delivery of drug to site within the small intestine: Provided is an enteric-coated preparation comprising an enteric coating material capable of delivering a drug to a site within the small intestine in a site-specific manner. More specifically, provided is an enteric-coated preparation for delivering a drug to a site within the small intestine in a site-specific manner, comprising a... Agent: Roberts, Mlotkowski & Hobbes

20070196396 - Controlled release pharmaceutical compositions with improved bioavailability: The present invention provides a controlled release oral pharmaceutical composition having a therapeutically effective amount of one or more pharmacologically active agent having low bioavailability; one or more solubilizers; one or more biocompatible swelling agents; and a swelling enhancer. The swelling agent, in combination with swelling enhancer, swells in the... Agent: Merchant & Gould PC

20070196398 - Fluoroquinolone fatty acid salt compositions: The invention relates to pharmaceutical compositions of a fatty acid salt of a fluoroquinolone and to methods of treating a condition in an animal by administering to an animal in need thereof the pharmaceutical composition of the invention.... Agent: Kenyon & Kenyon LLP

20070196397 - Method and device for producing micro-droplets: A method and an apparatus for producing various types of microdroplets. The apparatus has a cross intersection portion at which a first continuous phase, a first dispersion phase, and a second dispersion phase intersect with each other. A first liquid feed device controls the first dispersion phase and a second... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070196403 - Anhydrous cosmetic compositions: An anhydrous cosmetic composition may comprise an inorganic heat generating agent which generates a heat by mixing with water; from about 0.1% to about 10% of a polyoxyalkylene derivative; from about 0.2% to about 20% of a phase-changing material; from about 0.1% to about 10% of a cationic conditioning agent;... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070196402 - Method of preparing a cosmetic composition, and an assembly and a refill for implementing such a method: A method of preparing a cosmetic composition includes selecting at least one enclosure from a plurality of enclosures containing different substances, and causing a fluid to flow through the enclosure(s). The enclosures may be disposed on a common extractor apparatus and/or form part of a common refill. The fluid passing... Agent: Oliff & Berridge, PLC

20070196401 - Nano-fiber compound solutions, emulsions and gels, production method thereof, nano-fiber synthetic papers, and production method thereof: This invention provides compound solutions, emulsions and gels excellent in homogeneous dispersibility and long-term dispersion stability and also excellent in the properties as cosmetics, using disarranged nanofibers not limited in either form or polymer, widely applicable and small in the irregularity of single fiber diameter. This invention also provides a... Agent: Ip Group Of Dla Piper US LLP

20070196400 - Spherical cosmetic preparations for topical application: A cosmetic or dermatological preparation based on a W/O emulsion which is present as a plurality of shaped bodies. The shaped bodies are solid, semisolid and/or dimensionally stable at room temperature and comprise one or more of a wax, a lipid, an emulsifier, a natural polymer and a synthetic polymer.... Agent: Greenblum & Bernstein, P.L.C

20070196405 - Fibrous structures comprising volatile agents: Fibrous structures that comprise volatile agents, sanitary tissue products comprising such fibrous structures, articles of manufacture comprising such fibrous structures and processes for making same are provided. More particularly, fibrous structures that comprise unrestrained volatile agents, sanitary tissue products comprising such fibrous structures, articles of manufacture comprising such fibrous structures... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070196404 - Laminates of chitosan films: Chitosan films and laminates made from the films are provided. The films and laminates can be used to make a variety of finished articles that can be used to provide protection from hazardous chemical and biological agents.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070196406 - 1,3-dimethylbutyl carboxanilides for controlling undesirable micro-organisms: i

20070196407 - Alkoxyphenylcarboxylic acid derivatives: Use of compounds of formula (I) wherein R1 is substituted or unsubstituted C8-C30alkyl or substituted or unsubstituted C3-C7cyclo-alkyl, and R2 is H, COOH or substituted or unsubstituted O-C1-C30alkyl, in the antimicrobial treatment of surfaces, in the preservation of cosmetics, household products, textiles and plastics, and for use in disinfectants.... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070196409 - Compositions and methods for the treatment and prevention of disease in plants: Non-toxic, naturally derived and economical compositions for treating and preventing bacterial or fungal disease in plants, especially citrus canker, wherein such compositions include various combinations of d-limonene, wax and monohydric alcohol are provided. Methods for making and using such compositions are also provided.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20070196408 - Nontoxic starch-based contact pesticide and method of using the same: A nontoxic starch-based contact pesticide solution which is nontoxic to humans, pets, birds, vegetation, and other non-targeted organisms, which is safe for use in agricultural applications, and which can be used without risk of harmful effects on soil systems, ground water systems , air quality, or any portion of the... Agent: Rader Fishman & Grauer PLLC

20070196411 - Microencapsulated pyrethrin: A microcapsule comprising a core material containing pyrethrin and a capsule shell wall which surrounds said core material, said shell wall material comprises gelatin and at least one polysaccharide selected from the group consisting of gum arabic and pectin is effective for controlling insects.... Agent: Sughrue Mion, PLLC

20070196410 - Slow-release microcapsule composition for safe delivery of agriculturally active material: A slow-release microcapsule composition for the safe delivery of agriculturally active material is formed using an encapsulation process. A microencapsulated suspension of agriculturally active material includes an encapsulating agent formed from a graft copolymer of starch and at least on vinyl monomer.... Agent: Jones, Tullar & Cooper, P.C.

20070196412 - Composition for the impregnation of fibers, fabrics and nettings imparting a protective activity against pests: Insecticide composition for application to a textile material or plastics material selected from the group consisting of yarn, fibers, fabric, knitgoods, nonwovens, netting material, foils, tarpaulins and coating compositions, which insecticide composition comprises a mixture including at least one insecticide and/or at least one repellent, and at least one binder;... Agent: Connolly Bove Lodge & Hutz LLP

20070196413 - Surfactant enhanced quick release pesticide granules: Provided herein are granular carriers which are impregnated with an agriculturally active ingredient and a surfactant. The compositions of the invention provide increased efficacy over granules of the prior art.... Agent: Huntsman Petrochemical Corporation

20070196415 - Depot compositions with multiple drug release rate controls and uses thereof: Injectable depot compositions with dual mechanisms of release rate control are provided for sustained beneficial agent delivery in a patient. The composition includes bioerodible particles and an injectable depot vehicle containing a bioerodible polymer in an organic solvent, for forming a bioerodible depot implant after administration to the patient. The... Agent: Philip S. Johnson Johnson & Johnson

20070196414 - Device to prevent blood leakage using intravenous catheters: A device for preventing blood leakage during use of an intravenous catheter and needle using a stopper made of a material that is air permeable when dry; upon exposure to blood or other liquids bercomes rapidly liquid impermeable; is non-toxic and validated to use on humans; is inexpensive; is stable... Agent: Lynn E Barber

20070196416 - Pharmaceutical compositions with enhanced stability: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a beneficial salt of a peptide agent formed with a strong acid that minimizes or prevents the interaction/reaction between the peptide agent... Agent: Cohen, Pontani, Lieberman & Pavane

20070196417 - Therapeutic polyanhydride compounds for drug delivery: Polyanhydrides which link low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure into polymeric drug delivery systems are provided. Also provided are methods of producing polymeric drug delivery systems via these polyanhydride linkers as well as methods of administering... Agent: Viksnins Harris & Padys Pllp

20070196419 - Composite materials based on polysilicic acid and method for the production thereof: The invention relates to composite materials based on polysilicic acid, said materials containing novel compositions which have improved material properties and can be in the form of dispersions, pastes, powders, granulated materials, layers or compact moulded bodies. The aim of the invention is to produce composite materials based on polysilicic... Agent: Jordan And Hamburg LLP

20070196418 - Drug delivery methods and devices: The invention provides devices and methods for delivering therapeutic agents to patients.... Agent: Clark & Elbing LLP

20070196420 - Fibers and yarns useful for constructing graft materials: The present invention discloses a composite yarn comprising at least one wear-resistant polymeric fiber and at least one flexible polymeric fiber. The present invention also discloses a co-extruded filament comprising a polymeric inner core and a polymeric outer sheath. The polymeric inner core comprises a flexible polymeric material and the... Agent: Philip S. Johnson Johnson & Johnson

20070196423 - Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent: A coated medical device, such as a stent, that elutes a therapeutic agent in a controlled manner is provided. The medical device may be coated with a layer of therapeutic agent and a layer of bioabsorbable elastomer over the layer of therapeutic agent. Methods of manufacturing a coated medical device... Agent: Brinks Hofer Gilson & Lione/indy/cook

20070196422 - Medical device with coating that promotes endothelial cell adherence and differentiation: Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize... Agent: Kelley Drye & Warren LLP

20070196424 - Nitric oxide generating medical devices: Medical devices having a catalyst capable of catalyzing the generation of nitric oxide attached to the medical device and methods of treating a vascular condition using the devices are provided.... Agent: Squire, Sanders & Dempsey LLP

20070196421 - Soft tissue implants and drug combination compositions, and use thereof: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.... Agent: Clark & Elbing LLP

20070196425 - Thermosensitive and biodegradable microgel and a method for the preparation thereof: The present invention provides a thermosensitive and biodegradable microgel and a method of synthesizing such microgels. The thermosensitive and biodegradable microgel is synthesized from a macromer comprising a thermosensitive block polymer co-polymerized with a biodegradable moiety encapped with a cross-linkable or polymerizable moiety at either end. The microgels of the... Agent: Morgan & Finnegan L.l.p Maria C.h. Lin

20070196426 - Biocompatible crosslinked gel: The invention relates to a method for producing a biocompatible crosslinked gel consisting in crosslinking a determined quantity of at least one type of liquid biocompatible polymer by adding a quantity of crosslinking agent, in carrying out a crosslinking reaction, in adding an additional quantity of liquid polymer whose molecular... Agent: Young & Thompson

20070196427 - Method for preparing adjustably bioresorbable sol-gel derived sio2: The present invention relates to a method for preparing a sol-gel derived SiO2 with a very fast bioresorption rate wherein a sol-gel derived SiO2 is prepared from a sol comprising water, an alkoxide or inorganic silicate and a lower alcohol using a mineral acid or a base as a catalyst... Agent: James C. Lydon

20070196428 - Nitric oxide generating medical devices: Medical devices having a catalyst capable of catalyzing the generation of nitric oxide attached to the medical device and methods of treating a vascular condition using the devices are provided.... Agent: Squire, Sanders & Dempsey LLP

20070196429 - Proteins of natural origin and materials made therefrom: The present invention is directed to proteins of natural origin and materials made therefrom, in particular to threads, fibers, foams and gels derived therefrom. The invention further provides the use of these proteins/threads and materials in the field of technology, biotechnology and/or medicine, in particular in the manufacture of wound... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070196431 - Polymeric fluorinated dioxole and medical devices comprising same: A polymeric material having improved gas permeability comprises units of fluorinated dioxole. The polymeric material may further comprise units of a hydrophobic monomer, a hydrophilic monomer, or combinations thereof. Such a polymeric material is desirably used to produce medical devices, such as ophthalmic devices that provide increased comfort to a... Agent: Bausch & Lomb Incorporated

20070196430 - Synthetic muscle-based multi-powered active contact lens: A novel active contact lens system configured to allow the wearer to alter the corrective features of the contact lens by means of a biasing force. The biasing force can, for example, be different eye drop solutions having different pH levels.... Agent: V. Gerald Grafe, Esq.

20070196432 - Antimicrobial lenses and methods of their use: This invention relates to antimicrobial lenses containing coated zeolites and methods for their production.... Agent: Philip S. Johnson Johnson & Johnson

20070196433 - Methods and devices for the sustained release of multiple drugs: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The... Agent: Edwards Angell Palmer & Dodge LLP

20070196434 - Methods of preventing or treating sinusitis with oxidative reductive potential water solution: Provided is a method for preventing or treating sinusitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable... Agent: Leydig Voit & Mayer, Ltd

20070196438 - Compositions for the treatment of osteoarthritis and to nourish the synovial fluid: The present invention relates to the use of compositions comprising hyaluronic acid and dermatan sulphate for the preparation of medicaments to be orally administered for the treatment of osteoarthritis and osteoarthritis-associated articular pain. The present invention also relates to the use of compositions comprising hyaluronic acid and dermatan sulphate for... Agent: Sughrue Mion, PLLC

20070196446 - Conjugated fatty acid esters: A conjugated fatty acid glyceride, which is formed by converting conjugated fatty acids having conjugated double bond(s) in the molecule into glycerol esters, to more effectively exert the inherent physiological effects of the conjugated fatty acids and control the bitterness or astringency of the conjugated fatty acids, thereby making the... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070196435 - Drug and food or drink for improving hyperglycemia: A compound having a cyclolanostane skeleton such as 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.... Agent: Knobbe Martens Olson & Bear LLP

20070196439 - Lactose-reduced dairy compositions and related methods: Compositions for ameliorating the symptoms associated with lactase deficiency, the composition including a lactose reduced dairy product, and an effective amount of a probiotic, a prebiotic, or a mixture thereof. The lactose reduced dairy product is selected from a fluid milk, a smoothie, a liquado, ice cream, yogurt, and a... Agent: Philip S. Johnson Johnson & Johnson

20070196442 - Method for improving the oral administration of alpha-lipoic acid: The invention provides a method for reducing esophageal irritation associated with alpha-lipoic acid upon oral administration through the use of the trometamol salt of alpha-lipoic acid. The present invention also provides for the increased solubility of alpha-lipoic acid through the use of the trometamol salt of alpha-lipoic acid. The trometamol... Agent: Kenyon & Kenyon LLP

20070196445 - Method for the prevention and treatment of cachexia and anorexia: The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of ω-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of... Agent: Thomas D. Brainard Abbott Laboratories - Ross Products Division

20070196443 - Pantoprazole multiparticulate formulations: Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose(hypromellose) and water, an enteric coat on... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070196444 - Pantoprazole multiparticulate formulations: A method of treating gastroesophageal reflux disease (GERD), ulcers of the stomach or duodenum, or Zollinger-Ellison Syndrome in a human, by administering pantoprazole sodium multiparticulates is described. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070196441 - Process for making orally consumable dosage forms: The present invention is concerned with a process for making rapidly dissolving and dispersing dosage forms, particularly orally consumable films, for the delivery of pharmaceutically active agents and with the dosage forms so obtained.... Agent: Pfizer Inc.

20070196436 - Process for preparing an edible composition comprising steroidal glycosides: A process for preparing an edible aqueous dispersion of one or more steroidal glycosides, the edible dispersion comprising one or more steroidal glycoside, and a food product comprising the dispersion, as well as methods of controlling body weight or obesity by ingesting the food product.... Agent: Unilever Intellectual Property Group

20070196437 - Slowly digesting starch and fermentable fiber: Compositions which provide slowly digestible starch and a source of fermentable dietary fiber. Microparticles in which starch is entrapped in a crosslinked matrix to provide dietary benefit. Such microparticles are used to deliver glucose to targeted regions in the small intestine for beneficial physiological effects, and fermentable dietary fiber to... Agent: Greenlee Winner And Sullivan P C

20070196440 - Treatment methods requiring phyto-ingredients: Methods of treatment of conditions which require phytosterol therapy without adversely affecting the bioavailability of lipophilic vitamins or lipophilic drugs, consisting of administering a mixture of phytosterol ester(s) (PS-E) and 1,3-diglyceride(s) (DAG) dissolved in an edible oil or fat are described herein, together with a method of improving weight management... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20070196447 - Use of antifungal compositions to treat upper gastrointestinal conditions: The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal... Agent: Baker Botts L.L.P.

20070196448 - Enantioselective oligomerization of alpha-hydroxy carboxylic acids and alpha-amino acids: An enzymatic synthesis and composition of oligomers and co-oligomers comprised of α-hydroxy carboxylic acids and α-amino acids or peptides is disclosed. In a preferred embodiment, a α-hydroxy carboxylic acid with a specific chiral configuration is linked by an amide linkage to a α-amino acid specific with a specific chiral configuration... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070196449 - Mutants of aspergillus niger phya phytase and aspergillus fumigatus phytase: The present invention is directed to an isolated nucleic acid molecule encoding mutant phytases and the isolated mutant phytases themselves. The present invention further relates to methods of using the isolated nucleic acid molecules and the isolated mutant phytases of the present invention.... Agent: Nixon Peabody LLP - Patent Group

20070196450 - Delivery system for topical medications: The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.... Agent: William J. Mcnichol, Jr. Reed Smith LLP

20070196451 - Extendable rolled delivery system: The present invention relates to a device and method for delivery of a patch, graft, implant, therapeutic agent, or other device onto tissue using a rolled delivery mechanism. In one embodiment, a rolled delivery mechanism is provided for delivering a patch to tissue when the rolled delivery mechanism is unrolled.... Agent: Kenyon & Kenyon LLP

20070196452 - Flux-enabling compositions and methods for dermal delivery of drugs: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent,... Agent: Thorpe North & Western, LLP.

20070196453 - Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs: The present invention is drawn to adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can have a volatile solvent system including at least one volatile solvent, and... Agent: Thorpe North & Western, LLP.

20070196454 - Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices: One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070196458 - Compositions and methods for dermally treating neuropathic pain: The present invention is drawn to adhesive solidifying formulations for treating neuropathic pain. The formulation can include a drug suitable for treating neuropathic pain, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent... Agent: Thorpe North & Western, LLP.

20070196459 - Compositions and methods for treating dermatitis or psoriasis: The present invention is drawn to adhesive solidifying formulations for treating skin disorders, such as dermatitis or psoriasis. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent... Agent: Thorpe North & Western, LLP.

20070196455 - Crosslinkable pressure-sensitive adhesive for skin: It is an object of the invention to provide a crosslinkable pressure-sensitive adhesive for skin that exhibits satisfactory adhesion and releasability for human skin and low irritation to skin, and a crosslinkable pressure-sensitive adhesive sheet for skin that is suitable for medical and cosmetic use, as well as to provide... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20070196456 - Smart patch: A combination of a patch and a low-frequency (inductive, LF) radiating radio transceiver tag, and antenna system, may be used to track and control electrophoretic/electro-osmotic transdermal drug delivery systems and provide fill data logs of use without complex belts that are worn by the patient or other patient-based attachments.... Agent: Oppedahl Patent Law Firm LLC - Vai

20070196457 - Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs: The present invention is drawn to adhesive formulations and methods of drug delivery. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least two volatile solvents, and a non-volatile solvent system including at least one... Agent: Thorpe North & Western, LLP.

20070196460 - External preparation for treating skin or mucosal injury caused by viral infection: An external preparation containing acetylsalicylic acid or a pharmacologically acceptable salt thereof as an active ingredient, which is used for treatment of vesicle, sore or ulcer of skin or mucosa caused by a viral infection.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070196462 - Composition and method for neuromuscular blockade: A neuromuscular blocking preparation for blocking and/or alleviating a vasospasm is provided, the preparation comprising a plurality of gas-or a gas precursor-filled microspheres, and a neuromuscular blocking agent. Methods for using such a preparation for blocking and/or alleviating a vasospasm are also provided.... Agent: Dla Piper US LLP

20070196461 - Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070196463 - Enteric soft gelatin capsule containing esomerpazole and method of preparation: The present invention relates to an improved pharmaceutical composition, in the form of a soft gel capsule resistant to digestive juice. The composition of the present invention is made up of gelatin and an enteric polymer in the form of free acid or its salt, containing used in the treatment... Agent: Merchant & Gould PC

20070196464 - Solid oral dosage form containing an enhancer: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to promote absorption of the bisphosphonate at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length... Agent: Synnestvedt & Lechner LLP

20070196465 - Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof: Combinations of one or more dihydropyridine calcium channel blockers with mixtures of omega-3 fatty acids, methods of administering such combinations, and unit dosages of such combinations.... Agent: Arent Fox PLLC

20070196470 - Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity: The present invention relates to a dietary supplement and method for a rapidly dissolving and disintegrating solid oral dosage form. Specifically, the present invention provides dietary supplements and methods for the delivery of dietary supplements comprising Arginine or derivatives thereof and Xanthinol Nicotinate or derivatives thereof. By way of oral... Agent: Kenyon & Kenyon LLP

20070196467 - Indium supplement compositions and methods therefor: A tablet for oral administration of nutritional indium comprises about 10-50 mg indium sulfate, about 4-20 mg caffeine, about 2-10% by weight cocoa powder, and about 5-10% by weight ethyl cellulose, in combination with about 50-150 μg of each of zinc oxide, copper (II) oxide, magnesium oxide, potassium iodide, selenium... Agent: David Landman, Ph.d.

20070196469 - Magnesium microtablets with sustained release: The present invention relates to magnesium coated microtablets with sustained release, i.e. magnesium slow-release products, to a regular bulk material formed therefrom, and to a bag filled with such bulk material, and to a process for producing such microtablets.... Agent: Renner Otto Boisselle & Sklar, LLP

20070196471 - Micronized eplerenone compositions: The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.... Agent: Pharmacia Corporation Global Patent Department

20070196473 - Pharmaceutical compositions containing flibanserin: The invention relates to oral pharmaceutical compositions containing flibanserin, methods for the preparation thereof and use thereof as a medicament.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070196466 - Pharmaceutical formulations containing flavouring substances with improved pharmaceutical properties: The invention relates to flavouring-containing pharmaceutical formulations with improved pharmaceutical properties, and to process for the production thereof.... Agent: Jeffrey M. Greenman

20070196472 - Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions: Compositions of tannate salts of phenylephrine and pyrilamine produced by a method that allows for the in-situ conversion and incorporation of the tannate salts in a single dosage form. The conversion process includes dissolving a salts of phenylephrine and pyrilamine in a solvent and mixing with a dispersing agent and... Agent: Moore & Van Allen PLLC

20070196468 - Simethicone solid oral dosage form: The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing... Agent: Philip S. Johnson Johnson & Johnson

20070196478 - Antiviral compositions: The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and... Agent: Philip S. Johnson Johnson & Johnson

20070196474 - Rapidly disintegrating low friability tablets comprising calcium carbonate: This invention pertains to the ability to provide rapidly disintegrating tablets through the inclusion of a calcium carbonate material in combination with other common tablet components. Such a calcium carbonate material must exhibit a sufficiently low surface area in order to boost the ability of the tablet to separate quickly... Agent: J.m. Huber Corporation Legal Department

20070196475 - Rapidly disintegrating low friability tablets comprising silica materials: This invention pertains to the ability to provide rapidly disintegrating tablets through the inclusion of a silica material in combination with other common tablet components. Such a silica material must exhibit a sufficiently low surface area in order to boost the ability of the table to separate quickly when introduced... Agent: J M Huber Corporation

20070196477 - Rapidly dissolving tablets comprising low surface area calcium phosphates: This invention pertains to the ability to provide rapidly disintegrating tablets through the inclusion of a calcium phosphate material in combination with other common tablet components. Such a calcium phosphate material must exhibit a sufficiently low surface area in order to boost the ability of the table to separate quickly... Agent: J.m. Huber Corporation Legal Department

20070196476 - Rapidly dissolving tablets comprising low surface area titanium dioxide: This invention pertains to the ability to provide rapidly disintegrating tablets through the inclusion of a titanium dioxide material in combination with other common tablet components. Such a titanium dioxide material must exhibit a sufficiently low surface area in order to boost the ability of the tablet to separate quickly... Agent: J M Huber Corporation

20070196479 - Method for the timed dosage of medicaments: The invention relates to a method for the controlled dosage of a medicament as a function of time by means of a method for the determination of a corresponding dosage profile and corresponding control of a dosage instrument.... Agent: Norris, Mclaughlin & Marcus, Pa

20070196480 - Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof: The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 hrs. Accordingly, the sustained... Agent: Sughrue Mion, PLLC

20070196482 - Sustained release torsemide dosage forms: Disclosed in certain embodiments is a sustained release oral dosage form comprising an effective amount of torsemide or a pharmaceutically acceptable salt thereof and a sustained release excipient, wherein the dosage form provides a mean sodium (Na+) excretion and mean sodium (Na+) excretion rate as disclosed herein.... Agent: Davidson, Davidson & Kappel, LLC

20070196481 - Sustained-release tablet composition: A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises an active pharmaceutical agent having solubility not less than about 10 mg/ml, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm−2 at a solid... Agent: Pharmacia Corporation Global Patent Department

20070196483 - Taste-masked drugs in rupturing multiparticulates: A pharmaceutical composition comprises multiparticulates comprising a drug, a matrix material, and swelling agent. In one aspect, the multiparticulates comprise a core comprising a drug, and a coating surrounding the core. The coating is selected from the group consisting of (i) a water-permeable, substantially drug-impermeable coating, and (ii) an anti-enteric... Agent: Pfizer Inc.

20070196484 - Poorly water-soluble drug-containing solid formulation: Even when being released in a region from a lower small intestine to a large intestine with various coatings, bisacodyl is inadequately effective because of its hardness to dissolve due to its poor solubility, and thus a more drug should be contained. In the related art, there have been no... Agent: Sughrue Mion, PLLC

20070196485 - Stable benzimidazole formulation: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range... Agent: Dr. D. Graeser Ltd. C/o The Discovery Dispatch

20070196486 - Stable oral formulation containing benzimidazole derivative: An enteric formulation containing at least one benzimidazole compound, said formulation containing: a core containing at least one benzimidazole compound and at least one lipophilic antioxidant, and an enteric envelope protecting the core at least at a pH of 3 to 5, preferably at a pH of 1 to 5.... Agent: Merchant & Gould PC

20070196487 - Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy: The present invention relates to apparatus and methods for the manufacture of osmotic tablets, wherein near-infrared spectroscopy systems are used.... Agent: Philip S. Johnson Johnson & Johnson

20070196488 - Oral matrix formulations comprising licarbazepine: The invention relates to pharmaceutical compositions comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide (also referred to as “licarbazepine”) as drug substance.... Agent: Novartis Corporate Intellectual Property

20070196489 - Taste masked pharmaceutical particles: Taste masked particles and chewable tablets made therefrom are disclosed. The taste masked particles comprise a core containing an active ingredient and a polymeric coating covering said core, said coating comprising a mixture of a) an enteric polymer; and b) an insoluble film forming polymer, the surface of said particle... Agent: Philip S. Johnson Johnson & Johnson

20070196490 - Method of enhancing needleless transdermal powered drug delivery: A method is provided for enhancing the transdermal or intradermal delivery of a therapeutic agent using a needleless syringe drug delivery system. In one embodiment, the method entails first administering to a predetermined area of skin or mucosa particles comprising the therapeutic agent, a placebo and/or a permeation enhancing agent.... Agent: Foley And Lardner LLP Suite 500

20070196491 - Drug delivery systems comprising weakly basic drugs and organic acids: A pharmaceutical dosage form such as a capsule, a conventional or orally disintegrating tablet capable of delivering a nitrogen (N)-containing therapeutic agent having a pKa in the range of from about 5 to 14 into the body in a sustained-released fashion, in order to be suitable for a twice- or... Agent: Thompson Hine L.L.P. Intellectual Property Group

20070196493 - Doxorubicin formulations for anti-cancer use: Doxorubicin block copolymer formulations for use in preparing injectable compositions for treating cancer patients which contain lactose for solubilizing the doxorubicin and block copolymers in said formulations and methyl paraben for stabilizing these formulations, as well as a method of preparing and using these injectable compositions.... Agent: Gibbons P.C.

20070196492 - Stimuli-responesive hydrogel,production method of stimuli-responsive hydrogel,and polymer actuator using stimuli-responsive hydrogel: A stimuli-responsive polymer hydrogel is provided. The stimuli-responsive polymer hydrogel has a high breaking strength and excellent stimuli-responsive function and is highly stable with elapse of time. The stimuli-responsive polymer hydrogel is capable of gelating as a result of absorbing and swelling with water and capable of changing its degree... Agent: Bell, Boyd & Lloyd, LLP

20070196494 - Low-friability, patient-friendly orally disintegrating formulations: The present invention relates to a rapidly disintegrating orally administratable solid dosage formulation that includes at least one active ingredient, at least one first disintegration agent that is at least one type-C methacrylic acid copolymer according to the U.S. Pharmacopoeia National Formulary US/NF, a second disintegration agent of crospovidone or... Agent: Winston & Strawn LLP Patent Department

20070196496 - Delivery systems for functional ingredients: Oral gel delivery systems are provided that comprise an ingestible matrix within which one or more functional ingredients are substantially uniformly and completely dispersed and in which degradation of the functional ingredient(s) is minimised or eliminated. The matrix of the delivery systems comprises a carbohydrate component that comprises one or... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070196495 - Method for administering medicaments to subjects with swallowing difficulties and disorders: The present invention is a variably thickened pharmaceutical dosage form, its composition and its use for orally administering medications to patients that have difficulty swallowing other solid dosage forms such as tablets or capsules.... Agent: John Culley

20070196498 - Megestrol acetate suspension: Suspension comprising spray-dried particles which comprise megestrol acetate and a surfactant.... Agent: Nixon & Vanderhye, PC

20070196497 - Pharmaceutical formulations for the prolonged release of active principle(s) and their applications: The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of active principle(s), particularly protein active principle(s), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a fluid pharmaceutical formulation for the... Agent: Patton Boggs LLP

20070196499 - Residual solvent extraction method and microparticles produced thereby: Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a... Agent: Covington & Burling, LLP Attn: Patent Docketing

20070196500 - Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same: A composition for oral administration of tamsulosin hydrochloride and a controlled release granule formulation comprising the same exhibited excellent stability and sustained release characteristics of tamsulosin hydrochloride regardless of pH changes for an extended period of time.... Agent: Sughrue Mion, PLLC

20070196502 - Flowable particulates: The present invention relates to particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions or alone such particles provide controlled dosing and improved performance without the negatives that are associated with fluid products.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070196501 - Formulations for a tight junction effector: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20070196503 - Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070196504 - Pharmaceutical composition: A pharmaceutical composition containing a drug (A), a waxy substance (B), and synthetic aluminum silicate and/or hydrous silicon dioxide (C). The invention provides a granular pharmaceutical composition suitable for providing a pharmaceutical characterized in that adhesion of granules thereof onto a granulation apparatus during granulation is minimized and caking of... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070196505 - Compositions and methods for improving skin health and pelage quality: Compositions and methods for improving animal skin health and/or pelage quality that utilize one or more omega-6 fatty acids and one or more omega-3 fatty acids at a total omega-6 to total omega-3 fatty acid ratio of from about 1 to less than 5.... Agent: Colgate-palmolive Company

20070196506 - Improved tolerance nutritional product to supplement human milk: The invention relates to a nutritional supplement for human milk in powder or liquid form to feed premature infants comprising protein, fat and carbohydrates wherein the carbohydrate content is limited to no more than 10% dry weight of the nutritional supplement, and the fat content is at least about 35%... Agent: Nelson Mullins Riley & Scarborough, LLP

20070196507 - Compositions and methods containing high purity fatty alcohol c24 to c36 for cosmetic applications: The present invention discloses the cosmetic applications of alkylalkanols collectively referred to as policosanol, for control of sebum secretion, as anti-acne component and as emollient.... Agent: Sabinsa Corporation

20070196508 - Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise: The present invention relates to a dietary supplement that comprises at least Creatine or derivatives thereof, Taurine or derivatives thereof and a source of Phosphate. The dietary supplement may further comprise one or more of the following: Double Fermented Triticum aestivum, Dextrose, Isomalt, Trehalose, D-Mannose, Mulberry extract, Enicostemma littorale Blume,... Agent: Iovate Health Sciences Research Inc.

20070196509 - Biomimetic hydroxyapatite synthesis: A method for preparing nanoscale hydroxyapatite particles by combining an amount of a calcium ion source, which includes calcium acetate, and an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale hydroxyapatite particles and the amounts are combined under ambient conditions to produce the hydroxyapatite... Agent: Synnestvedt Lechner & Woodbridge LLP

20070196510 - Method for treating resistant hypertension: A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of... Agent: Harness, Dickey, & Pierce, P.l.c

20070196511 - Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker: A nutritional composition that includes creatinol, e.g., creatinol O-phosphate, wherein the nutritional composition includes a timed release delivery system. The timed release delivery system may include one of quick release, slow release and controlled release delivery system. Ingestion of the nutritional composition provides a method for, e.g., promoting muscle performance... Agent: Kenyon & Kenyon LLP

20070196512 - Combinations of vanadium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070196513 - Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome x: Compositions and related methods of Cissus quadrangularis plant extracts and soy albumin that improve various cardiovascular risk factors and metabolic risk factors that cause Syndrome X. In one exemplary embodiment, university studies demonstrated that a formulation of 300 mg Cissus quadrangularis plant extract, 3 mg niacin-bound chromium, 500 mg of... Agent: Greenberg Traurig LLP (la)

20070196514 - Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors: A method of treating prostate cancers, including androgen refractory prostate cancers, using glycogen synthase kinase-3β inhibitors, such as lithium.... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20070196515 - Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome x: The present invention provides for compositions and related methods using extracts from the Cissus quadrangularis plant to improve and eliminate various cardiovascular risk factors and metabolic risk factors that cause Syndrome X. Controlled university studies demonstrated that 300 mg Cissus quadrangularis plant extract provided to obese humans daily for six... Agent: Greenberg Traurig LLP (la)

20070196517 - Modified saponin molluscicide: Saponins from plant materials are alkaline modified and used as molluscicides.... Agent: Myers Wolin, LLC

20070196516 - Sugar substitute and rapid localized delivery system: A film composition for orally delivering a variety of substances to a person. In one embodiment, the substance is a reduced calorie sugar substitute derived from species of the plant genus Synsepalum. The reduced calorie substitute can be utilized to control calorie intake or to make the delivery of drugs,... Agent: Lacy Kolo

20070196518 - Composition and method for mitigating a negative effect of alcohol consumption: A composition for the prevention and treatment of symptoms (for example, a hangover) associated with ethyl alcohol consumption. The composition may comprise a gingerol, a silymarin, a catechin, and a group B vitamin. Treatment of symptoms associated with the consumption of ethyl alcohol may comprise administration of the composition prior... Agent: Suzannah K. Sundby

20070196519 - Method for making therapeutic compositions containing trimethoprim and cranberry extract for treating urinary tract infections: A method for making an over-the-counter therapeutic composition for treating urinary tract infections in warm-blooded animals, including humans, includes the steps of obtaining a combination of trimethoprim or pharmaceutically salts thereof and cranberry extract in an effective amount to prevent, reduce or eliminate symptoms associated with the infection, and a... Agent: Kenneth Watov, Esq. Watov & Kipnes, P.C.

20070196520 - Methods and materials for reducing or eliminating risk factors associated with syndrome x: A composition containing cinnamon extract reduces and/or eliminates one or more risk factors associated with Syndrome X. The composition also includes optionally one of more components selected from the group consisting of vitamins, cholesterol lowering agents, lipid lowering agents, and glucose lowering agent. Also described is a method of reducing... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070196521 - Bioadhesive from distillers' dried grains with solubles (ddgs) and the methods of making those: A bioadhesive composition from distillers' dried grains with solubles (DDGS) is produced by reaction with an aqueous solution of a base, particularly, sodium hydroxide. Optionally, urea is included with the base. The bioadhesive composition is filtered as a solution from the residue of the reaction with the base. The bioadhesive... Agent: Ian C. Mcleod Ian C. Mcleod, P.C.

20070196523 - Parthenolide free bioactive ingredients from feverfew (tanacetum parthenium) and processes for their production: The present invention relates to bioactive ingredients that include isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant. The bioactive fractions are either free of or substantially free of α-unsaturated γ-lactones (e.g., parthenolide). Further, the bioactive fractions have anti-inflammatory and antioxidant activity. The... Agent: Nixon Peabody LLP - Patent Group

20070196522 - Methods and compositions for nerve regeneration: A method of promoting nerve regeneration in a subject that includes administering to the subject a therapeutically effective amount of a composition that includes at least one therapeutically-active extract fraction of Centella asiatica. One example of making the extract fraction of Centella asiatica involves extracting Centella asiatica plant material resulting... Agent: Klarquist Sparkman, LLP

20070196524 - Morinda citrifolia based antifungal formulations and methods: The present invention provides a formulation which may be utilized in agricultural practice that is eco-friendly and effective as plant growth promotion agent, soil improvement agent, bactericide and insecticide agent, disease and harmful insect prevention agent, and is suitable for organic farming. The formulation of the present invention is comprised... Agent: Michael F. Krieger Kirton & Mcconkie

20070196525 - Composition to enhance hdl cholesterol and to decrease intima-media thickening in animals and humans and a method for its preparation: A method of producing a product to correct hypercholesterolemia including pulping fruits of Emblica Officinalis with demineralized water to create a slurry. The slurry is treated with pectinase. The pectinase-treated slurry is filtered to create a solution. The solution is concentrated to create a product. A product having an extract... Agent: Jyoti C. Iyer, Esq.

20070196526 - Agent for substitution of blood plasma and a method of its production: The agent for substitution of the blood plasma is made up of the vegetal protein substance edestin, advantageously a product from the hemp seeds. Advantageously, edestin is a component of the solution comprised of 5%-40% in weight of edestin, 0.5%-7% in weight of inorganic substances, 0.5%-7% in weight of organic... Agent: Hershkovitz & Associates

20070196527 - Preventative and treatment effects of morinda citrifolia on osteoarthritis and its related conditions: The present invention embraces methods for improved treatment of osteoarthritis by featuring a naturaceutical formulation or composition for treating osteoarthritis and its associated or related conditions. The present invention further features methods of treating osteoarthritis and its related conditions. In particular, the present invention relates to providing a treatment for... Agent: Kirton And Mcconkie

20070196528 - Cosmetic composition based on caper flower bud extract: A caper flower bud extract is obtained by supercritical fluid extraction. The supercritical fluid preferably contains carbon dioxide and at least one cosolvent. A cosmetic composition contains between 0.1 and 10% of the extract.... Agent: Heslin Rothenberg Farley & Mesiti PC

20070189971 - Contrast agents: P

20070190000 - Matting cosmetic composition: The present invention relates to a non-compacted cosmetic composition for caring for and/or making up keratin fibres, comprising, in a physiologically acceptable medium, at least 22% by weight of water relative to the total weight of the composition and at least one fatty phase comprising at least one dispersion of... Agent: Oliff & Berridge, PLC

20070189964 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic... Agent: Mchale & Slavin, P.A.

20070189962 - Mutated anti-cd22 antibodies and immunoconjugates: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22... Agent: Townsend And Townsend And Crew, LLP

20070189963 - Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis: The present invention relates to antibodies with sub-nanomolar affinity specific for a characteristic epitope of the ED-B domain of fibronectin, a marker of angiogenesis Furthermore, it relates to the use of radiolabeled high affinity anti ED-B antibodies for detecting new-forming blood vessels in vivo and a diagnostic kit comprising comprising... Agent: Millen, White, Zelano & Branigan, P.C.

20070189965 - Copper-complex isonitrile positron emission tomography (pet) imaging agent and method: A novel method is set out of preparation of Copper isonitrile as a radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized from by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The Copper radiopharmaceutical is can be reconstituted and administered to a... Agent: Brooke Schumm Iii

20070189966 - Diagnostic agents for pancreatic exocrine function: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070189967 - Agents for imaging soluble a-beta: Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.... Agent: General Electric Company Global Research

20070189969 - Perfluoroalkyl-containing complexes, process for their production as well as their use: The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with nitrogen-containing radicals of general formula I, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography and in blood-pool imaging.... Agent: Millen, White, Zelano & Branigan, P.C.

20070189973 - Contrast medium comprising liposomes containing hydrophobic chelate compound: A liposome containing a hydrophobic chelate compound as a membrane component, and an MRI contrast medium containing the liposome for use in imaging of, preferably, a vascular disease. An MRI contrast medium that accumulates in a lesion of a vascular disease caused by abnormal proliferation of vascular smooth muscle cells... Agent: Birch Stewart Kolasch & Birch

20070189974 - Glycerophosphoric acid ester derivative having polyfunctional metal chelate structure: wherein R1 and R2 independently represent a substituted or unsubstituted alkyl or alkenyl group having 8 to 30 carbon atoms; L represents a divalent bridging group (L is constituted by atoms selected from the group consisting of carbon atom, oxygen atom, nitrogen atom and hydrogen atom, wherein the total number... Agent: Birch Stewart Kolasch & Birch

20070189970 - Contrast medium for thrombus formation: It is intended to provide a contrast medium for thrombus capable of binding specifically to a thrombus, lowering background noise and thus improving the resolution in a contrast examination for thrombus formation; and a method of detecting a thrombus by using the same. A contrast medium for thrombus comprising, as... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070189972 - Method of forming nanobubbles: The present invention relates to a method of forming nanobubbles that have potential utility in every industrial application and that impart special functions, especially to water. The present invention is a method of forming nanobubbles by applying physical irritation to microbubbles contained in a liquid so that the microbubbles are... Agent: Ladas & Parry

20070189968 - Gel composition for filling a breast milk duct prior to surgical excision of the duct or other breast tissue: The invention is a gel composition for delivery to a breast milk duct prior to surgical excision of breast tissue including cancerous lesions. The invention also provides methods of mapping all or nearly all of a breast milk duct prior to surgical excision of breast tissue, and method of identifying... Agent: Cytyc Corporation

20070189975 - Hydrophilic matrix for delivery of active agent and product containing same: A sustained drug delivery system is disclosed comprising an open cell or reticulated, hydrophilic polyurethane.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20070189976 - Administering pharmaceutical compositions to the mammalian central nervous system: Methods, compositions and systems are provided for the non-invasive transnasal and transocular drug delivery to the central nervous system using eriodictyon fluid extract technology. By administration through the olfactory nerve or the optical nerve, the delivery of a biologically active substance of interest into the CNS and CSF can be... Agent: Morgan, Lewis & Bockius LLP (sf)

20070189978 - Compositions and methods for dermally treating musculoskeletal pain: The present invention is drawn to solidifying formulations for dermal delivery of a drug for treating musculoskeletal pain, inflammation, joint pain, etc. The formulation can include a drug selected from certain drug classes, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system having... Agent: Thorpe North & Western, LLP.

20070189977 - Spray-on formulations and methods for dermal delivery of drugs: The present invention is drawn to sprayable formulations, methods of drug delivery, and resultant solidified layers for dermal delivery of a drug. The formulation can include a drug, a non-volatile solvent system, a solidifying agent, and a propellant. The formulation can have an initial viscosity suitable to be expelled out... Agent: Thorpe North & Western, LLP.

20070189979 - Particles: The invention relates to particles for drug delivery by inhalation, said particles incorporating at least one active ingredient which is non-crystalline. The may be a plurality of active ingredients and moreover the outer surface of the particles may be substantially smooth. By providing non-crystalline particles with an outer smooth surface,... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070189980 - Compositions and methods for treating alopecia: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for topical delivery of drugs for treating alopecia. The formulation can include a drug for treating alopecia, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system having... Agent: Thorpe North & Western, LLP.

20070189982 - Diagnostics and treatments of periodontal disease: This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis and in particular a multimeric cell association protein complex comprising the PrtR and PrtK proteins. Accordingly the invention provides a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis. The complex comprises... Agent: Nixon & Vanderhye, PC

20070189981 - Porphorymonas gingivalis polypeptides and nucleotides: The present invention relates to isolated Porphorymonas gingivalis polypeptides and nucleotides. The polypeptides include; an amino acid sequence selected from the group consisting of SEQ. ID. NO. 265 to SEQ. ID. NO. 528, SEQ. ID. NO. 531 and SEQ. ID. NO. 532; or an amino acid sequence at least 85%,... Agent: Nixon & Vanderhye, PC

20070189983 - Tooth whitening composition: The present invention provides an anhydrous liquid tooth whitening composition comprising a peroxide-containing compound and an orally acceptable carrier wherein the carrier includes a humectant, a bioadhesive agent, and a film-forming agent consisting essentially of a water-insoluble film-forming agent and a solvent for the film-forming agent.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070189984 - Agents for use on skin and/or hair containing quadruply substituted cyclohexene compounds: The invention relates to agents for use on skin or hair, particularly for increasing skin tanning and the synthesis of melanin in skin or hair. The invention contains, in particular, cosmetic or dermatological preparations containing quadruply substituted cyclohexene compounds. The use of the preparations leads to the induction and intensification... Agent: Greenblum & Bernstein, P.L.C

20070189987 - Composition comprising a monomeric compound with an optical effect, process using said composition, monomeric compound, polymer comprising the same and use thereof: The invention relates to a cosmetic or pharmaceutical composition containing, in a physiologically-acceptable medium, at least one polymer comprising at least one novel monomeric compound having optical effect properties. The invention also relates to a cosmetic method of making up or caring for keratin materials, such as the skin belonging... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070189988 - Cosmetic and dermatologic oxygen carrier system: The invention relates to an oxygen carrier system which is suitable for apply gaseous oxygen to the skin in cosmetic and dermatological forms of application. Said system comprises 0.1 to 10 percent by weight of a liquid perfluorinated or partially fluorinated hydrocarbon or hydrocarbon mixture, 10 to 85 percent by... Agent: Norris, Mclaughlin & Marcus, P.A.

20070189989 - Cosmetic compositions and methods of making and using the compositions: Cosmetic compositions which, when applied to the skin, mask skin imperfections and provide more uniform skin tone are described. The compositions can be formulated to address the needs of users having a specific skin tone. The compositions include one or more pigments (e.g., iron oxides) and may also include reflective... Agent: Merchant & Gould PC

20070189991 - Cosmetic compositon comprising a (thio)urethane/ (thio)urea copolymer capable of forming at least 3 hydrogen bonds, and a method of cosmetic treatment: The present application relates to cosmetic compositions comprising, in a physiologically acceptable medium, a copolymer having a (thio)urethane/(thio)urea polymer skeleton, resulting from the reaction: of a first monomer having at least two polymerizable groups, which may be identical or different, chosen from —N═C═O and —N═C═S, of a monomer (b1) having... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070189986 - Organic acid anion containing aluminum salt hydroxide particles, production method thereof, and use thereof: e

20070189993 - Stabilized photoprotective composition: Sunscreen compositions contain the active ingredients avobenzone, zinc oxide and phenylbenzimidazole sutfonic acid. The phenylbenzimidazole sulfonic acid protects avobenzone against photodegradation.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070189992 - Sunscreen safety and efficacy enhancement with manganese complexes via urocanate pathway: The present invention discloses safety and efficacy enhancement of sunscreens with certain heterocyclic base complexes of manganese via urocanate pathway modulation. The present invention also discloses a method for topical application of said complexes, which causes the reduction of topical peroxide including hydrogen peroxide, the reduction of topical inflammation including... Agent: Shyam K. Gupta Bioderm Research

20070189990 - Ultraviolet absorber for cosmetics and polymeric materials: Esters of cinnamic acids with sugar alcohols and anhydro-sugar alcohols are described. The esters have ultraviolet light absorbing properties. In particular, the diester of ferulic acid with isosorbide is a UV-absorber derived from natural materials and has use as a UV-absorber for polymeric materials and as a UV-absorber for cosmetics.... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. Suite 2500

20070189985 - Use of a compound modifying an interleukin 5, interleukin 6 and/or interleukin 10 secretion for preparing a pharmaceutical composition for rosacea treatment: The invention relates to the use of a compound which modifies, and advantageously inhibits, the secretion of at least one interleukin chosen from the group comprising IL-5, IL-6 and IL-10, for the preparation of a pharmaceutical composition for treating rosacea.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070189994 - Light protecting composition with reduced total amount of uv filter containing a polysiloxane-based uv filter: The present invention is directed to a lightprotecting composition containing at least one polysiloxane-based UV filter. The composition has an increased ratio of the sunprotecting factor to the total UV filter amount. This is achieved by the combination with at least one UV filter which chromophore contains appropriate bulky (sterically... Agent: Stephen M Haracz Bryan Cave

20070189995 - Custom-colored nail compositions: A process for making a custom-colored cosmetic nail composition involving the steps of: (a) providing a first and second gelled nail polish composition, each of which having a Brookfield viscosity of at least 20 poise, the compositions containing: (i) at least one gelling agent; (ii) at least one film former;... Agent: L'oreal Usa/ Patent Department

20070189996 - Nail compositions in gelled form: A process for making a nail polish varnish involving the steps of: (a) providing a gelled nail polish composition having a Brookfield viscosity of at least 20 poise, the composition containing: (i) at least one gelling agent; (ii) at least one film former; (iii) at least one solvent; and (iv)... Agent: L'oreal Usa/ Patent Department

20070189997 - Skin-whitening agent containing polyphenol compound: This invention relates to a method for inhibiting melanin formation in a subject comprising administering an effective amount of an acerola-derived polyphenol compound, an acerola polyphenol fraction, or the other polyphenol compound to a subject. This method comprises whitening the subject's skin by the inhibition of melanin formation. This method... Agent: Sughrue Mion, PLLC

20070190001 - Cosmetic composition comprising an ester of polyol(s) and of fatty diacid dimer and a polyamide: The present invention relates to a cosmetic composition for making up and/or caring for keratin materials, combining at least one ester of polyol(s) and of fatty diacid dimer, or an ester thereof, with at least one polyamide with an average molecular mass of less than 100,000, comprising a) a polymer... Agent: Oliff & Berridge, PLC

20070190002 - Oil-based cosmetic preparation: wherein R1 to R4 are each independently hydrogen atom, a fatty acid residue or a polycarboxylic acid residue, and R5 and R6 are each independently hydrogen atom, a fatty acid residue or a polycarboxylic acid residue, provided that all of R1 to R4 do not represent hydrogen atom at the... Agent: Buchanan, Ingersoll & Rooney PC

20070189999 - Oil-in-oil dispersions stabilized by solid particles and methods of making the same: In a composition comprising an oil-in-oil emulsion containing a first oil phase dispersed as liquid droplets in a continuous second oil phase, which liquid droplets have a number median diameter of about 1 μm to 10 μm, the liquid droplets are substantially covered with a layer of relatively smaller hydrophobically... Agent: Paul A. Leipold Patent Legal Staff

20070189998 - Oil-in-oil emulsions: An stable oil-in-oil emulsion is disclosed containing a first oil phase dispersed as droplets in a continuous second oil phase, which droplets have a number median diameter of 10 nm to 1000 nm, wherein the first oil phase is substantially immiscible in the second oil phase and wherein the first... Agent: Paul A. Leipold Patent Legal Staff

20070190003 - Cosmetic composition comprising a particular ester, and uses thereof:

20070190004 - Substances with a probiotic action used in deodorants: A method for promoting probiotic activity on the skin comprises contacting the skin with a probiotic effective amount of a substance having a probiotic effect selected from the group consisting of a plant extract, a glycerol monoalkyl ether, and a fatty acid ester or a combination of the plant extract... Agent: Paul & Paul

20070190006 - Methods for measuring moisture as a predictor of scalp health: Methods provide for measuring moisture content of skin, such as the scalp. More particularly, the present invention is directed to a method comprising the steps of: (a) providing a means for measuring skin moisture content; (b) using the means for measuring skin moisture content to obtain at least one measured... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070190005 - Synergistic preservative systems and their use in cosmetic compositions: The present invention provides a preservative system having at least one preservative component and at least one oil-miscible glycol component, and cosmetic compositions formulated with the preservative system. It has unexpectedly been found that the preservative system according to the present invention results in a synergistic preservative effect. This synergistic... Agent: Charles N.j. Ruggiero, Esq. Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070190012 - Low molecular weight silicone oil-in-water emulsion: Oil in water emulsion compositions, and methods for preparing such emulsions, where the oil phase component of the emulsion contains at least 50 weight percent of a low molecular weight siloxane are disclosed. The oil in water emulsions are stabilized by a combination of a silicone polyether and anionic surfactant.... Agent: Dow Corning Corporation Co1232

20070190015 - Cosmetic composition comprising at least one cationic poly(vinyllactam), at least one fatty alcohol, and at least polyol, cosmetic process for treating keratin fibers and use of the composition: Disclosed herein a cosmetic composition for treating keratin fibers, for instance, human keratin fibers such as the hair, comprising, in a cosmetically acceptable medium, at least one cationic poly(vinyllactam) polymer, at least one fatty alcohol, and at least one polyol with a molecular weight of greater than 80.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070190016 - Cosmetic composition comprising at least one cationic poly(vinyllactam), at least one fatty alcohol and at least one amino silicone, cosmetic process and use of the composition: The present disclosure relates to a cosmetic composition for treating keratin fibers, including human keratin fibers such as the hair, comprising, in a cosmetically acceptable medium, at least one cationic poly(vinyllactam) polymer, at least one fatty alcohol and at least one amino silicone.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070190013 - Film and film-forming compositions: The invention provides films and film forming compositions that can be applied onto a tissue surface. The film and the film forming composition comprise at least one polycarboxylated polymer and at least one polysaccharide.... Agent: National Starch And Chemical Company

20070190014 - Oil - in - polyhydric alcohol type warming base agent: The present invention is an oil-in-polyhydric-alcohol type warming base agent containing the following ingredients: 1. Polyhydric alcohol; 20.0-99.0 wt % of the total amount 2. Sucrose fatty acid ester; 0.5-10.0 wt % of the total amount 3. Oil: 30.0-80.0 wt % of the total amount The object of the present... Agent: Townsend & Banta C/o Portfolio Ip

20070190007 - Method and composition for reducing malodor in permanently waved hair: A method and composition treatment is used to reduce post permanent odor in permed or waved hair. The malodor in permed hair is reduced by applying a leave-in aqueous treatment of pH 2.5-4.5 containing, hydrolyzed vegetable protein, polyquaternium-7, dimethicone and fragrance containing at least four components with water/octanol partition coefficient... Agent: Melvin I. Stoltz

20070190008 - Process for permanently reshaping the hair, comprising applying to the hair at least one precipitated fixing polymer, and multi-compartment device: A process for permanently reshaping keratin fibers, comprising applying a reducing composition (A) comprising at least one salt chosen from organic and mineral salts-, shaping the keratin fibers by styling and applying a composition (B) comprising at least one fixing polymer; after a period of leave-on time, applying a fixing... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070190009 - Hair cosmetic composition: p

20070190011 - Cosmetic composition comprising a polyolefin and fumed silica particles: The present invention relates to a cosmetic composition for making up and/or caring for keratin materials, comprising at least one polyolefin with a melting point of less than or equal to about 40° C. and fumed silica particles, the said composition not flowing under its own weight, and having a... Agent: Oliff & Berridge, PLC

20070190010 - Mascara containnig fiber components: The invention relates to a mascara containing fibre components and a method for producing the same. Said mascara contains (in % by weight) 0.1-10 of at least one oil-soluble or oil-dispersible polymer or copolymer, 0.3-10 of a natural or synthetic fibre with an average length of between 3 and 6... Agent: Millen, White, Zelano & Branigan, P.C.

20070190017 - Porous cellulose aggregate and formed product composition comprising the same: A porous cellulose aggregate which has a secondary aggregation structure formed by the aggregation of primary cellulose particles, has a pore volume within a particle of 0.265 cm3/g to 2.625 cm3/g, contains I type crystals, has an average particle diameter of more than 30 μm and 250 μm or less,... Agent: Staas & Halsey LLP

20070190019 - Compositions and methods for topical administration: Vanishing cream base compositions and vanishing cream compositions suitable for topical application of an active agent to an animal or plant comprising water, at least one alcohol, a polymeric thickening agent, a skin penetration enhancing compound, and an emulsifying agent are provided. Methods for the use and manufacture of such... Agent: Nutter Mcclennen & Fish LLP

20070190020 - Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture: The present invention provides pharmaceutical compositions comprising aliphatic amine polymers such as for example Sevelamer HCl as the active pharmaceutical ingredient, wherein the aliphatica amine polymers are spray granulated. The present invention further provides methods of preparing stable pharmaceutical compositions of aliphatic amine polymers such as for example Sevelamer HCl,... Agent: Kenyon & Kenyon LLP

20070190018 - Dual phase drug release system: The present invention relates to conjugate comprising a carrier substituted with one or more occurrences of a moiety having the structure (I): wherein each occurrence of M is independently a modifier having a molecular weight≦10 kDa; denotes direct of indirect attachment of M to linker LM; and each occurrence of... Agent: Choate, Hall & Stewart LLP

20070190021 - Poly(diallylamine)-based bile acid sequestrants: The present invention relates to a method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a poly(diallylamine)polymer which is substituted with hydrophobic... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070190022 - Combination methods of treating cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070190023 - Methods and compositions for modulating the mobilization of stem cells: Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells from the bone marrow to the peripheral blood are disclosed. In particular, the invention relates to the use of adrenergic agonists that act in concert with a mobilization compound... Agent: Klauber & Jackson

20070190024 - Il-11 muteins: The present invention relates to new IL-11 muteins of which site I hydrophobocity has been increased. These muteins act as IL-11 agonist or hyperagonist, and are notably useful as anti-thrombocytopenia agents, and as agents improving the resistance of an organism to the deleterious in vivo effects induced by radiation or... Agent: Nixon & Vanderhye, PC

20070190025 - Method to enhance hematopoiesis: The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF... Agent: Morrison & Foerster LLP

20070190026 - Method of treatment using interferon-tau: A composition for use in preparation of a medicament for treating a condition responsive to interferon therapy in a human subject is described. The composition includes interferon-tau in dosage form suitable for oral administration to the intestinal tract in an amount effective to produce an increase in the subject's blood... Agent: Perkins Coie LLP

20070190029 - Listeria-induced immunorecruitment and activation, and methods of use thereof: Provided are reagents and methods for administering an attenuated bacterium for use in treating a cancerous or infectious condition. Reagents and methods for administering an attenuated bacterium for use in inducing an immune response against a tumor, cancer cell, or infective agent are further provided. Also provided are methods of... Agent: Morrison & Foerster LLP

20070190028 - Method and apparatus for heat or electromagnetic control of gene expression: A gene regulatory system controls biomarker, gene therapy or endogenous gene expression by emitting one or more forms of energy that regulate gene expression. The system may include a sensor to sense a signal indicative of a need for therapy. The regulation of gene expression is controlled based on the... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070190030 - Method of treating arthritis using lentiviral vectors in gene therapy: Novel methods for treating and preventing arthritis, such as rheumatoid arthritis, are disclosed which employ lentiviral gene delivery vectors, including HIV-based lentiviral vectors, to deliver a therapeutic gene to a subject. Lentiviral-based vectors treat arthritis by promoting high-level expression of the transferred therapeutic gene in the target tissue of the... Agent: Lahive & Cockfield, LLP

20070190031 - Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv: The invention provides a DNA plasmid comprising: (a) a first transcriptional unit comprising a nucleotide sequence that encodes a first polypeptide operably linked to regulatory elements including a first promoter and a first polyadenylation signal; (b) a second transcriptional unit comprising a nucleotide sequence that encodes a second polypeptide operably... Agent: Wyeth Patent Law Group

20070190027 - Targeting of herpes simplex virus to specific receptors: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a... Agent: Marshall, Gerstein & Borun LLP

20070190032 - Use of local immune suppression to enhance oncolytic viral therapy: Provided herein are methods for treating or ameliorating a solid tumor in a subject comprising administering oncolytic viruses and immunosuppressive agents at or near the site of the tumor.... Agent: Fish & Richardson P.C.

20070190039 - Novel cell lines, and methods of preparation and use thereof: The present invention provides, in some embodiments, hippocampal neuron-derived cell lines that display voltage-gated calcium channels of various types, including the N-type channels. Such mixed calcium channel activity is similar to that observed in the hippocampal neurons from which they were originally derived. The cells also can be differentiated into... Agent: Cozen O'connor, P. C.

20070190040 - Recombinant p53 adenovirus methods and compositions: Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct. observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals... Agent: Fulbright & Jaworski L.L.P.

20070190033 - Bacteriophage-containing therapeutic agents: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a... Agent: Morrison & Foerster LLP

20070190037 - Artificial vascular grafts, their construction and use: The present relates to artificial vascular grafts, methods for manufacturing and uses for them. The grafts comprise an inner surface on which cells genetically altered to express or over-express one or more cell adhesion factors or one or more cell adhesion factors and one or more cell proliferation growth factors... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070190038 - Closed cell culture system: An object of the present invention is to provide a tissue cell culture system whereby a call tissue can be efficiently and quickly proliferated in vivo and the onset bacterial infection in an injured part can be avoided in the course of a treatment. More specifically, a closed cell culture... Agent: Oliff & Berridge, PLC

20070190035 - Diabetes treatment methods and drug targets therefor: Provided are methods of treating insulin resistance or type II diabetes. Disrupting CAP in the macrophage can alter the inflammatory response associated with impaired insulin action and ultimately result in improved insulin action in target tissues. One aspect of the invention involves administering a CAP antagonist to a patient afflicted... Agent: Biotactica, LLC

20070190034 - Immunomodulation using placental stem cells: The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.... Agent: Jones Day

20070190036 - Microencapsulation of pancreatic islets within a thin coat of glucagon-like peptide-1 functionalized poly(ethylene glycol): Microencapsulation of pancreatic islets within a thin poly(ethylene glycol) (PEG) coat is provided. The PEG coat is functionalized with an insulinotropic agent, glucagon-like peptide 1 (GLP-1). The encapsulated pancreatic islets may be used for the treatment of type I diabetes.... Agent: Brinks Hofer Gilson & Lione

20070190041 - Novel benzothiazepine and bensothiepine compounds: A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive... Agent: Young & Thompson

20070190042 - Composition for collecting and preserving placental stem cells and methods of using the composition: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ... Agent: Jones Day

20070190043 - Use of a topical medicament comprising riluzole: The present invention relates to the use of Riluzole if needed with suitable adjuvants and additives for the production of a medicament for the treatment of diseases characterized by hyperproliferation of keratinocytes and/or T cells, in particular psoriasis and neurodermatitis as well as compositions comprising Riluzole and use thereof.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070190045 - Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity: The invention provides methods for treating autoimmunity and for reestablishing tolerance. The methods involve the coadministration of anti-CD3 antibodies and self-antigens. The coadministration has the potential to provide a synergistic effect of protecting or reducing autoaggressive immune processes and/or of reestablishing tolerance towards self-antigens. An underlying rationale behind the methods... Agent: Wilmerhale/columbia University

20070190044 - Compositions and methods for manipulating levels of antigen-specific antibodies in a mammal: The invention provides compositions and methods for increasing the levels of an autoantigen-specific IgM antibody in a mammal and, thus, decreasing the levels of a circulating autoantigen in a mammal. Using these autoantigen-specific IgM anti-bodies, the invention provides compositions and methods for ameliorating an autoimmune disease in a mammal. In... Agent: Morrison & Foerster LLP

20070190046 - Anti-abeta antibody: This present invention provides a composition that is suitable for administration to a human subject comprising an anti-Aβ antibody that is free of Aβ peptide or that has acceptably low levels thereof, free of non-human Aβ peptide or that has acceptably low levels thereof, or having an undetectable concentration of... Agent: Eli Lilly & Company

20070190047 - Formulations that inhibit protein aggregation: Disclosed is a stable pharmaceutically acceptable formulation containing a pharmaceutically acceptable amount of a protein. Also disclosed are methods for preparing such formulations and methods for inhibiting protein aggregate formation induced by physical stresses associated with processing, manufacture, shipping, and storing protein formulations, particularly freeze/thaw stress.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070190048 - Method of inducing physiological process in a body cavity and a device for using it: The invention also relates to a device for using said method comprising a hollow body (1) provided with a heat source on the inside as well as with a means (13, 27) of removal of said hollow body from the vaginal or rectal cavity and a means (6, 8, 10)... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20070190049 - Use of a33 antigens and jam-it: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.... Agent: Heller Ehrman LLP

20070190050 - Apparatus and method for down-regulating immune system mediators in blood: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target... Agent: Knobbe Martens Olson & Bear LLP

20070190051 - Antibodies to cd40: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070190052 - Regulatory cd8cells induced with anti-cd3 antibody: The invention provides methods for treating autoimmunity, for reestablishing tolerance, and for generally dampening or suppressing the activation state of the immune system. The methods involve the induction or activation of a particular regulatory T cell population, characterized by its expression of CD8, CD25 and Foxp3.... Agent: Wilmerhale/columbia University

20070190053 - Treament of lupus nephritis with anti-cd40l compounds: This invention relates to methods for treatment of nephritis associated with immune complex disease using anti-CD40L compounds. According to one embodiment of this invention, anti-CD40L compounds are administered to a patient with immune complex disease who has received a kidney allograft, to inhibit the development of immune complex glomerulonephritis within... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070190057 - Methods for modulating mannose content of recombinant proteins: The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins.... Agent: Amgen Inc.

20070190056 - Muscle regeneration compositions and uses therefor: The present invention relates to a method of treating and/or ameliorating one or more symptoms of sarcopenia and age-related muscle degeneration in a mammal.... Agent: Knobbe Martens Olson & Bear LLP

20070190055 - Ccr3 inhibition for ocular angiogenesis and macular degeneration: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.... Agent: Buchanan, Ingersoll & Rooney PC

20070190058 - Method for treating intraocular neovascular diseases: A method is provided for administering to a mammal suffering from, or at risk for, an intraocular neovascular disorder with regular dosing of a therapeutically effective amount of VEGF antagonist, followed by less frequent dosing of a therapeutically effective amount of VEGF antagonist.... Agent: Genentech, Inc.

20070190054 - Prevention and treatment of complement-associated disorders: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV).... Agent: Heller Ehrman LLP

20070190059 - Antithrombotic agents: Monoclonal antibodies directed against coagulation factor IX and their use in inhibiting thrombosis are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070190062 - Mcm6 and mcm7 monoclonal antibodies and methods for their use in the detection of cervical disease: Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided.... Agent: Alston & Bird LLP

20070190061 - Peptides for stimulating an immune response against melanoma: Provided in the present invention are recombinant peptides and a method for using the peptides in stimulating an immune response against human high molecular weight-melanoma associated antigen (HMW-MAA). The peptides were designed from the identification of regions of structural and amino acid sequence homology between HMW-MAA and the mouse anti-idiotypic... Agent: Hodgson Russ LLP

20070190063 - Antibody-mediated enhancement of immune response: Provided are reagents and methods for administering an attenuated bacterium and a binding compound for treating a cancerous or infectious condition, where the binding compound comprises an antibody or an antigen binding site derived from an antibody.... Agent: Morrison & Foerster LLP

20070190060 - Passive targeting of cytotoxic agents: The present invention provides methods of treating cancer cells comprising administering to a patient in need thereof a therapeutically effective amount of a non-specific antibody conjugated to a cytotoxin, wherein the cancer cells do not express an antigen to which the non-specific antibody binds. In one embodiment, the non-specific antibody... Agent: Wyeth Patent Law Group

20070190064 - Enteral composition for the prevention and/or treatment of sepis: Enteral compositions and use thereof, which compositions contain proteins and lipids, for the prevention and/or treatment of sepsis; the lipid fraction being particularly rich in phospholipids.... Agent: Young & Thompson

20070190066 - Cationic steroid antimicrobial compositions and methods of use: The invention provides methods for decreasing or inhibiting poxvirus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with poxvirus infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of poxvirus infection or pathogenesis in... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070190065 - Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein: Nucleic acid molecules, polypeptides, immunogenic compositions, vaccines, and methods of making and using the nucleotides and encoded polypeptides associated with the Spike protein of SARS Corona Virus (SARS CoV) are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070190067 - Cationic steroid antimicrobial compositions and methods of use: The invention provides methods for decreasing or inhibiting human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo, or... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070190068 - Upar-binding molecule-drug conjugates and uses thereof: The present invention relates to the use of uPAR-binding molecule-drug conjugates capable of specifically binding a urokinase plasminogen activator receptor (uPAR) as therapeutic and diagnostic reagents for the treatment and monitoring of metastases. The present invention provides methods of treatment of metastases, comprising administering to a subject a uPAR-binding molecule-chemotherapeutic... Agent: Jones Day

20070190071 - 9-substituted 8-oxoadenine compound: e

20070190069 - Immunotherapy for food allergy by reduced and alkylated food allergens: The invention relates to a treatment of human individuals suffering from food allergy. The treatment involves a specifically modified food allergen and is based on immunotherapy. The modified allergen is derived from a dietary protein, preferably a tree nut protein and is modified by reduction and alkylation.... Agent: Morrison & Foerster LLP

20070190070 - Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system: Methods of treating, preventing and/or managing central nervous system disorders, such as Parkinson disease, Alzheimer disease, mild cognitive impairment, Huntington disease, Amytophic Lateral Sclerosis, depression and defective long-term memory, and related syndromes are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt,... Agent: Jones Day

20070190073 - Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof: The invention provides classes of immunomodulatory compositions which comprise an average of one or more immunostimulatory sequence (ISS) containing polynucleotide conjugated, or attached, to antigen. The extent of conjugation affects immunomodulatory properties, such as extent of antigen-specific antibody form ration, including Th1-associated antibody formation, and thus these various conjugate classes... Agent: Morrison & Foerster LLP

20070190072 - In vivo efficacy of ny-eso-1 plus adjuvant: The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly.... Agent: Foley And Lardner LLP Suite 500

20070190074 - Modified hpv e6 and e7 genes and proteins useful for vaccination: Described are DNA sequences encoding an E6 or E7 fusion protein of HPV, wherein said DNA sequences are characterized by a combination of the following features: original codons are exchanged by codons which lead to an enhanced translation in a mammalian cell, they contain a deletion resulting in the production... Agent: Intellectual Property / Technology Law

20070190075 - Hair growth stimulant composition: Fibroblast growth factor 5 (FGF-5) has a function of inhibiting hair growth and thereby shifting hair cycle of hair matrix cells from the growing stage to the regression stage. Extracts obtained by extraction preferably from rose fruit, loquat, burnet, bearberry, mate, cat's claw, mugwort, Uncaria rhynchophylla, tea and brown algae... Agent: The Webb Law Firm, P.C.

20070190076 - Gram positive bacteria preparations for the treatment of disease comprising an immune dysregulation: Compositions comprising components prepared from Gram positive bacteria such as Gram positive facultative intra-cellular bacteria, for example mycobacteria, including extended freeze-dried killed Gram positive bacteria, their method of preparation and their use in humans and animals, for the prevention and/or the treatment of disorders comprising an immune dysregulation such as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070190077 - Anti-hiv agents: Anti-HIV agents are disclosed. The agents comprise as the active component one of ligand molecules that bind to CD87. Examples of such ligand molecules included the high molecular weight urokinase-type plasminogen activator, its amino-terminal fragment, their analogues and anti-CD87 antibodies.... Agent: Millen, White, Zelano & Branigan, P.C.

20070190078 - Filamentous haemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders: Filamentous haemagglutinin (FHA) or a derivative or mutant or fragment or variant or peptide thereof is useful in the prophylaxis and/or treatment of an immune-mediated disorder and/or an autoimmune disease. The FHA may include self or foreign antigens or peptides thereof.... Agent: Heller Ehrman LLP

20070190079 - Methods for the selective modulation of ppar: The present invention relates to methods of selective modulation of peroxisome proliferator activated receptors (PPARs) over G-protein coupled receptor 40 (GPR40), and the use of therapeutically effective amounts of compounds and pharmaceutical compositions which selectively modulate PPAR over GPR40 for the treatment of diseases in patients in need thereof. The... Agent: Global Patent Group Attn: Ms Lavern Hall

20070190081 - Aqueous suspension for nasal drops: e

20070190083 - Medical implants with reservoir (s), and materials preparable from same: Described is a medically useful article comprising a three-dimensional body including one or more implantable substances, wherein the body defines one or more reservoirs for receiving amounts of a biocompatible wetting liquid. In certain embodiments the body is disruptable upon wetting with the biocompatible liquid to form a conformable implantable... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070190080 - Non-aqueous compositions for oral delivery of insoluble bioactive agents: The present invention provides a composition of low water solubility drug, dissolved or dispersed in a non crystalline or low crystalline form in an emulsion type composition of internal oily-solvent and external non-hydrous and water soluble solvent, whereas 1) emulsifying stabilizer comprises low fraction of the composition, and 2) emulsions... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070190082 - Perflurochemical treatment process and apparatus: A subject is confined in a closed environment at an elevated pressure through which perfluorochemical fluid containing dissolved oxygen is circulated to treat disease or injury.... Agent: Paul And Paul

20070190084 - Polymer network compositions and associated methods: Biomimetic polymer networks comprising a heteropolymer network having a cavity, the cavity having a selective affinity for a moiety, methods for making biomimetic polymer networks, and methods for using biomimetic polymer networks.... Agent: Chalker Flores, LLP

20070190085 - Stable pharmaceutical compositions, processes for making the same and methods of their use: The present invention is generally related to alcohol free, liquid ranitidine formulations for oral administration. In particular, the present invention is related to stable, syrup formulations having ranitidine as an active ingredient for oral administration, processes for making the same, and methods of their use. The ranitidine of the present... Agent: Blank Rome LLP

20070190089 - Antiperspirants with water soluble esters: This invention provides antiperspirants to combat axillary body odor by preventing or reducing perspiration, wherein the antiperspirant comprises a water-soluble ester to reduce the problems associated with stickiness and residue. The present invention provides a new class of detackifying agents that are easily formulated into clear, aqueous based antiperspirant formulations.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070190090 - Sialagogue based oral care products: Biofilm-responsive oral care products containing emulsion/sialagogue mixtures, provide the user with increased and prolonged saliva flow.... Agent: Banner & Witcoff, Ltd.

20070190087 - Method for stabilizing oil-based thickening gel composition: The present invention relates to (1) a stabilized oil-based thickening gel composition comprising (a) an anionic surfactant having a lipopeptide structure, (b) water and/or a polyhydric alcohol having a valence of 3 or more, (c) a tocopherol compound and (d) an oil component, (2) a method for improving storage ability... Agent: Sughrue Mion, PLLC

20070190091 - Perfuming or flavouring microcapsules comprising an explosion suppressant: Perfuming or flavoring microcapsules that include, further to a perfuming or flavoring ingredient and a carrier material, an explosion suppressant, proved to undergo, when suspended in hot air during their preparation, an explosion of a reduced violence. The explosion suppressant is selected from C1 to C12 carboxylic acids, their salts... Agent: Winston & Strawn LLP Patent Department

20070190088 - Polyaphron dispersions containing a complex internal phase: A polyaphron dispersion comprising an external phase and polyaphrons having an internal phase, the internal phase comprising (i) a first phase which is liquid and (ii) a second phase which is liquid or gaseous.... Agent: Dykema Gossett PLLC

20070190086 - Solid oral tooth whitening confectionary composition: The present invention provides a solid, oral tooth whitening confectionary composition comprising a tooth whitening agent comprising an alkaline or alkaline earth metal pyrophosphate, preferably calcium pyrophosphate. In one embodiment, the composition of the invention comprises an additional tooth whitening agent.... Agent: Greenblum & Bernstein, P.L.C

20070190095 - Coffee and its derivatives as an animal repellent composition and its use in a molluscicide bait: An animal repellent composition containing coffee and or its derivatives. This composition may be used alone or in conjunction with molluscicidal co-active agents and/or fertilizers.... Agent: Hughes Law Firm, PLLC

20070190097 - Compositions and methods for suppressing cracking and water loss from cherries: In one aspect, the present invention provides methods for suppressing cracking, stem browning, and water loss in fruit or vegetables, such as cherries. The methods comprise applying to fruit or vegetables an amount of a wax emulsion effective to suppress cherry cracking, stem browning, and water loss. The wax emulsion... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070190093 - Nonflammable propellant blend: Propellants comprising a combination of: (a) a liquid component that is soluble in the organic chemical-based material; (b) a soluble gas component that has a solubility of at least about 3% by weight in the organic chemical-based material; and, (c) a substantially insoluble gas component that has a solubility of... Agent: Whyte Hirschboeck Dudek S C

20070190094 - Pesticidal compositions containing isopropyl-containing compounds as pesticidally active ingredients: Pesticidal compositions containing a pesticidally acceptable carrier, at least one isopropyl-containing compound as a pesticidally active ingredient, and methods for using same, are disclosed.... Agent: Nixon & Vanderhye, PC

20070190096 - Repellent to insects harmful to a plant and method for repelling the same: The invention provides a repellent to harmful flying insects which comprises as an effective ingredient at least one selected from the group consisting of glycerin fatty acid ester, sorbitan fatty acid ester, acetylated monoglyceride, organic acid monoglyceride, propylene glycol fatty acid ester, polyoxyethylene sorbitan, fatty acid, sucrose fatty acid ester,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070190092 - Sustained release pheromone formulation: It is an object of the present invention to provide a sustained release pheromone formulation, which is not affected by the air temperature, is able to release a sex pheromone at a constant rate, does not require troublesome recovery after use, and does not pollute the environment. The present invention... Agent: Christie, Parker & Hale, LLP

20070190098 - Rodenticide: The invention provides a rodenticide comprising cellulosic material which is non-toxic to humans but which causes rodents to excrete body fat and/or adipose tissue. Suitable material is obtainable from the core of the cob of maize hybrid DK 446, a hybrid characterised by normally growing to a height of 2.7... Agent: Morgan Lewis & Bockius LLP

20070190100 - Engineering of material surfaces: The invention provides a device having a surface and a functional layer associated with the surface, where the functional layer includes particles having a structure substituted with a functional group, where the functional group is adapted to modify a property of the device, the device is sufficiently biocompatible for application... Agent: Ratnerprestia

20070190099 - Method of use of bioactive materials: A bioactive material is made using fibroin solutions and suspensions designed to support the constructions, repair, regeneration or augmentation of bone and other tissues of the body. The fibroin solutions, suspensions, and composites can be injected to fill cavities or to replace missing tissue. After injection, the materials can produce... Agent: Cantor Colburn, LLP

20070190109 - Implant material: Form bodies, which can be rotationally-symmetrical or irregularly-shaped, consist of at least one member of the group of the antibiotic salts, gentamicin myristate, gentamicin palmitate, gentamicin stearate, tobramycin myristate, tobramycin palmitate, tobramycin stearate, amikacin myristate, amikacin palmitate, amikacin stearate, vancomycin palmitate, vancomycin stearate, ramoplanin palmitate, ramoplanin stearate, levofloxacin palmitate, levofloxacin... Agent: Norris, Mclaughlin & Marcus, Pa

20070190105 - Local system for the release of active principle and process for its manufacture: r

20070190110 - Agents and devices for providing blood clotting functions to wounds: Hemostatic agents and devices are made from oxidized cellulose fiber, the oxidized cellulose having a carboxylation content increased by the action of nitrogen dioxide on virgin cellulose fiber. A composition may be incorporated into the oxidized cellulose fiber to cause a pharmacological effect on a wound to which the hemostatic... Agent: Michaud-duffy Group LLP

20070190107 - Cell selective implant surface with controlled release of bioactive agents: The present invention relates to an implant (1) with at least partially a roughened surface (2), which is at least partially covered by an organic or polymeric intermediate layer (3) and attached thereto a top layer (4). The top layer (4) provides for a controlled release of at least one... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070190104 - Coating comprising an adhesive polymeric material for a medical device and method of preparing the same: This invention is directed to a coating for a medical device in which the coating comprises an adhesive polymeric material, having a certain degree of surface tack, disposed on at least a portion of the medical device surface. The coating also comprises an outermost coating layer comprising a biologically active... Agent: Jones Day

20070190101 - Flowable bone grafts: The present invention is directed to bone graft compositions suitable for administration to the body via a cannula, where the compositions contain mineralized collagen particles and a fluid biocompatible carrier having the mineralized collagen particles substantially uniformly distributed there through, which particles contain bound mineralized collagen fibrils substantially uniformly distributed... Agent: Philip S. Johnson Johnson & Johnson

20070190108 - High performance reticulated elastomeric matrix preparation, properties, reinforcement, and use in surgical devices, tissue augmentation and/or tissue repair: This invention relates to reticulated elastomeric matrices, their manufacture, their post-processing, such as their reinforcement, compressive molding or annealing, and uses including uses for implantable devices into or for topical treatment of patients, such as humans and other animals, for surgical devices, tissue augmentation, tissue repair, therapeutic, nutritional, or other... Agent: Jones Day

20070190103 - Implantable medical device with surface-eroding polyester drug delivery coating: The present invention relates to an implantable medical device comprising therapeutic agents coated on the device using polyesters for the drug reservoir layer that exhibit surface-eroding characteristics.... Agent: Squire, Sanders & Dempsey LLP

20070190102 - Method of preparing hydroxyapatite based drug delivery implant for infection and cancer treatment: A bioresorbable material is incorporated with bioactive agents to form an implant used for treatment against hard tissue or soft tissue defects and diseases. Antibiotics or anti-cancer agents are incorporated to treat hard or soft tissue infections or cancers. Sustained release of the bioactive agents or drug molecules may be... Agent: Berkeley Advanced Biomaterials, Inc.

20070190106 - Phosphorus-containing compounds & uses thereof: b

20070190111 - Ocular therapeutic agent delivery devices and methods for making and using such devices: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121,... Agent: Leydig Voit & Mayer, Ltd

20070190112 - Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Stephen Donovan Allergan, Inc.

20070190113 - Agent for inhibiting postprandial increase in blood neutral fat level and foods containing the same: The present invention herein provides an agent or a food for inhibiting a postprandial increase in blood neutral fat level. The agent or food comprises, as an effective component, a water-soluble and hardly digestible starch decomposed product having a content of hardly digestible components of at least 35% by mass.... Agent: Sughrue Mion, PLLC

20070190114 - Antioxidant health lozenges: Compositions and methods related to combining antioxidant-promoting agents and breath masking agents in a single oral delivering formulation are provided. The composition includes a blend of antioxidants directed to reducing oxidative stress associated with smoking and exposure to other environmental toxins. The active ingredients of the oral composition are in... Agent: Bell, Boyd & Lloyd, LLP

20070190115 - Feed additive for laying hen and feed containing the same: A feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed characterized by containing a feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed. Namely, a feed additive for laying hens, which is excellent in effect of... Agent: Sughrue Mion, PLLC

20070190116 - Solid calcium bolus product with quick dissolution: A preparation of a solid calcium bolus product with quick dissolution for preventing or treating hypocalcemia of dairy cows is described. Calcium chloride or the mixture with calcium propionate, calcium carbonate, calcium phosphate, calcium oxide, magnesium oxide, vitamin D, calcium acetate, calcium iodate, calcium lactate or their combination in particle... Agent: Rigel Technology Corporation

20070190120 - Administration of non-oral androgenic steroids to women: The present invention provides compositions, methods, and kits for improving health in a woman having elevated SHBG levels, or who is receiving oral estrogen supplementation, by non-orally administering an effective amount of an androgenic steroid. Further, the present invention provides compositions, methods, and kits for coadministering an effective amount of... Agent: Thorpe North & Western, LLP.

20070190119 - Antimicrobial product and method for using the same: An antimicrobial product and a method for using the same display and/or store a first food product and/or a second food product. The antimicrobial product has a base layer having a first side and a second side for contacting and/or for abutting the first food product and/or the second food... Agent: Patents+tms, P.C.

20070190117 - Buccal formulations of galanthamine and uses thereof: Film-shaped medicaments for buccal administration of galanthamine or of a salt or derivative thereof comprise at least one layer which contains a cholinergic active agent acting on the central nervous system or a combination of at least two such active agents, the said substance(s) being selected from the group comprising... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070190121 - Non-absorbent articles containing additives for inhibiting the production of tsst-1: Non-absorbent articles, such as tampon applicators, containing an additive are disclosed. The non-absorbent articles include an effective amount of an inhibitory compound, such as thiolactomycin or thiomalonate, for example, to substantially inhibit the production of TSST-1 or exoprotein by Gram positive bacteria.... Agent: Senniger Powers (kcc)

20070190118 - Resin composition and utilizing the same, furniture, electrical household appliance and molding: A resin composition that excels in antibacterial action and realizes high aestheticity and safety, these properties retained for a prolonged period of time; and a relevant furniture, electrical household appliance and molding. Coating layer is superimposed on the surface of top board of table (furniture) This coating layer is formed... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070190122 - Skin dressings: A skin dressing of the general form disclosed in WO 03/030800 comprises oxidoreductase enzyme in hydrated condition in a hydrated hydrogel of hydrophilic polymer material, wherein hydrogel comprises at least 25% by weight of the polymer material. A currently preferred dressing comprises a lower, skin-contacting layer (18) comprising a hydrated... Agent: Morgan Lewis & Bockius LLP

20070190123 - Cover material and plaster with cover material: The present invention provides a cover material 10, adapted to be attached to skin in a manner covering over the entirety of a patch 20, comprising a pressure-sensitive adhesive layer 12 on one side of a support 11, wherein said patch 20 comprises a drug-containing layer 22 for contacting with... Agent: Nath & Associates

20070190125 - Positioning feature for aiding use of film or strip product: A film or strip product is provided with a positioning feature formed to aid a user in differentiating or distinguishing or otherwise identifying one or more features of the film or strip product. The positioning feature thus may be used to facilitate proper or desired use of the film product... Agent: Philip S. Johnson Johnson & Johnson

20070190124 - Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and at least two solidifying agents. The solvent vehicle can include a volatile solvent system including at least one... Agent: Thorpe North & Western, LLP.

20070190126 - Method for treating generalized and focal peripheral neuropathies: A composition providing cobalamine, cobalamine subtype or cobalamine analog as an effective agent for topical or transdermal administration to alleviate pain associated with a generalized or focal peripheral neuropathic condition, such as carpal tunnel syndrome.... Agent: Dla Piper US LLP

20070190128 - Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds: Esters of L-carnitine and alkanoyl L-carnitines are described which can be used as cationic lipids for the intracellular delivery of pharmacologically active compounds. New esters of L-carnitine and alkanoyl L-carnitines of formula (I) are also disclosed wherein the R groups are as defined in the description.... Agent: Nixon & Vanderhye, PC

20070190127 - Extended release of neuregulin for improved cardiac function: The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin.... Agent: Jones Day

20070190130 - Protein hydrolysate excipients: A pharmaceutical composition comprising an effective amount of a pharmaceutical active and up to about 99.8% wt/wt water soluble protein hydrolysate to total weight of composition is provided. Whey protein hydrolysate is exemplary of a suitable soluble protein hydrolysate. A method for preparing such a composition is also provided.... Agent: Andrews Kurth LLP Intellectual Property Department

20070190129 - Sustained release dosage forms of ziprasidone: A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.... Agent: Pfizer Inc

20070190131 - Press-fit rapid release medicament and method and apparatus of manufacturing: A caplet having press-fit gelatin capsule shell halves includes one or more dimples formed in one or both ends of the caplet shells, which significantly reduces the thickness of the gelatin which thereby dissolves more quickly, allowing the medicament to be rapidly released into the body's digestive system. In one... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070190132 - Pharmaceutical compositions for oral and topical administration: d. 5 to 50% of one or more compounds selected from triglyceride macrogol glycerol esters, partial glycerides or fatty acids or macrogol esters of fatty acids in which the average quantity of reacted ethylene oxide in the synthesis of these substances ranges between 50 to 150 mols and concurrently the... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070190134 - Compositions containing nicorandil, preparation method and use: The present invention provides a composition comprising (i) Nicorandil, and (ii) a lubricant selected from a saturated higher aliphatic acid and its salts and/or a saturated higher alcohol, which is solid at ambient temperature, wherein the lubricant is not micronized; processes for preparing such composition; processes for preparing tablets from... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070190133 - Dosage forms having a microreliefed surface and methods and apparatus for their production: The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of... Agent: Philip S. Johnson Johnson & Johnson

20070190135 - Phosphate-binding polymer and tablets using the same: Disclosed are a phosphate-binding polymer having a true specific gravity of 1.18-1.24, tablets that solely consist of the particles of a phosphate-binding polymer having an average particle size of no more than 400 μm, with at least 90% being occupied by particles no larger than 500 μm, and having a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070190136 - Process for producing fenofibrate tablets: The invention provides processes using suspensions to produce fenofibrate compositions. The resulting fenofibrate compositions can be made in the form of a tablet.... Agent: Venable LLP

20070190137 - Osmotic dosage form with controlled release and fast release aspects: Disclosed are osmotic dosage forms including a semi-permeable membrane; a first and a second orifice in the semi-permeable membrane located at opposite ends of the semi-permeable membrane; a controlled release drug layer located adjacent to the first orifice and within the semi-permeable membrane; a fast release drug layer located adjacent... Agent: Philip S. Johnson Johnson & Johnson

20070190138 - Stabilized atorvastatin: A stable pharmaceutical composition for oral administration comprising atorvastatin and an amount of a pharmaceutically acceptable organic alkalizing compound capable of establishing a microenvironment for atorvastatin having a pH of at least about 5, for example 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol).... Agent: Darby & Darby P.C.

20070190139 - Delayed release pharmaceutical oral dosage form and method of making same: The present invention relates to a multi layer pharmaceutical oral dosage form having delayed release and immediate release properties and method of making same. The delayed release formulation substantially behaves as an enterically coated dosage form but without the formulation and the application of an enteric coating. The delayed release... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070190141 - Extended release opiate composition: The present invention relates to an extended release opiate pellets that contain an opiate and an inorganic osmagent in the core. The extended release pellets can be used alone or combined with an immediate release opiate form to prepare extended release oral pharmaceutical tablets or capsules.... Agent: Hedman & Costigan P.C.

20070190140 - Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle: The disclosure concerns a pharmaceutical composition in the form of a gastric resident matrix tablet, comprising an active principle, characterized in that when contacted with an environment representing gastric fluid, it increases after 15 minutes in volume, by a swelling of at least 200%.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070190142 - Dosage forms for the delivery of drugs of abuse and related methods: A dosage form and method for the delivery of drugs, particularly drugs of abuse, characterized by resistance to solvent extraction, tampering, crushing, or grinding, and providing an initial burst of release of drug followed by a prolonged period of controllable drug release.... Agent: Robert Deberardine Abbott Laboratories

20070190143 - Disintegrating tablets comprising licarb azepine: The invention relates to pharmaceutical compositions comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide (also referred to as “licarbazepine”) as drug substance.... Agent: Novartis Corporate Intellectual Property

20070190145 - Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids: A pharmaceutical dosage form such as a capsule, a conventional or orally disintegrating tablet capable of delivering a weakly basic, nitrogen (N)-containing selective serotonin 5-HT3 blocking agent having a pKa in the range of from about 5 to 14 and a solubility of not more than about 200 μg/mL at... Agent: Thompson Hine L.L.P. Intellectual Property Group

20070190144 - Multilayer tablet: A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active compound, and at least one release-modulating layer laminated to each side of the core layer. The dosage form can be prepared using simple, inexpensive... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070190146 - Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility: The present invention relates to a pharmaceutical controlled release multilayer tablet comprising at least two layers, at least one active ingredient with highly pH-dependent solubility, at least one pharmaceutically acceptable pH maintaining excipient and at least one pharmaceutically acceptable matrix forming excipient, characterized in that said at least one active... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070190147 - Pharmaceutical tablets with active and inactive segments: An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die... Agent: Accu-break Technologies, Inc.

20070190149 - Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor: The present invention provides a method for treating a vertebrate subject suffering from a degenerative disc disease by administering an inhibitor of a matrix metalloprotease (MMP) to the subject in an amount effective to treat the subject.... Agent: Cooper & Dunham, LLP

20070190148 - Gel compositions, apparatuses and fluid separation methods: Compositions including a liquid or liquid-like carrier and first and second particles dispersed therein. The first and second particles differ from each other in at least one surface chemistry property, such as hydrophobicity. The gel compositions can be used in a variety of applications, including the separation of blood samples... Agent: Dade Behring Inc. Legal Department

20070190152 - Method for providing an active agent topically to the skin: A method of providing an active agent topically to the skin is provided and includes providing a topical preparation having an internal phase and an external phase, wherein the internal phase is dispersed within the external phase. The internal phase includes at least one hydrophilic carrier, at least one hydrophilic... Agent: Dinsmore & Shohl LLP

20070190151 - Method of preparing dendritic drugs: Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs... Agent: MckellarIPLaw, PLLC

20070190150 - Polymer actuator: The polymer actuator 1 is composed of a plurality of gel/electrode complexes arranged in an electrolytic aqueous solution 6, said gel/electrode complex being composed of a polymer gel (2a, 2b) containing at least either of acidic or basic functional groups and electrodes (3a, 3b) placed in the polymer gel, said... Agent: Bell, Boyd & Lloyd, LLP

20070190153 - Delivery systems for non-steroidal anti-inflammatory drugs (nsaids): Oral gel delivery systems for non-steroidal anti-inflammatory drugs (NSAIDs) are provided comprising an ingestible matrix within which one or more NSAIDs are substantially uniformly and completely dispersed. The delivery systems may optionally include one or more other functional ingredients that complement or enhance the function of the NSAID(s) within the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070190157 - Film lined packaging and method of making same: The present invention relates to packaging in the form of a pouch, which may contain active substances, such as food products, pharmaceutical agents, nutraceuticals and cosmetic agents, or the like. More specifically, in some embodiments, the present invention provides a pouch, which includes at least one porous substrate encompassing a... Agent: Hoffmann & Baron, LLP

20070190156 - Ion channel modulating compounds and uses thereof: Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local... Agent: Seed Intellectual Property Law Group PLLC

20070190154 - Method for the production of emulsion-based micro particles: The apparatus and methods of the present invention are of use for the production of emulsion-based microparticles containing a biological or chemical agent. In particular, the apparatus provides a vessel; packing material situated inside such vessel and may further provide material capable of insertion into both ends of said vessel... Agent: The Mccallum Law Firm, P. C.

20070190155 - Molecular programming of nanoparticle systems for an ordered and controlled sequence of events for gene-drug delivery: The disclosure provides a nanodelivery system and related process having complex, multilayered nanoparticles for sophisticated drug/gene delivery systems to intracellular portions of a cell. Outermost layers can include cell targeting and cell-entry facilitating molecules. The next layer can include intracellular targeting molecules for precise delivery of the nanoparticle complex inside... Agent: Locke Liddell & Sapp LLP Attn:IPDocketing

20070190158 - Pharmaceutical compositions in particulate form: A method of preparing a pharmaceutical composition is described, comprising 1) atomizing a liquid formulation of a therapeutic agent to produce an atomized formulation; 2) freezing said atomized formulation to form solid particles; and 3) drying said solid particles at about atmospheric pressure to produce a powder, wherein said drying... Agent: Becton, Dickinson And Company (alston & Bird LLP)

20070190159 - Polyamino acid-based insulin preparation: This invention relates to sustained release preparations of insulin comprising poly-amino acid particles, insulin and one or more preservative agents, and a method of preparing such preparations.... Agent: Novo Nordisk, Inc. Patent Department

20070190160 - Nanoparticles for drug-delivery: This invention relates to polymeric nanoparticles useful for drug delivery with target molecules bonded to the surface of the particles and having sizes of up to 1000 nm, preferably 1 nm to 400 nm, more preferably 1 nm to 200 nm, that are dispersed homogeneously in aqueous solution. The target... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070190161 - Solid formulation for dialysis and process for producing the same: The present invention relates to a solid formulation for dialysis and a method for producing the same. The formulation is a mixture of: first particles having a coating layer containing magnesium chloride and sodium acetate on surfaces of sodium chloride particles; and second particles having a coating layer containing calcium... Agent: Kubovcik & Kubovcik

20070190162 - Colloidal suspension of submicronic particles for delivering active principles and method for preparing same: The present invention is directed to a suspension of particles for delivering active principles, in particular proteins. Said particles are based on a diblock copolymer consisting of a neutral hydrophobic alpha hydroxy carboxylic acid polymer block and a hydrophilic linear polyaminoacid block with peptide alpha chaining, at least partly ionized.... Agent: Patton Boggs LLP

20070190163 - Technology for preparation of macromolecular microspheres: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.... Agent: Fish & Richardson, PC

20070190164 - Combination: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/M2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with... Agent: King & Spalding

20070190165 - Tissue-specific basement membrane gels: Methods are provided for basement membrane extraction and gellation whereby a biologically active, stable, three dimensional gel can be induced within five minutes or less with basement membrane components from substantially any tissue selected by the preparer. The three dimensional gel can further be substantially free of cellular contaminants. Thus,... Agent: Pauley Petersen & Erickson

20070190166 - Processes for making selectively permeable laminates: Processes for fabricating selectively permeable laminates are provided. In various embodiments, the laminates are useful for fabrication as a protective article and are substantially impermeable to hazardous chemical and biological agents, but sufficiently permeable to water vapor that, if worn as protective apparel, it is both protective and comfortable to... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070190167 - Use of cobratoxin as an analgesic: A composition of matter for an analgesia and its method of use is disclosed. The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological conditions, rheumatoid arthritis, viral infections and lesions... Agent: Robert J. Van Der Wall Gables One Tower

20070190168 - Method of the treatment and prophylaxy of some diseases and rejuvenation of the organism: The invention is intended for treatment and prophylaxy of infectious diseases and others in which urine from a sick person contains antigens or gaptens from the incitant of the disease (for reception autourine vaccine or urine vaccine). It is also exposed to necessary processing as well as for treatment of... Agent: Flaster/greenberg P.C. 8 Penn Center

20070190169 - Dendritic cells, pharmaceutical composition comprising said dendritic cells, therapeutic method and yo t-cell culture method utilizing said dendritic cells: The present invention provides dendritic cells capable of efficiently activating and/or proliferating γδ T-cells in vivo and/or in vitro, pharmaceutical compositions comprising said dendritic cells, therapeutic methods and γδ T-cell culture methods utilizing said dendritic cells. By pulsing immature dendritic cells derived from peripheral blood monocytes with a bisphosphonate-based bone... Agent: Foley And Lardner LLP Suite 500

20070190170 - Composition and therapeutic uses thereof: A physiologically ingestible composition comprising microstructured water consisting essentially of hydrogen and oxygen atoms and having a boiling point higher than the boiling point of double distilled water is used. The physiologically ingestible composition may be administered to heal a wound or increase a rate of wound healing.... Agent: The Fleshner Group, PLLC

20070190171 - Methods for altering stool quality and/or stool frequency: Methods for altering and therefore improving stool quality and/or stool frequency for an animal by adjusting the balance of metabolizable cations to metabolizable anions consumed by the animal.... Agent: Colgate-palmolive Company

20070190172 - Enhanced activity biocidal hydrogen peroxide composition: t

20070190173 - Antioxidant skin compositions and methods of production of the same: Antioxidant dry powder compositions are produced and topically administered externally to skin to enhance the ability of the skin to combat free radicals.... Agent: Tod R Nissle

20070190176 - Antimicrobial composition: An antiseptic composition suitable for use on skin and wounds comprising a source of an antimicrobial agent and an agent which disrupts biofilms. More, particularly the invention relates to a composition capable of providing effective antimicrobial activity while at the same time avoiding wound and skin irritation and retardation of... Agent: Bristol-myers Squibb Company

20070190174 - Antiviral colloidal silver composition: We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5-40 ppm, and wherein the composition manifests significant antimicrobial properties... Agent: Venable LLP

20070190175 - Skin care composition for dermatological disorders: A topical skin care composition is provided to improve skin texture, diminish fine lines and wrinkles and decrease the appearance of hyper-pigmented areas. In addition, another embodiment of the skin care composition can be used to treat burns, insect bites and diminish the pain and scarring caused by such injuries.... Agent: Sonnenschein Nath & Rosenthal LLP

20070190177 - Zinc composition and their use in anti-microbial applications: The invention relates generally to antimicrobial compositions that are non-toxic to mammals and plants, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The antimicrobial compositions contain at least one zinc compound that is microbicidal to at least one microorganism. The antimicrobial compositions of the invention can... Agent: Morgan Lewis & Bockius LLP

20070190178 - Composition and method for the therapeutic modulation of matrix metalloproteinase: A synthesized composition containing one or more of zinc ions, calcium-ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when administered to a patient in need thereof, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method is disclosed.... Agent: O'melveny & Myers LLP

20070190179 - Lipiodol-ferrofluid, and a process for preparation thereof: The present invention discloses a Lipiodol-ferrofluid, and a process for preparation thereof, wherein the Lipiodol-ferrofluid includes the ferrofluid including a magnetic component, γ-Fe2O3 or Fe3O4; and the Lipiodol.... Agent: Bruce H. Troxell

20070190182 - Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally: One aspect of the invention relates to methods of treating cancer in a patient comprising administering intraperitoneally to a patient in need thereof a cancer treating effective amount of a lipid-based platinum compound formulation wherein the concentration of the platinum compound of the lipid-based platinum compound formulation is greater than... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070190180 - Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously: In one aspect, the present invention relates to methods of treating cancer in a patient comprising administering intravenously to a patient in need thereof a cancer treating effective amount of a lipid-based platinum compound formulation wherein the concentration of the platinum compound of the lipid-based platinum compound formulation is greater... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070190181 - Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously: In one aspect, the present invention relates to methods of treating cancer in a patient comprising administering intravenously to a patient in need thereof a cancer treating effective amount of a lipid-based platinum compound formulation.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070190183 - Treatment of respiratory diseases: A method for treating a mammal suffering from a respiratory disease characterized by acute intermittent or chronic obstruction of the airways of the lungs, such as asthma, acute asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis comprising delivering to the lungs of the mammal a perfluorocarbon and a gas mixture... Agent: Bennett Jones C/o Ms Roseann Caldwell

20070190184 - Method and apparatus for generating nitric oxide for medical use: A method and system for generating and delivering nitric oxide directly to a patient. A reaction chamber is provided that is located at or in close proximity to the patient and reactants within the reaction chamber react together to produce a predetermined amount of nitric oxide. The reaction is controlled... Agent: Gibbons P.C.

20070190186 - Fat compositions: Fat compositions that contain a vegetable oil and a plant-derived wax component are described. Food and cosmetic products containing such fat compositions also are described.... Agent: Cargill, Incorporated

20070190187 - Formulation for enhanced delivery of phenethylamine: The present invention is directed to a formulation comprising phenethylamine or a derivative thereof, and an MAO-B enzyme inhibitor. The present invention is also directed to a method of increasing the absorption of phenethylamine or a derivative thereof, into the bloodstream, cells and tissue. The method includes administering phenethylamine or... Agent: Law Office Of Steven B. Leavitt, L.L.P.

20070190185 - Plant extract mixtures and their uses: A composition comprising extract of one or more plants of one or more of the following plant families: Cissus, Vernonia and Brillantasia. Such compositions have benefical activity principally in controlling weight gain and obesity, especially in conjunction with chitosan or a chitosan derivative and an antioxidant such as vitamin C.... Agent: Greenberg Traurig LLP (la)

20070190188 - Controlling toxicity of aminoquinoline compounds: A method of controlling toxicity to a user caused by administration to the user of an aminoquinoline compound comprising administering to the user a toxicity controlling amount of at least one inhibitor of a cytochrome P450 (CYP) enzyme.... Agent: Hunton & Williams/new York Intellectual Property Dept.

20070190189 - Extract of mad-dog skullcap: An extract of Scutellaria lateriflora L. having a content of flavonoids, calculated as the sum of baicalein, scutellarin, dihydrobaicalin, ikonnikoswide I, lateriflorin, baicalein, lateriflorein and wogonin, of at least 18% by weight. A method of obtaining such an extract includes combining dried Scutellaria lateriflora L. plant material with a solvent.... Agent: Kevin M. Farrell Pierce Atwood

20070190190 - Conditioning compositions and methods of use thereof: Compositions and methods of treating skin irritation are disclosed where a conditioning composition is applied to the skin of a user. The compositions and methods are useful to prevent, reduce and/or eliminate irritation of the skin subjected to topical treatment.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070190192 - Novel abietane diterpenoid compound, and composition comprising extract of torreya nucifera, or abietane diterpenoid compounds or terpenoid compounds isolated from them for prevention and treatment of cardiovascular disease: T. nucifera extracts or abietane diterpenoid compound or terpenoid compound isolated from the same of the present invention not only shows excellent anti-oxidative activity to LDL but also effectively inhibits ACAT activity. Further, T. nucifera extracts of the present invention reduce blood LDL cholesterol and total cholesterol. Therefore, the composition... Agent: Lucas & Mercanti, LLP

20070190191 - Use of geraniol in antitumoral therapy: The present invention is relative to the use of geraniol for blocking the development and differentiation of tumor cells, and potentiating the cytotoxic effect of antitumoral drugs.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070183982 - Pharmaceutical composition for aerosols with two or more active substances and at least one surfactant: Disclosed are new pharmaceutical formulations for aerosols with at least two or more active substances together with at least one surfactant for inhalative or nasal application.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070184005 - Hydrolysis resistant organomodified trisiloxane surfactants: s

20070184006 - Process for preparing organically modified siloxanes: The invention provides a process for preparing siloxanes modified with organic esters, by hydrosilylating siloxanes with terminally unsaturated esters, which comprises preparing the terminally unsaturated esters used using at least one enzyme as catalyst.... Agent: Frommer Lawrence & Haug

20070184011 - Shaving gel combinations and devices: A shaving composition is described that combines a shaving gel, foam, or cream, and a liquid hand or bath soap, along with razors having improved cleaning characteristics and designs, along with methods for using such shaving compositions and razors.... Agent: Wesley B. Ames

20070184016 - Composition and method for pre-surgical skin disinfection: This invention provides a pre-surgical disinfecting composition that includes at least about 50 percent by weight of a C1-6 alcohol, based upon the total weight of the disinfecting composition, an acid, and a cationic oligomer or polymer. A method for pre-surgical skin disinfection with rapid antiseptic efficacy without the use... Agent: Renner, Kenner, Greive, Bobak, Taylor & Weber

20070184013 - Antiviral method: This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.... Agent: Renner, Kenner, Greive, Bobak, Taylor & Weber

20070184017 - Anti-aging treatment using copper and zinc compositions: Composition and methods for alleviating or eliminating age related skin conditions by providing an effective amount of one or more copper, zinc and copper-zinc compositions are disclosed. Treatment is accomplished through the use of topical compositions containing one or more copper or zinc salts and/or copper-zinc compounds or complexes, particularly... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070184033 - Methods and compositions for repair of cartilage using an in vivo bioreactor: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living, core component, but also as an inducer of... Agent: Fulbright & Jaworski, LLP

20070183969 - Cln101 antibody compositions and methods of use alone and in combination with prostate specific antigen and other cancer markers: This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone... Agent: Licata & Tyrrell P.C.

20070183970 - Chimeric, human and humanized anti-granulocyte antibodies and methods of use: The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocyte related disorders and diseases, such as leukemia.... Agent: Faegre & Benson LLP Patent Docketing

20070183971 - Immunoconjugates targeting syndecan-1 expressing cells and use thereof: Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20070183972 - Compounds and methods for the treatment of cancer: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070183973 - Direct application of non-toxic crosslinking reagents to resist progressive spinal deformity: A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize... Agent: Berliner & Associates Robert Berliner

20070183974 - Method and apparatus for production of a skin graft and the graft produced thereby: A micro-organ structure comprising at least two micro-organ portions formed from a tissue, in which said at least two micro-organs are linked one to the other by means of a junction formed from said tissue of which the micro-organs were formed therefrom.... Agent: Pearl Cohen Zedek Latzer, LLP

20070183975 - Polypeptide absorbable into digestive organs: A polypeptide absorbable into digestive organs, which is linked with a bioactive polypeptide, and assists absorption of the bioactive polypeptide into digestive organs when it is orally taken; a fusion polypeptide comprising the polypeptide absorbable into digestive organs and the bioactive polypeptide; and an oral composition comprising the fusion polypeptide... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070183976 - Composition for ultrasound therapy and pharmaceutical liquid composition containing the same: The present invention provides pharmaceutical liquid compositions, comprising a liquid, a prodrug, and a large quantity of microbubbles formed by a gas dispersed in the liquid, the microbubbles having a diameter between about 0.1 μm and 100 μm, wherein a majority of the prodrug is present outside the microbubbles. The... Agent: Dla Piper US LLP

20070183977 - Fluorescein-labelled peptides: The invention relates to new peptide-based compounds and their use in diagnostic optical imaging. More specifically the invention relates to the use of such peptide-based compounds as targeting vectors that bind to receptors associated with angiogenesis. The compounds are labeled with fluorescein and may be used as contrast agents in... Agent: Ge Healthcare, Inc.

20070183978 - Methods and compositions for diagnosis and immunotherapy of pollen allergy: A diagnostic pollen array includes allergens extracted from pollen coat material and pollen cytoplasm. Diagnostic pollen arrays are useful to diagnose allergy in individuals, identify novel allergens, identify genetic loci responsible for allergy in hosts, and to develop personalized treatment plans for allergy.... Agent: Barnes & Thornburg LLP

20070183979 - Abuse-proofed dosage form: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse... Agent: Perman & Green

20070183980 - Dosage form that is safeguarded from abuse: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse... Agent: Perman & Green

20070183981 - Air treatment device with controlled pore size substrate: Disclosed are substrates suited for dispensing air treatment chemicals upon being heated. Granular particles, preferably sand with a phenolic binder, are adhered together to form a substrate body having a network of pores. A volatile air treatment chemical is disposed in the pores. The particle size and pores are such... Agent: S.c. Johnson & Son, Inc.

20070183983 - Medical composition containing nf-kb decoy for treating and preventing respir atory diseases and method of using the same: A pharmaceutical composition for treating and preventing diseases, disorders and/or conditions of airway inflammation, airway stenosis or nasal cavity inflammation caused by the expression of a gene regulated by NF-kappaB which contains an NF-kappaB decoy and a pharmaceutically acceptable carrier. The above diseases may be asthma, COPD or rhinitis. Moreover,... Agent: James F Haley Fish & NeaveIPGroup

20070183984 - Calcium phosphate salts in oral compositions suitable as a tooth remineralizing agent: The present invention is generally directed to an oral composition comprising a calcium phosphate salt and a combination of acids having differing solubilities in the oral cavity, for tooth mineralization or remineralization. The presence of a combination of acids in the oral composition acts to maximize the release of calcium... Agent: Senniger Powers (wwy)

20070183985 - Antibacteric composition to be used as mouthwash for sanitizing the buccal cavity: Are herein disclosed novel preparations of antibacteric emulsified mouthwash compositions, which are emulsified in a stable manner, and the formula of which comprises particular ‘lipophile compounds”; in these oil compounds, having a high substantiveness for the dentinal and gingival tissue, antiseptic substances, exclusively soluble in an oil phase can be... Agent: Hedman & Costigan P.C.

20070183986 - Methods and systems for mixing a multi-part fluoride varnish composition: Methods and related systems for mixing a multi-phase fluoride varnish composition preparatory to applying it to a person's teeth. The method includes the steps of providing a multi-phase fluoride varnish composition including a liquid hydrophobic adhesive phase and a solid fluoride salt (e.g., sodium fluoride) phase that is substantially insoluble... Agent: Workman Nydegger (f/k/a Workman Nydegger & Seeley)

20070183989 - Oral compositions comprising zinc citrate and/or tocopherol agents: Methods and oral compositions for reducing one or more of plaque, tartar, caries, dentinal sensitivity, malodor, and/or inflammation are provided. The composition comprise an active ingredient that comprises a zinc salt.... Agent: Colgate-palmolive Company

20070183987 - Peroxide gel compositions: The present invention is the use of Poly(2-ethyl-2-oxazoline) in the creation of peroxide gels for various applications. Such applications include bleaching of hair, teeth, laundry or any other bleachable item. Blending of the gel is accomplished by mixing the Poly(2-ethyl-2-oxazoline) with a peroxide such as hydrogen peroxide, carbamide peroxide, sodium... Agent: Geoffrey E. Dobbin, Patent Attorney

20070183988 - Tooth whitening delivery system: (a) 10% to 75% of a complex which is (i) a mixture of 78 to 90% of water soluble polyvinylpyrrolidone (PVP) having K-values of K-12 to K-120 and (ii) 10 to 22% of H2O2; releasing 1 to 20% of active H2O2 from said complex onto a tooth surface; (b) 0... Agent: H. Jay Spiegel

20070183990 - Confectionary compositions with magnolia bark extract: A confectionary composition and a method for oral care that includes Magnolia Bark Extract in combination with a surface active agent. The effectiveness of Magnolia Bark Extract in inhibiting biofilm formation in the oral cavity is increased by a synergistic combination of the Magnolia Bark Extract with a surface active... Agent: Brinks Hofer Gilson & Lione

20070183991 - Toothpaste composition: Provided is a toothpaste composition providing a pleasant cooling sensation and has excellent storage stability. The toothpaste composition contains from 30 to 60 wt % of erythritol having an average particle size of 200 μm or less as Component (A), from 15 to 30 wt % of water as Component... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070183992 - Cosmetic composition comprising porous particles incorporating optically active substances: An object of the invention is to offer an optical additive capable of adequately activating the effects of incorporated optically active substances, providing the base with such optical effects, having a suitable sensation and level of safety, and having exceptional cosmetic properties. A cosmetic composition comprising in a physiologically acceptable... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070183993 - Personal care compositions: Personal care compositions comprising a PPARG antagonist, use of such compositions, and methods of marketing such compositions. The personal care compositions can be applied topically, ingested orally, injected, or used as part of a regimen.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070183994 - Self-tanning product having slimming, firming and toning properties associated therewith: A sunless or self-tanning composition having slimming, firming and toning properties associated therewith. The composition is an emulsion containing safe effective amounts of sunless tanning agents and slimming, firming and toning constituents. A method for preparing such composition is disclosed.... Agent: Dunlap, Codding & Rogers P.C.

20070183995 - Compounds useful as agonists of a2a adenosine receptors, cosmetic compositions with a2a agonists and a method for using the same: Compounds useful as agonists of A2A adenosine receptors are described. Also described is a cosmetically acceptable composition having an agonists of A2A adenosine receptors where the composition is suitable to apply to human skin to reduce the effects of melanin, resulting in skin whitening.... Agent: Unilever Intellectual Property Group

20070183996 - Para-coumaric acid or para-hydroxycinnamic acid derivatives and their use in cosmetic or dermatological compositions: m

20070183997 - Composition comprising particles of at least one polymer dispersed in at least one fatty phase and at least one apolar oil: The present disclosure relates to a cosmetic composition comprising particles of at least one polymer dispersed in a fatty phase, the at least one fatty phase is free of volatile oil or comprises less than 50% by weight of volatile oil relative to the weight of the at least one... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070183998 - Cosmetic composition: The present invention relates a cosmetic composition comprising: at least one pigment comprising: an elongated core, a red organic colorant coating at least partially the core, and at least one binder between the core and the organic colorant.... Agent: Oliff & Berridge, PLC

20070184000 - Composition for inhalation therapy and methods of use: A composition for providing aromatherapy, and in particular, symptomatic relief of nasal and sinus congestion is provided in unit dosage format. The composition includes a penetrating aromatic vapor whose release from a preparation of warm water is augmented by an effervescent component which reacts in the warm water to promote... Agent: Jagtiani + Guttag

20070183999 - Method of preparing a cosmetic composition, and an apparatus for implementing such a method: A method of preparing a cosmetic composition includes causing at least one fluid to flow through an enclosure containing at least one substance to be extracted, and collecting the extraction solution in a receptacle. The method further includes delivering more of the same fluid to the receptacle that does not... Agent: Oliff & Berridge, PLC

20070184003 - Apparatus and method for optimizing hair growth: A system for enhancing and promoting hair growth addresses the problem of premature or undesirable hair loss with the use of i) laser energy applied to the scalp in conjunction with ii) certain topical applications that can be applied to the scalp on a periodic basis and iii) certain supplements... Agent: Wright Law Group, PLLC

20070184004 - Shea butter dimethicone copolyols: Novel silicone compounds prepared by the reaction of a dimethicone copolyol with shea butter, preferably mild-processed shea butter (MPSB). These compounds are useful as cosmetic and personal care ingredients, allowing for the delivery of highly desirable active ingredients present in shea butter, including natural antioxidants, in compounds are substantive to... Agent: Louis C. Paul & Associates, PLLC

20070184007 - Use of di-or oligosaccharide polyester in hair styling products: The present invention relates to the use of fully esterified di- or oligosaccharide polyesters in hair styling products selected from hair styling waxes, hair styling creams, hair styling foam wax products, and hair styling spray wax products. Preferred saccharide polyesters are octaesters of sucrose and C8 to C30 fatty acids... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070184001 - Cosmetic composition comprising a nonionic fixing polymer and a specific ester of polyethylene glycol and of fatty acid, and a method for fixing the hairstyle: R1, R4 and R5 are chosen, independently of one another, from C10 to C30 alkyl groups and C10 to C30 alkylene groups. The present disclosure is also targeted at a method for the shaping or the form retention of the hairstyle comprising applying the cosmetic composition to hair, for example,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070184009 - Shea butter alkoxylates: Novel alkoxylates prepared by the reaction of mild-processed shea butter (MPSB) with ethylene oxide, propylene oxide or mixtures thereof. These compounds are useful as cosmetic and personal care ingredients, allowing for the delivery of highly desirable active ingredients present in MPSB, including natural antioxidants, in a water-soluble form that is... Agent: Louis C. Paul & Associates, PLLC 9th Floor

20070184008 - Shea butter polyoxyalkylene glycol esters: Novel polyoxyalkylene glycol esters prepared by the reaction of a polyoxyethylene glycol (PEG) or polyoxypropylene glycol (PPG) or mixtures thereof with shea butter, preferably mild-processed shea butter (MPSB) under specific mild-processing conditions. These materials are useful as cosmetic and personal care ingredients, allowing for the delivery of highly desirable active... Agent: Louis C. Paul & Associates, PLLC

20070184002 - Non-washing cosmetic composition comprising at least one ionic fixing polymer and at least one ester of polyethylene glycol and of fatty acid, and method for fixing a hairstyle: Disclosed herein is a non-washing cosmetic composition comprising, in a cosmetically acceptable medium chosen from aqueous/alcoholic and alcoholic mediums, at least one ionic fixing polymer, at least one ester of polyethylene glycol and of fatty acid, and at least one thickening agent. Also disclosed herein is a process for the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070184010 - Shaving gel combination: A shaving composition is described that combines a shaving gel, foam, or cream, and a liquid hand or bath soap.... Agent: Wesley B. Ames AmesIPLaw

20070184012 - Has2-stimulating plant extracts: The invention relates to plant extracts for stimulating the synthesis of hyaluronan synthase, particularly the synthesis of hyaluronan synthase 2 (HAS2). Specific aims of the invention are to increase firmness and/or elasticity and/or tissue moisturization, and/or increase the skin barrier effect, and/or increase tissue resilience, and/or modulate angiogenesis, or the... Agent: Basf Catalysts LLC

20070184014 - Modulation of pathogenicity: In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of microbial damages and diseases, in particular for diseases where there is an... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing 32nd Floor

20070184015 - Novel pegylation agent: To address the issue of degradation by enzymatic reactions to proteins and peptides, polyethylene glycol (PEGylation) of the proteins and peptides has been established. PEGylated proteins and peptides have increased plasma half-lives and reduced immunogenicity. To further improve and extend the plasma half-life of desired protein or peptide therapeutics, a... Agent: Michael E. Klicpera

20070184018 - Anthranilamide insecticides: This invention provides compounds of Formula (1), N oxides and suitable salts thereof, wherein R1 is Me, Cl, Br or I; R2 is Cl, Br, I or —CN; R3 is Cl, Br, CF3, OCH2CF3 or OCF2H; R4 is H; or C1-4alkyl, C2-4alkenyl or C2-4alkynyl, each optionally substituted with CN or... Agent: Linda D Birch E I Du Pont De Nemours And Company

20070184020 - Combination of radio waves with pharmacologically active substances: The invention relates to a combination of radio waves with pharmacologically active substances chosen from the group: a) monoclonal antibodies and/or b) tyrosine-kinase inhibitors and/or c) angiogenesis inhibitors and/or d) farnesyl-transferase inhibitors and/or e) topoisomerase-I or -II inhibitors and/or f) cytokines and/or g) antisense oligonucleotides. optionally together with one or... Agent: Amin, Turocy & Calvin, LLP

20070184019 - Pharmaceutical composition comprising an active principal and sulphobetaine: The present invention relates to the pharmaceutical composition comprising a non-detergent sulphobetaine (NDSB).... Agent: Novartis Corporate Intellectual Property

20070184024 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070184023 - Method for down-regulation of vegf: The present invention provides for novel immunogenic variants of VEGF (vascular endothelial growth factor) which are useful in active specific immunotherapy against diseases that are characterized by overexpression of VEGF. The invention also relates to methods of treating such diseases (for instance cancer) as well as to various tools in... Agent: Birch Stewart Kolasch & Birch

20070184022 - Microsome vaccine: A vaccine composition is provided which comprises inverted microsomes or fragments thereof from an animal cell in association with an externally disposed peptide antigen and a protein of the MHC.... Agent: Pepper Hamilton LLP

20070184021 - Use of caspase inhibitors as a therapeutic agent against radiation-induced injury: The present invention provides methods for the treatment of radiation-induced injury by providing to a subject a caspase inhibitor. The caspase inhibitor may be provided before or after the radiation injury, and further may be provided in combination with a second caspase inhibitor, an anti-apoptotic molecule, a radioprotectant, a cytokine... Agent: Fulbright & Jaworski L.L.P.

20070184025 - Chimaeric vector system: This invention relates to a process for producing a Simian Immunodeficiency Virus (SIV) encoding a heterologous gene, which process comprises infecting a host cell with a first vector which is capable of producing SIV capsid and a second vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal sufficient... Agent: Klarquist Sparkman, LLP

20070184028 - Conditional gene vectors regulated in cis: The present invention is directed to a conditional gene vector system and to a host cell, which has been transfected with such a vector system. The present invention is further directed to a combined preparation comprising the vector system of the invention and an interfering agent. Furthermore, a pharmaceutical composition... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070184027 - Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or... Agent: Dla Piper US LLP Attn: Patent Group

20070184026 - Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts: The present invention relates to methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. The invention thus provides a method, comprising contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No: 194-309; and measuring... Agent: Synnestvedt & Lechner, LLP

20070184036 - Isolated cd4+ t cells defined by cmrf-35: The present invention relates generally to a method for the treatment or prophylaxis of a condition which provokes, or is exacerbated by, an immunological response. The present invention further enables methods of diagnosis of conditions which provoke, or are exacerbated by, an immunological response. The present invention further provides therapeutic... Agent: Knobbe Martens Olson & Bear LLP

20070184037 - T cell immune response inhibitor: The present invention discloses a T-cell immune response inhibitor. The T-cell immune response inhibitor supplied in the present invention comprises a targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen; or it comprises a targeted pathogen nucleic acid vaccine and said nucleic acid vaccine expression protein... Agent: Cozen O'connor, P.C.

20070184038 - Therapeutic uses for mesenchymal stromal cells: Human mesenchymal stromal cells can be induced to differentiate into oligodendrocytes and neurons, respectively. For these cell types, therefore, MSCs can be a therapeutic source, either in vitro or in vivo, in the context of treating pathologies of the central nervous system which are characterized by neuron loss, such as... Agent: Dann, Dorfman, Herrell & Skillman

20070184039 - Process for the selective withdrawal of bacterial strains adhering to intestinal mucosa through endoscopy: The present invention relates to a novel process for collecting and isolating bacterial strains adhered to the intestinal mucosa by the endoscopic route by means of an innovative technique called “brushing”.... Agent: Pearne & Gordon LLP

20070184035 - Artificial stabilized composition of calcium phosphate phases particularly adapted for supporting bone cell activity: This invention relates to a bioactive artificial sintered composition for providing a morphology capable of consistently supporting bone cell activity thereon. The composition comprises stabilized calcium phosphate phases developed by the conversion of a hydroxyapatite substance in the presence of stabilizing entities at sintering temperatures into insolubilized and stabilized tricalcium... Agent: Alston & Bird LLP

20070184034 - Combination pressure therapy for treatment of hypertension, blood production, and stem cell therapy: Methods for administering pressure changes to a user for the treatment and prevention of diseases and conditions are disclosed herein. Methods of administering Cyclic Variations in Altitude Conditioning Sessions (CVAC Session(s)) for the treatment of hypertension, blood production, and stem cell therapy are disclosed herein.... Agent: Wilson Sonsini Goodrich & Rosati

20070184030 - Large scale storage of viable somatic stem and/or progenitor cells: A large scale storage system of viable somatic stem and/or progenitor cells for use in a method of treatment of a disease or a disorder of a patient is described. The storage system includes a large number of solid supports having cryopreserved/frozen viable somatic stem and/or progenitor cells from patients,... Agent: Knobbe Martens Olson & Bear LLP

20070184029 - Method of treating cancer using platelet releasate: Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were... Agent: Knobbe Martens Olson & Bear LLP

20070184032 - Tissue harvesting device and method: A tissue harvesting method and device for obtaining micrograft tissue particles within the size range of 50-1500 microns, and more preferably 500-1000 microns, and most preferably 600 microns. The particles may be processed after a piece of donor tissue has been excised from the donor site, or processed into the... Agent: Legal Department Intellectual Property Kinetic Concepts, Inc.

20070184031 - Uses of bispecific antibody coated dendritic cells pulsed with antigens and gm-csf in immune regulation: GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells... Agent: Barnes & Thornburg LLP

20070184040 - Compositions for delivery of coenzyme q10: The present invention pertains to the beneficial fusibility of ubiquinone (CoQ10) into digestible carrier fats that are solid at room temperature. By melting the CoQ10 into a properly chosen digestible carrier fat(s), recrystallization and phase separation issues are solved and a substrate is supplied for improved action upon CoQ10 by... Agent: Dallas L. Clouatre

20070184041 - Methods and compositions related to production of coenzyme q10: Disclosed are methods, compounds, and compositions related to the production of coenzyme Q.... Agent: Needle & Rosenberg, P.C.

20070184042 - Method of cancer treatment by p53 protein control: Method of cancer treatment by controlling cellular p53 protein levels. The invention concerns, in particular, the use of a compound capable of modulating calpaine activity.... Agent: Wiley Rein LLP

20070184043 - Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof: The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic... Agent: Klauber & Jackson

20070184044 - Thermoprotective compositions of pkg pathway inhibitors and method of use thereof: Neural thermoprotective compositions comprising a pharmacological inhibitor of the PKG pathway are described, as are methods of treating patients and providing neural thermoprotection with the same.... Agent: Woodcock Washburn LLP

20070184045 - Large-scale production of human serum butyrylcholinesterase as a bioscavenger: Disclosed herein are methods for the large-scale preparation of human butyrylcholinesterase (HuBChE) preparations from Cohn Fraction IV-4. As disclosed, the methods provide HuBChE preparations that are about 99% or more pure with recovery yields of about 60%. Also disclosed are the pharmacokinetics, safety and toxicity, stability and efficacy of the... Agent: Office Of The Staff Judge Advocate (sks) U.s. Army Med. Research & Materiel Command

20070184046 - Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phosphol: The invention relates to the use of phospholipases, v.gr. sPLA2, as an active agent in the production of pharmaceutical and/or cosmetic compositions for the treatment of diseases caused by micro-organisms, the envelope or membrane of which comprises phospholipids, particularly glycerophospholipids. In particular, said invention relates to the use of sPLA2... Agent: Leopold Presser Scully, Scott, Murphy & Presser

20070184047 - Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction: A method and composition for inhibiting phagocytosis of blood cells. The method involves providing a nitrophenyl compound or thimerosal with administration of the compound to a host having an auto or alloimmune disease to inhibit phagocytosis of blood cells.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070184049 - Antibody therapy for treatment of diseases associated with gluten intolerance: The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis.... Agent: Elmore Patent Law Group, PC

20070184048 - Re-targeted toxin conjugates: The present invention provides a method for designing a re-targeted toxin conjugate for use in treating a medical condition or disease. Also provided, is the use of said conjugates in the manufacture of a medicament for treating medical conditions or diseases. The conjugates include a Targeting Moiety, which directs the... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070184051 - Anti cd44 antibodies for eradicating stem cells: The present invention provides the use of an anti-CD44 antibody, a (Fab′)2, Fab, Fab′ fragment thereof, an IgG or IgM isotype thereof, in the preparation of a medicament for eradicating pathological stem cells in cancer therapy, and more specifically in acute myeloid leukaemia therapy.... Agent: Buchanan, Ingersoll & Rooney PC

20070184050 - Stable water-based medicinal preparation containing antibody: A stable liquid medical formulation containing an antibody is provided, which contains a therapeutically effective amount of an antibody in a glutamate buffer and/or a citrate buffer and has a pH between 4.0 and 6.0.... Agent: Foley And Lardner LLP Suite 500

20070184052 - Soluble tgf-b type iii receptor fusion proteins: Soluble fusion proteins of the TGF-β type III receptor and novel methods for their production are disclosed herein for the first time. The fusion proteins of the invention competitively inhibit the binding of members of the TGF-β superfamily to their cell-surface receptors. Also provided are methods for using these fusion... Agent: Clark & Elbing LLP

20070184053 - Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the enzyme peptides, and methods of identifying... Agent: Celera Attn: Victor Lee, Vice President

20070184054 - Use of a novel eimeria gene and corresponding protein: The invention relates to a novel oocyst sporocyst protein (EtOs22) belonging to the parasite of the species Eimeria tenella and to the polynucleotide encoding this protein, to vectors which contain this polynucleotide, to cells which are transformed with these vectors, to antibodies which are directed against the protein, to vaccines... Agent: Jeffrey M. Greenman

20070184055 - Treatment with anti-erbb2 antibodies: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand activation of an ErbB receptor.... Agent: Genentech, Inc.

20070184057 - Use of weak stressors to enhance the effectiveness of ionizing radiation and other treatments of disease: Enhancing the effectiveness of therapeutic ionizing radiation and other treatments of disease in which cells are to be destroyed or modified, by subjecting cells in need thereof to low-dose radiation to increase the sensitivity of the cells to subsequent subjection with a lethal dose of high dose radiation (HDR), a... Agent: Jagtiani + Guttag

20070184058 - Glucocerebroside treatment of pulmonary or respiratory diseases or disorders: This invention relates to the use of naturally occurring mammalian intermediary metabolites, Tcell ligands or Tcell receptor ligands, preferably glycosylceramides, for the treatment or prevention of immune mediated or immune related diseases or disorders. Specifically, the present invention provides compositions and methods for the treatment or prevention of pulmonary, respiratory... Agent: Enzo Biochem, Inc.

20070184061 - Indolylmaleimide derivatives: Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.... Agent: Novartis Corporate Intellectual Property

20070184059 - Method of cancer screening; method of cancer treatment; and method of diabetes treatment: A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering an needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood... Agent: Michael A. O'neil Michael A. O'neil, P.C.

20070184060 - Method of using abscisic acid to treat and prevent diseases and disorders: The present invention provides compositions and methods for treating and/or preventing diseases and disorders associated with expression of PPAR γ and/or infiltration of macrophages into skeletal muscle tissue and/or white adipose tissue. The method treats such diseases and disorders with abscisic acid (ABA). Exemplary diseases and disorders include diabetes, including... Agent: LatimerIPLaw, LLP

20070184056 - Use of weak stressors to enhance the effectiveness of ionizing radiation and other treatments of disease: Enhancing the effectiveness of therapeutic ionizing radiation and other treatments of disease in which cells are to be destroyed or modified, by subjecting cells in need thereof to low-dose radiation to increase the sensitivity of the cells to subsequent subjection with a lethal dose of high dose radiation (HDR), a... Agent: Jagtiani + Guttag

20070184062 - Epitope synchronization in antigen presenting cells: Disclosed herein are vaccines and methods for inducing an immune response against cancer cells and cells infected with intracellular parasites. Vaccines having housekeeping epitopes are disclosed. The housekeeping epitope is formed by housekeeping proteasomes in peripheral cells, but not by professional antigen presenting cells. A vaccine containing a housekeeping epitope... Agent: Knobbe Martens Olson & Bear LLP

20070184063 - Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070184064 - Chimeric peptide immunogens: Chimeric peptide epitopes can serve as effective immunogens against hormones and other small peptides or proteins. Thus, immunogenic peptides are selected from promiscuous Th epitopes and synthesized together with self antigenic peptide sequences fused with or without end to end spacer peptide interconnections. A peptide sequence which may be of... Agent: White & Case LLP Patent Department

20070184065 - Compositions and methods for inhibiting viral adhesion: The present invention provides compositions and methods for treating or preventing viral infections.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070184066 - Agaricus extract for preventing the induction or metastasis of cancer: A foodstuff capable of preventing the induction or metastasis of cancer is provided. In particular, an Agaricus blazei Murill extract comprising an ingredient capable of preventing the induction or metastasis of cancer is provided. The ingredient can be a chromatographic main elute fraction of 100 to 2000 molecular weight, obtained... Agent: Perkins Coie LLP

20070184067 - Alimentary compositions and methods for metabolic modulation: Contemplated food products include compounds with cytokinin activity to modulate glucose and/or lipid metabolism, and in especially preferred aspects contemplated food products include one or more naturally occurring cytokinins (e.g., kinetin, N2-acetylguanine, zeatin, dihydrozeatin) at a concentration effective to prevent or treat pre-diabetes, insulin resistance, type-2 diabetes, syndrome X, and/or... Agent: Rutan & Tucker, LLP. Hani Z. Sayed

20070184068 - Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070184069 - Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines: Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070184070 - Recombinant toxin fragments: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the... Agent: Merchant & Gould PC

20070184071 - Multivalent pneumococcal polysaccharide-protein conjugate composition: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic... Agent: Alston & Bird LLP

20070184072 - Multivalent pneumococcal polysaccharide-protein conjugate composition: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic... Agent: Alston & Bird LLP

20070184074 - Fusion proteins of mycobacterium tuberculosis: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and... Agent: Townsend And Townsend And Crew, LLP

20070184073 - Tb diagnostic based on antigens from m. tuberculosis: The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as diagnostic reagents containing the polypeptides.... Agent: Birch Stewart Kolasch & Birch

20070184075 - 39-desmethoxyrapamycin, compositions and methods of use thereof: The present invention relates to medical uses of 39-desmethoxyrapamycin.... Agent: Dann, Dorfman, Herrell & Skillman

20070184077 - Container: A container and more specifically a container such as a capsule used to deliver dosages of pharmaceuticals, medicines, vitamins, etc. to an individual is discussed. In one embodiment, the invention includes a container comprising: a cap; a body slidably engagable inside the cap; and a fluid gap positioned between the... Agent: Rosemary M. Miano Attorney For Applicant

20070184076 - Liquid-filled nanodroplets for anti-cancer therapy: A nanodroplet composition is provided, the nanodroplets include a lipid encapsulating a biologically compatible oil, a fluorocarbon composition including one or more fluorinated hydrocarbons, and a therapeutically active compound, where the fluorocarbon composition is in a liquid state at a temperature that is equal to, or lower than, the body... Agent: Dla Piper US LLP

20070184078 - Packaging system: In certain embodiments, the invention is directed to a package for dispensing a combination of a proton pump inhibitor and a non-steroidal anti-inflammatory drug.... Agent: Davidson, Davidson & Kappel, LLC

20070184079 - Antimicrobial and antiviral polymeric materials: The invention provides an antimicrobial and antiviral polymeric material, having microscopic particles of ionic copper encapsulated therein and protruding from surfaces thereof.... Agent: Townsend And Townsend And Crew, LLP

20070184081 - Methods and devices for depopulating avian species: A method of depopulating livestock is provided. The method comprises restricting the livestock in a defined space, and depositing foam into the defined space, forming a foam blanket covering the livestock. The livestock can be avians, such as chickens, ducks, and turkeys. A device for making medium expansion foam comprising... Agent: Mccarter & English, LLP Basil S. Krikelis

20070184080 - Post harvest treatment of crops: Novel processes and combinations of matter for treating fresh produce to seal fresh-cut stems to reduce moisture loss and inhibit fungus, mold, rot and insect infestation at the site where the produce was separated from the plant stalk. Natural and commercially produced waxes are modified with elastomers to render efficacy... Agent: James J Mullen Attorney At Law

20070184082 - Biocompatible polymeric delivery systems for sustained release of quinazolinones: The present invention relates to biocompatible polymeric delivery systems for controlled or sustained release of quinazolinone derivatives, including the compound halofuginone. In particular the invention relates to a polymeric delivery system comprising biocompatible polymeric beads having a two-phase core and shell structure, or polymeric films, beads or complexes that provide... Agent: Docketing Specialist Sullivan & Worcester LLP

20070184083 - Drug-eluting device for treatment of chronic total occlusions: A drug-eluting medical device and method for treating a chronic total occlusion. The drug-eluting medical device is implanted into the chronic total occlusion and elutes a drug that softens or dissolves the plaque of the occlusion over a period of time. After the medical device has resided in the occlusion... Agent: Medtronic Vascular, Inc.IPLegal Department

20070184084 - Implantable elastomeric caprolactone depot compositions and uses thereof: Methods and compositions for systemically or locally administering a beneficial agent to a subject are described, and include, for example, implantable elastomeric depot compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a prolonged duration of time. The compositions... Agent: Philip S. Johnson Johnson & Johnson

20070184086 - Biomedical device having crosslinked biopolymer micro pattern and preparation thereof: This invention proposes a novel technique for fabricating a gelatin micro pattern for cell culture. The gelatin micro pattern is formed by photolithography and then crosslinked with a crosslinking agent such as glutaraldehyde. The gelatin micro pattern can be used as an excellent cell culture platform for in-vitro observations of... Agent: Bacon & Thomas, PLLC

20070184088 - Diatom device: Diatom devices are disclosed including devices for biocompatible implantation. The diatom structures are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20070184087 - Polysaccharide compositions for use in tissue augmentation: A composition of matter and method for preparation of a tissue augmentation material. A polysaccharide gel composition is prepared with a programmable rheology for a particular selected application. The method includes preparing a polymeric polysaccharide in a buffer to create a polymer solution or gel suspending particles in the gel... Agent: Foley & Lardner LLP

20070184085 - Ultrasound activated medical device: A medical device comprising a medical device body having drug-loaded vesicles thereon. The vesicles are ultrasound sensitive and release the drug upon ultrasound stimulation. Also provided is a method for controlling drug release from a medical device using drug-loaded vesicles that are ultrasound sensitive.... Agent: Kenyon & Kenyon LLP

20070184089 - Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use: Solid or semi-solid intraocular implant compositions are disclosed. The compositions contain a lipophilic compound but lack a polymeric ingredient.... Agent: Alcon

20070184090 - Pufa supplements: Edible formulations, such as polyunsaturated fatty acids (PUFAs) such as pharmaceutical compositions or nutritional supplements, are disclosed comprising arachidonic acid (ARA). They are adapted to deliver from 150 mg to 1 g per day of ARA and may contain other PUFAs, for example docosahexaenoic acid (DHA). The DHA dosage is... Agent: Nixon & Vanderhye, PC

20